head office register office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel g sk change register number print uk paper annual report production document post consumer waste pulp bleach totally chlorine free process feel well live long glaxosmithkline annual report wwwgskcomavailable online year significant change gsk review progress visit wwwgskcomannualreport website glaxosmithkline website wwwgskcom give additional information group notwithstanding reference annual report glaxosmithkline website information available website constitute annual report shall deem incorporate reference cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factor include document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor page annual report content business review performance overview business review financial trend discuss financial product intellectual property competition nonfinancial activity resource global manufacturing supply development performance research development outline employee factor include trend responsibility principal risk uncertainty regulation likely affect future world market economy outlook development financial review financial position resource risk factor governance remuneration financial review discuss management structure governance governance remuneration procedure set board remuneration policy operate corporate executive team director corporate governance policy executive team member dialogue shareholder internal control framework committee report financial statement remuneration policy director term condition financial statement provide summary group financial director senior management remuneration performance director interest position st december directors interest contract consolidate financial statement prepare accordance ifrs adopt european union financial statement ifrs issue international director statement responsibility accounting standard board independent auditor report financial statement note financial statement shareholder information financial statement glaxosmithkline plc include product prepare uk gaap development pipeline discuss shareholder return form dividend share price movement shareholder information quarterly trend year record product development pipeline share price dividend nature trading market annual general meeting investor relation registrar taxation information shareholder glossary term index gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp notice limitation director liability english law uk company act safe harbour limit liability director respect statement omission report director contain page english law director liable company party report director contain error result recklessness know misstatement dishonest concealment material fact liable report director page inclusive comprise report director draw present accordance reliance english company law liability director connection report shall subject limitation restriction provide law chairman ceo summary strategy deliver believe gsk moving position deliver longterm financial performance sustainable basis shareholder sir christopher gent andrew witty chairman chief executive officer gsk annual report chairman ceo summary dear shareholder continue look well decision pipeline progression maintain strategy increase level annual report gsk significant progress externally source compound pipeline transform business model optionbase agreement strategy deliver believe gsk move addition reduce rd investment associate position deliver longterm financial performance infrastructure therapy area believe prospect sustainable basis shareholder successful registration launch differentiate medicine low return sale growth see gsk return sale growth strategic base investment late stage pipeline priority diversify drive growth key investment area longterm sale expectation estimate project rate rd emerge market consumer healthcare vaccine return believe improvement support growth industry average year longterm goal realise aspirational rate return gsk develop engine growth rd company increase diversification help reduce risk low sale volatility evident responsive flexible open gsk absorb impact lose billion equally important gsk financial social responsibility sale genericisation market ensure longterm success sustainability business course sale influenza product government determine company responsive respond hn pandemic contribute sale flexible open societys expectation year invest develop influenza continue progress area improve capability month declare hn global access medicine enhance research opportunity flu pandemic gsk able supply approve vaccine neglect tropical disease raise ethical standard government world continue work conduct research commercial activity closely respond need transparent way run business new product momentum sustain progressive dividend remain focused broaden strengthen ftse dividend payer strongly believe product portfolio year gsk receive product approval importance return fund shareholder line complete new filing gsk progressive dividend policy board approve total dividend year penny increase year gsk obtain fda approval year dividend new medicine vaccine company improve longterm prospect month potential launch conclusion make progress strategic number brand new medicine vaccine include benlysta priority see good progress sale performance new treatment systemic lupus maintain strong focus cost reduction year deliver new medicine vaccine consumer momentum set continue goal maintain healthcare product continue new initiative asset late stage pipeline build societys trust accomplish like recognise enormous contribution employee improve return investment wide network partner remain mindful need improve demonstrate well return investment entire business doubt operate challenge continue implement restructure programme simplify environment successful execution operation reduce cost programme deliver strategy believe gsk longterm prospect improve billion annual saving enhance position leadingedge healthcare company particular research development strongly focus allocate capital area good return investment sir christopher gent andrew witty chairman chief executive officer gsk annual report strategy focus deliver strategic priority transform gsk company deliver growth risk improve longterm financial performance successful sustainable business fulfil social responsibility make company responsive flexible open strategic priority grow diversified global business diversify business create balanced product portfolio away reliance traditional white pill western market invest key growth area emerge market japan vaccines consumer healthcare business deliver product value aim sustain industryleade pipeline product ensure demonstrate value healthcare provider rd strategy build focus good science diversify externalisation research improve return investment simplify operating model gsk large complex organisation transform operating model reduce complexity improve efficiency reduce cost update progress priority measure operate responsibility integrity visit website wwwgskcomannualreport gsk annual report discover world gsk online choose case study demonstrate progress strategic priority gsk change story view online wwwgskcomannualreport gsk annual report performance overview cer growth earning share major restructuring cer growth free cash flow total shareholder return gsk annual report pp weiver ssenisub key performance indicator strategy focus business delivery strategic priority turnover bn grow diversified global business broaden balance portfolio diversify new product area capture opportunity exist establish geographic footprint penny deliver product value transform rd ensure deliver current pipeline able sustain flow product year come glaxosmithkline total return index glaxosmithkline pharma peer return index ftse total return index calculation cer growth describe calculation result major restructuring describe note financial statement presentation financial statement simplify operating model calculation free cash flow describe simplify operating model ensure fit purpose able support business cost efficient way performance overview measure progress use number measure track progress good progress year number strategic priority medium long notable success term include follow performance core pharmaceutical core pharmaceutical vaccine business vaccine business deliver sale billion grow year exclude genericise product avandia influenza product include pandemic product sale billion diversification sale sale white pillwestern market fall turnover contribution emerge market overall sale emerge market pharmaceutical sale growth business grow nearly billion represent group turnover complete bolton acquisition growth consumer healthcare market share consumer healthcare market share gain deliver otc oral healthcare business share decline nutritional healthcare consumer healthcare sale grow billion growth category otc oral healthcare nutritional healthcare expansion japanese business sale reach billion drive adoair relenza product launch year contribute million sale build biopharmaceutical portfolio arzerra launch usa positive opinion receive prolia positive phase iii datum announce benlysta pipeline comprise biopharmaceutical asset contribution sale new product new pharmaceutical product launch contribute sale billion billion include hn pandemic vaccine number reimbursable product approval receive product approval complete filing new filing year obtain fda approval new molecular entity vaccine company sustain latestage pipeline maintain asset phase iii registration new programme enter phase iii enhance rd productivity increase project rate return base investment externalisation drug discovery late stage pipeline expect future longterm sale performance longterm goal improve rate return rd externalise approximately discovery research external partner delivery major restructure programme annual cost saving billion achieve programme expand deliver annual saving billion gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp gsk annual report pp weiver ssenisub report director report director performance overview provide user financial financial trend product intellectual property competition statement complete global manufacturing supply picture gsk supplement research development employee information financial responsibility statement discussion regulation aspect activity world market economy outlook financial review future environment financial position resource operate risk factor financial review board corporate executive team governance policy dialogue shareholder share capital control business review donation political organisation discuss financial nonfinancial political expenditure activity resource development performance annual general meeting outline factor include internal control framework trend principal risk uncertainty committee report likely affect future development combine code law regulation corporate governance discuss management structure governance procedure include disclosure letter chairman remuneration compliance combine code corporate committee governance financial reporting council remuneration policy combine code law regulation executive director term condition nonexecutive director term condition fee remuneration report director senior management remuneration annual remuneration set remuneration policy operate nonexecutive director remuneration director corporate executive director interest team cet member disclosure incentive plan director remuneration include require pension benefit large mediumsize company director senior management group account report regulation director interest contract pp noitarenumer dna ecnanrevog pp stnemetat laicnanif pp noitamrofni redloherahsgsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial trend growth growth total result cer cer turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p result major restructuring turnover cost sale sell general administration research development operating income operate profit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p research development total pharmaceutical consumer healthcare total net finance cost cover total net finance cost cover time time time net finance cost cover profit tax plus net finance cost divide net finance cost tax rate total tax rate major restructuring borrowing net debt gearing gearing ratio calculate net debt percentage total equity cer represent growth constant exchange rate sterling represent growth actual exchange rate calculation result major restructuring describe note financial statement presentation financial statement gsk annual report pp weiver ssenisub history development company result major restructuring glaxosmithkline plc public limited company incorporate october board approve implementation th december english law share list detailed formal plan gsk announce significant new london stock exchange new york stock exchange operational excellence programme improve effectiveness th december company acquire glaxo wellcome productivity operation second formal plan represent plc smithkline beecham plc english public limit significant expansion operational excellence programme company way scheme arrange ment merger approved board announce february company gsk subsidiary associate expansion approve board announce undertaking constitute major global healthcare group engage february total cost implementation creation discovery development manufacture marketing expand programme expect increase billion pharma ceutical consumer healthrelate product approximately billion incur period programme expect deliver total gsk corporate head office london annual pretax saving approximately billion headquarter research triangle park north carolina saving realise business gsk present restructure operation country product sell cost incur solely direct result operational excellence country programme separate column income statement title annual report summary major restructuring addition restructuring cost operational excellence programme major restructuring column report annual report glaxosmithkline plc year income statement include restructuring cost incur solely end st december prepare accordance united direct result restructure programme follow kingdom requirement approve board director relate material acquisition operation acquire th february publish th february business overlap extensively gsk exist operation summary year intend shareholder need billion million acquisition reliant pharmaceutical detail annual report produce separate december billion billion acquisition document issue shareholder summary stiefel laboratory july acquisition constitute set summary financial statement define october meet criterion section company act annual report group result cost operational excellence issue shareholder elect receive programme acquisitionrelate restructuring programme document available gsk website meeting criterion describe describe result report glaxosmithkline group gsk mean major restructuring presentation gsk intend glaxosmithkline plc subsidiary undertaking company apply consistently future major restructuring programme mean glaxo smithkline plc glaxosmithkline share mean material impact gsk operating result ordinary share glaxosmithkline plc p american depositary manner gsk business conduct adopt share ad represent glaxosmithkline share clearly group result cost restructure programme management believe brand name presentation assist shareholder gain clear understanding brand name appear italic report group financial performance make projection trademark own andor license glaxosmithkline future financial performance result include cost associate company exception baycol levitra virtue size nature limited comparative value trademark bayer benlysta trademark human genome presentation consistent way management science bonivabonviva trademark roche citrucel trademark assess group financial performance merrell pharmaceuticals volibris trademark gilead nicoderm trademark elan johnson johnson merrell novartis cer growth sanofiaventis glaxosmithkline prolia trademark amgen order illustrate underlying performance group vesicare trademark astella pharmaceutical country practice discuss result term constant exchange rate yamanouchi pharmaceutical certain country cer growth represent growth calculate exchange certain country licence group rate determine result overseas company sterling remain unchanged previous currency year cer represent growth constant exchange rate currency influence group result remain represent growth actual exchange rate dollar euro yen sterling detail exchange rate group give note exchange commentary report present term cer rate state average sterling exchange rate weak exchange rate dollar euro yen compare group operate country earn revenue result significant currency movement incur cost currency result group see q year end sterling exchange rate actually report sterling affect movement exchange rate strong currency compare sterling currency average exchange rate st december prevail period translate result cash flow overseas subsidiary associate joint venture sterling period end rate translate net asset entity gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp product intellectual property competition pharmaceutical product pharmaceutical industry introduction new gsk principal pharmaceutical product currently direct product process competitor affect price main therapeutic area include dermatological follow result change pattern product use assurance acquisition stiefel laboratory july description product outmoded notwithstanding patent product page analysis sale therapeutic trademark protection addition increase government area pressure physician patient use generic pharmaceutical brandname medicine increase competition competition product long protect patent principal pharmaceutical competitor range small large intellectual property pharmaceutical company substantial resource company intellectual property key business asset company effective legal protection intellectual property abbott laboratories patent trademark register design copyright domain amgen registration critical ensure reasonable return investment rd astrazeneca bristolmyer squibb patent eli lilly policy try obtain patent commercially important protectable invention discover develop rd johnson johnson activities patent protection new active ingredient available merck major market patent obtain new drug novartis formulation manufacturing process medical use device pfizer administer product obtain patent product prevent challenge roche holding expire grant patent mean sanofiaventis issue patent necessarily hold valid enforceable pharmaceutical subject competition court court determine patent hold invalid product period patent protection non infringe unenforceable protect market patent generic version manufacturers party entry prior patent expiry significant litigation generic product typically incur significant research concern challenge summarise note development education marketing development cost financial statement legal proceeding consequently able offer product considerably life patent country year file low price brand competitor research date long development time pharmaceutical development base company normally seek achieve product result substantial patent life sufficiently high profit margin sale volume period launch market include usa patent protection repay original investment europe possible lose time restore generally substantial generate profit fund research lead variation patent life actually future competition generic product generally occur available product market certain country patent major market expire increasingly patent challenge provide period datum market exclusivity prevent prior patent expiry claim innovator patent party company rely clinical trial datum enter valid andor infringe generic product market copy period exclusivity follow loss patent protection generic product rapidly capture large share market particularly usa patent expiry date significant product follow table date provide expiry patent believe remain competitive dependent usa major european market active ingredient discovery development new product indicate include extension patent term include effective marketing exist product paediatric use usa available gsk annual report pp weiver ssenisub product intellectual property competition product compound indication major patent expiry date competitor brands usa eu respiratory seretideadvair salmeterol xinafoate asthmacopd singulair symbicort fluticasone propionate spiriva asmanex pulmicort combination combination foster diskus device diskus device flixotideflovent fluticasone propionate asthmacopd qvar singulair devices devices serevent salmeterol xinafoate asthmacopd foradil spiriva diskus device device veramyst fluticasone furoate rhinitis nasacort antiviral epzicomkivexa lamivudine abacavir hivaids truvada atripla combination combination combivir lamivudine zidovudine hivaids truvada atripla combination combination trizivir lamivudine zidovudine hivaids truvada atripla abacavir combination combination agenerase amprenavir hivaids prezista kaletra reyataz lexiva fosamprenavir hivaids prezista kaletra reyataz epivir lamivudine hivaids truvada atripla ziagen abacavir hivaids truvada atripla valtrex valaciclovir genital herpe coldsore famvir expire expire shingle zeffix lamivudine chronic hepatitis b hepsera relenza zanamivir influenza tamiflu central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expired expire seroxatpaxil paroxetine depression effexor cymbalta expire expire anxiety disorder lexapro wellbutrin sr bupropion depression effexor cymbalta expire expired lexapro requip ropinirole parkinson disease mirapex expire restless leg syndrome use treat parkinson disease treximet sumatriptan naproxen migraine zomig maxalt relpax na combination use cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax finasteride lovaza omega acid ethyl ester high triglyceride tricor na formulation coreg cr carvedilol phosphate mildtosevere heart failure toprol xl na hypertension leave ventricular dysfunction post mi fraxiparine nadroparin deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep arixtra fondaparinux deep vein thrombosis lovenox fragmin expire expire pulmonary embolism innohep vesicare solifenacin overactive bladder detrol detrol la enablex na sanctura uk irish patent revoke court generic competition possible follow conclusion patent proceeding gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp product intellectual property competition product compound indication major patent expiry date competitor brands usa eu metabolic avandia rosiglitazone maleate type diabetes actos januvia avandamet rosiglitazone maleate type diabete competact janumet metformin hci actoplus meet antibacterials augmentin amoxicillinclavulanate common infection expire expire potassium altabax retapamulin skin infection oncology emesis arzerra ofatumumab refractory chronic mabtherarituxan lymphocytic leukaemia hycamtin topotecan ovarian cancer small cell doxil gemzar lung cancer cervical cancer promacta eltrombopag idiopathic thrombocytopenic nplate revolade purpura tykerbtyverb lapatanib advanced metastatic herceptin breast cancer positive patient votrient pazopanib metastatic renal cell carcinoma sutent nexavar vaccine infanrixpediarix diphtheria tetanus pertussis diphtheria tetanus pertussis pentavac pentaxim polio hepatitis b hepb polio hepatitis b hepb pediacel pentacel inactivated antigen fluarix split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type b antigen influvac aggripal fluad flulaval split inactivated influenza virus seasonal influenza vaxigrip mutagrip fluzone subtype type b antigen influvac aggripal fluad cervarix hpv virus like particle human papilloma virus gardasil silgard vlp adjuvant mpl type aluminium hydroxide synflorix conjugate pneumococcal invasive pneumococcal prevenar na polysaccharide disease rotarix live attenuate rotavirus rotavirus gastroenteritis rotateq strain gip trademark gsk commercial product protect register trademark major market local variation example usa trademark advair cover product sell eu seretide trademark protection generally extend long trademark renew necessary gsk trademark important maintain brand identity product gsk enforce trademark right prevent infringement consumer healthcare product portfolio comprise main category overthecounter otc medicine oral healthcare nutritional healthcare sale key consumer healthcare product show lead consumer healthcare product include follow otc medicine alli licence weight loss medicine available prescription launch usa europe panadol global paracetamolacetaminophen analgesic smoking control product nicoderm niquitin cq nicabate usa nicorette brand include breathe right nasal strip tum citrucel contac fiberchoice gsk annual report pp weiver ssenisub product intellectual property competition oral healthcare global manufacturing supply gms aquafresh range toothpaste toothbrushe people work gms network mouthwash site country gms support commercial ambition sensodyne range toothpastes toothbrushe gsk deliver quality medicine consumer product mouthwash include pronamel protect patient customer world acid erosion scale manufacturing gsk huge manufacture b iotene acquire late lead treatment billion pack year different presentation dry mouth include tablet creamsointment inhaler injection liquid polident poligrip corega denture care cleanser sterile supply market adhesive billion spend gms production ther brand include odol macleans dr good gms operate procurement operation behalf group spend billion annually external supplier nutritional healthcare purchase active ingredient chemical intermediate package lucozade range energy sport drink component partfinishe finished product h orlick range milkbase malt food internal customer seek opportunity chocolate drink grow business focus costcompetitive ribena blackcurrant juicebase drink supply quality product meet ambition work consumer healthcare competition diligently leverage network site contractor builtin flexibility sustain future growth adapt emerge gsk hold lead global position key consumer product commercial business model increasingly rigorous external area worldwide second large otc medicine regulatory environment continue leverage technology large oral healthcare nutritional healthcare hold support process understand control capability leading position uk india ireland primary supply site supply high quality competitively price environment consumer healthcare business bulk active focus improvement primary technology operate challenging process new product global supply site work consumer demand well quality well value closely rd development team ensure right improve performance technical competency place support rapid successful r etailer consolidate globalise new product introduction site serve focal point strengthen negotiation power develop introduce new secondary manufacturing technology site regional pharma supply division focus cycle times innovation reduce reduce cost allow gsk compete effectively main competitor include major international company market consumer healthcare site deliver highquality colgatepalmolive johnson johnson procter gamble unilever competitively price product support rapid new product pfizer addition small company introduction highly innovative competitive business compete gsk certain market new technology fundamental platform drive innovation lower cost provide flexibility operation major competitor product otc medicine embed new way work simplify n usa metamucil laxative pepcid indigestion business achieve great efficiency focus private label smoking control product customer service include support new product launch n uk lemsip cold remedy nurofen anadin strong compliance culture commitment health safety analgesic nicorette nicotinell smoking control environment commitment develop people treatment deliver strong result gsk external oral healthcare major competitor colgatepalmolive environment demand colgate procter gamble crest vaccine manufacturing manage integral nutritional healthcare major competitor horlick biological business particularly complex requires use ovaltine milo malt food chocolate drink competitor innovative technology living microorganism sophisticated ribena primarily local fruit juice product lucozade quality assurance quality control procedure place compete energy drink ensure vaccine quality safety include animal use accord health authority requirement biological nature individual health authority subject vaccine second control guarantee high quality standard gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp research development research development pharmaceutical deliver medicine patient gsk rd build strong pipeline potential progression latestage development consist optimise new medicine industry pharmaceutical rd physical product property medicine ie actively manage project human clinical trial chemical step formulation require manufacture globe deliver pipeline patient safely efficiently deliver large scale study human number goal confirm efficacy safety combination result step regulatory file submission discover potential medicine regulatory agency approval patient use ur early research identifie biological target interfere responsibility regulatory team particular disease create small molecule biopharmaceutical interact disease target medicine development organise therapy area medicine development centre mdcs cardiovascular refocus good science lead create metabolic infectious disease neuroscience respiratory entrepreneurial environment discovery building mdc ultimate accountability develop success exist model centre excellence drug experimental drug regulatoryapprove medicine discovery cedd group focus define therapy patient mdcs responsible create value area take cedd model step create execution product development plan ensure number small discovery performance unit dpus strong partnership rest rd gsk particular cedd small integrate group cedd preclinical development regulatory scientist focus particular disease pathway commercial group manufacture dpus gsk number dpus cedd vary accord science standalone dpus emphasis simplification clinical create explore new therapy area ophthalmology development organisation focus investment new way work academic dpu form project spend versus infrastructure reflect increase drug discovery collaboration academia focus rd return investment cedd year year business plan adapt structure maximise chance succeed define overall budget clear objective business rds unit oncology biopharmaceutical plan review end year integrate discovery late stage development discovery organisation track deliver gsk objective group allow build critical mass growth area gsk focus deliver strong pipeline w e continue identify compound company integrate unit fully set enhance portfolio create innovative successful progressing pipeline collaboration ensure see partner pipeline chart choice large small company internal rd expertise allow strong position business china discovery team focus neurodegeneration development make able complement internal neuroinflammation celebrate second anniversary pipeline acquisition inlicense comarkete grow approximately employee copromotion deal future option collaboration develop impressive early stage portfolio product enter clinic team establish clinical capability gsk annual report pp weiver ssenisub research development governance vaccine rd key project reach significant milestone review gsk active field vaccine research development month product management board responsible production portfolio vaccine approve determine medicine meet criterion pass marketing scientist devote discover phase development innovative vaccine contribute health wellbee people generation world discovery gsk chief medical officer work global safety development new vaccine complex process require board ultimately accountable oversight major decision longterm investment vaccine clinical patient safety global safety board responsible development strong vaccine pipeline internally approve pivotal study investigate issue industry vaccine traditionally ward relate patient safety arise development programme illness gsk vaccine division work develop therapeutic postlaunch information gsk clinical trial widely immunotherapeutic aim educate patient immune easily available clinical study register gsk website system identify attack cancer cell highly specific manner oversight strategic issue budget management vaccine discovery involve collaboration academia rd own rd executive team radex biotech industry identify new vaccine antigen disease develop world express yeast bacteria mammalian cell purify continued investment research disease develop high level follow formulation clinical world essential longterm improvement lot vaccine involve mix antigen select health people live region gsk novel proprietary adjuvant system combination response challenge operate drug discovery unit select adjuvant design elicit appropriate immune base tre canto spain focus malaria response specific antigen right combination antigen tuberculosis additional rd site usa uk adjuvant system help body mobilise effective focus development new medicine treat hivaid immunological pathway design provide maximum drug resistant bacteria vaccine research conduct protection specific disease target population rixensart belgium formulate candidate vaccine evaluate safety rd effort address prevention efficacy perspective different phase preclinical treatment world health organization test clinical trial involve healthy individual priority infectious disease range safety analysis small group volunteer phase dose adjustment proof concept phase ii largescale safety efficacy analysis phase iii result obtain clinical trial datum development quality largescale production process facility combine regulatory file submit authority country vaccine available launch post marketing study considerable size set assess vaccination programme monitor vaccine safety gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp research development animal research ethical regulatory scientific reason research animal remain small vital research development new medicine vaccine use animal alternative constantly strive reduce number commit maintain high standard humane care treatment laboratory animal undertake internal external review assure standard vast majority experimental method use animal actively engage research develop validate test avoid use animal research reduce number need animal research measure take prevent minimise pain distress decide initiate funding study great ape th october voluntary decision provide tangible demonstration commitment rs animal research advocate replacement reduction animal research refining experiment improve animal welfare understand use animal research purpose command high level public interest public policy position care ethical use animal research information report available website research development consumer healthcare continuous creation development innovative product keep brand relevant vibrant valuable portfolio span major category otc medicine oral healthcare nutritional healthcare major brand dedicate rd team include regulatory partner work alongside commercial brand team colleague officefree hub environment foster collaboration fast decisionmake hub quickly preferred way work innovation centre weybridge uk parsippany usa expand model rapidly key consumer healthcare territory include china india gsk annual report pp weiver ssenisub research development diverse product development pipeline therapeutic compound key late stage project highlight comprise biopharmaceutical arzerra ofatumumab new chemical entity new combination formulation exist asset advanced status arzerra ofatumumab show include approval arzerra ofatumumab benlysta belimumab key ofatumumab phase iii otelixizumab large comparative study compound versus placebo andor prolia denosumab establish treatment patient establish clinical benefit syncria safety cardiovascular metabolic arixtra file follow successful phase iii trial file product avandamet xr approval regulatory authority avandia simvastatin approval darapladib approval grant begin market neuroscience almorexant medicine vaccine horizant pipeline page website retigabine oncology avodart duodart avodart alpha blocker votrient pazopanib tyverbtykerb revoladepromacta revoladepromacta revoladepromacta tyverbtykerb tyverbtykerb tyverbtykerb tyverbtykerb votrient pazopanib votrient pazopanib votrient pazopanib respiratory relovair vaccine cervarix magea asci magea asci menhibrix hibmencytt mosquirix new generation flu vaccine nimenrix menacwytt simplirix find visit inlicense alliance relationship party wwwgskcom note financial statement post balance sheet event asci antigen specific cancer therapeutic gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp research development indication phase file approve chronic lymphocytic leukaemia refractory patient diffuse large b cell lymphoma relapse patient follicular lymphoma refractory patient systemic lupus erythematosus rheumatoid arthritis type diabetes postmenopausal osteoporosis type diabete treatment acute coronary syndrome type diabetes extend release type diabete atherosclerosis insomnia restless leg syndrome epilepsy partial seizure reduction risk prostate cancer benign prostatic hyperplasia fix dose combination inflammatory breast cancer idiopathic thrombocytopaenic purpura chronic liver disease induce thrombocytopaenia hepatitis c induce thrombocytopaenia breast cancer line therapy breast cancer adjuvant therapy gastric cancer head neck squamous cell carcinoma resectable disease renal cell cancer ovarian cancer maintenance therapy sarcoma copd copd cervical dysplasia cancer prophylaxis cause hpv treatment melanoma treatment nonsmall cell lung cancer neisseria meningitis group c disease haemophilus influenzae type b disease prophylaxis malaria prophylaxis plasmodium falciparum seasonal influenza prophylaxis elderly neisseria meningitis groups c w disease prophylaxis genital herpe prophylaxis gsk annual report pp weiver ssenisub employee gsk value behaviour employee number region change healthcare market past decade necessitate usa transformation business model europe customercentric innovative perform collective organisation determine success order effective rest world grow complexity exponential speed change external environment gsk need create internal learning culture embody gsk value behaviour detail gsk value behaviour corporate responsibility report recruitment talent management leadership inclusion diversity development commit employment policy free discrimination like year recruit retain develop exist potential employee ground age employee critical enhancing sustain race ethnic national origin gender sexual orientation faith performance reputation proactive talent acquisition initiative disability gsk commit offer people disability underpin ability attract specialist leadership talent access range recruitment career opportunity externally assessment process align core set effort retain support employee competency ethic integrity central disabled work gsk detail diversity global view talent strategic capability require look measure corporate responsibility report quality depth breadth talent world healthy safe high performance need good succession plan senior role critical position organisation maintain meet mission strategy employee health robust leadership strategy identify develop highly skilled performance initiative focus health factor enable leadership cadre use systematic discipline approach employee perform high level sustain energy leadership development provide tool programme help engagement programme develop deliver leader master skill need meet customer employee health strategy range traditional immunisation investor expectation launch line leader smoking control weight management cuttingedge programme new leader new gsk new programme area team personal resilience manage people launch gskwide mentor ergonomic energy performance programme scheme senior leader mentor available language design address root individual cause excessive work pressure low energy engagement work home compliment commitment performance reward flexible working enable employee good work performance development planning pdp process mean environment help integrate work employee businessaligne objective behavioural personal life detail scope impact goal reward system support high performance help programme corporate responsibility report attract retain good people performancebase pay bonus sharebase equity plan align employee interest business target communication employee involvement communication channel design employee inform engaged involve activity area organisation encourage twoway open honest communication employee improvement web usage technology engage employee feedback monitoring mechanism major communication event qa feedback facility core feature web communication channel broad process include internal online opinion survey employee invite provide feedback individual empowerment employee engagement company value business evolve change affect employee remain committed consulting change number internal consultation forum discussion european employee consultation forum similar body country national practice gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp responsibility commitment corporate responsibility programme country gsk committed connect business decision ethical introduce orange card provide discount social environmental concern corporate responsibility certain gsk prescription medicine eligible patient number integral embed way gsk business country nature discount vary country way healthcare system operate improve access medicine patient advocacy access healthcare develop world easy solution challenge provide patient advocacy initiative demonstrate significant sustainable access healthcare develop country poverty progress inception initially launch single big barrier country people programme critical initiative gsk patient food access clean water supply hospital clinic advocacy team usa europe share good practice receive treatment healthcare professional care establish process optimise interaction patient group typically relationship provide mutual opportunity learn patient need priority patient group commit play address develop understand drug development challenge healthcare challenge develop world take innovative responsible sustainable approach continue partner patient group gsk make vital contribution develop country healthcare common issue advocate access medicine treatment action number area include preferential increase funding health program improve health pricing antiretroviral antimalarial tiere pricing care delivery consider trustworthy partner vaccine invest rd target disease particularly patient group work patient group affect develop world community trade association increase transparency investment activity partnership foster effective interaction healthcare seek innovative partnership work community solution cover contribution improve access work partner underserve community medicine extensively corporate responsibility report develop develop world support programme clear leader access medicine atm index innovative sustainable bring real benefit produce atm foundation continue community global community investment build product pricing partnership commitment help million compare million like improve healthcare develop world february like basis increase expansion patient announce series commitment un define list assistance programme increase humanitarian product donation develop country include flexible approach scale donation albendazole lymphatic intellectual property research neglect disease filariasis lf programme give comprise product commitment invest healthcare infrastructure price cap donation million cash give million inkind patent medicine significant increase resource donation million plus cost million manage global community need support rd provide deliver community programme country access resultant medicine vaccine product donation include million gsk patient assistance programme million worth albendazole achieve sustainable progress occur programme million humanitarian product donation significant barrier stand way well access product donation value cost healthcare tackle share responsibility sector average cost good wholesale price wac global society government international agency charity accurate reflection cost gsk believe academic institution pharmaceutical industry pharmaceutical company adopt practice access medicine develop world comparative purpose total value donation programme usa wac product million compare work provide access medicine people million limited financial resource prescription operate single charitable foundation drug insurance community investment programme number uninsured americans qualify medicare countrybase foundation grant include medicaid gsk pharmaceutical company create investment total rx access programme qualified individual offer reduction pharmacy cost medicine million rx access cardholder save million gsk annual report pp weiver ssenisub responsibility cash giving target primarily health education phase initiative follow phase programme personal hygiene sanitation education initiate provide education hundred thousand school child country improve health hygiene fight infectious disease health expand programme uganda extend phase education slum area mumbai india bring phase art culture uk pilot school hounslow near environment global headquarters humanitarian product donation donate essential product antibiotic nonprofit partner include americare direct relief global health programme international map international project hope support humanitarian relief effort community healthcare follow eliminate lymphatic filariasis lf series natural disaster asiapacific region central effort eliminate lf world disable america total value international humanitarian product disease continue close partnership government donations million average cost country disease endemic world health organization partner organisation founding immediately follow devastating earthquake strike partner leader global elimination effort haiti january gsk provide donation medicine commit donate antiparasitic drug million stock hold warehouse non albendazole require reach billion people risk profit partner continue donate request medicine country million albendazole treatment support medium longerterm need donate donate country donate billion british red cross support deployment albendazole treatment global elimination programme mass sanitation unit water sanitation need start community initiative positive action hivaid dedicated strengthen fabric community positive action pioneer global programme work provide health education initiative support community affect aid start support local civic cultural institution improve quality communitybase organisation deliver effective hiv aids life uk contribute million education prevention healthcare service july continue programme charitable activity support announce creation new positive action child organisation health medical research science education fund fund million available year art environment help prevent mothertochild transmission hiv support programme north america national local level focus orphan vulnerable child new fund complement improve public education increase access healthcare ongoing work support hiv community child homeless healthcare preventionaccess launch viiv healthcare positive action programme people deal breast gynaecologic cancer gsk impact manage new hivfocuse company award recognise organisation significantly improve glaxosmithkline african malaria partnership health local community expand coalition malaria create malaria uk philadelphia reach community near research advocacy programme mobilise malaria continue triangle park north carolina facility total funding north increase awareness malaria mobilise resource american programme million target country uk belgium france ethiopia mozambique gsk continue communitymark company award cameroon year announce launch excellence community investment award phase african malaria partnership project focus year community health worker educationbehaviour change community new malaria grant award total commitment million year include partnership save child uk kenya family health international ghana african medical research foundation amref tanzania plan parenthood federation nigeria gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp responsibility health initiative contribution improve healthcare include follow grant nonprofit partner purpose grant children health fund continue referral management initiative rmi usa ensure continuity specialist medical care highrisk child homeless general support gsk impact award recognise excellence nonprofit community health uk usa organisation charity receive unrestricted grant work deal diverse difficult social issue access healthcare medical research charity support medical research programme uk education initiative nonprofit partner purpose grant institute competitive workforce improve education create skilled workforce future usa working partnership broad business coalition staff chamber commerce science summer teach basic scientific concept inspire school child philadelphia pittsburgh north carolina enquirybase science education programme project enthuse support continue professional development cpd science uk teacher ultimately encourage child engage science pursue career science technology royal society chemistry support programme target science teacher uk uk chemistry specialist provide key skill confidence effective chemistry teach information gsk grant programme available wwwgskcom employee involvement employee encourage contribute local community employee volunteer scheme support include employee time cash donation charity employee volunteer match gift programme gsk match gift program match employee retiree gift value million plus million united way campaign gsk programme provide grant organisation employee volunteer ukbased nonprofit organisation gsk make difference programme groupwide volunteer initiative launch gsk employee pay day year volunteer good cause employee support wide range charity project include work local school shelter homeless community garden nursing home aid community affect natural disaster gsk pulse volunteer partnership new initiative launch april empower highperforme employee volunteer period month lend professional expertise pulse volunteer work fulltime partner nongovernmental organisation ngo create sustainable change impoverished community world intake pulse volunteer work different country nongovernmental organisation employee continue receive gsk salary placement represent inkind donation gsk annual report pp weiver ssenisub responsibility responsibility environment mass efficiency glaxosmithkline environmental responsibility span demand increase efficiency use material priority raw material convert product increase target originally introduce aiming impact use efficiency new product launch time set mass efficiency target vision environmental sustainability ultimately transform manufacturing site achieve additional improvement business follow principle industrial ecology process rd longterm aspiration renewable resource convert waste byproduct achieve efficiency time typical level input process pharmaceutical industry reduce input material step goal optimise efficiency waste process minimise use energy resource mass efficiency average waste generate need reduce carbon dioxide emission energy contribution tackle climate change environmental activity oversee sustainability council compose senior executive manage environmental issue occupational health safety management system align recognise international standard central audit group include environmental issue routine audits site process strategy plan strategy element begin embed environmental fundamental energy management waste reduction eliminate adverse impact operation second stage embrace sustainability business develop culture product stewardship climate change sustainable resource use strategy require transparency big direct climate impact come propellant inform stakeholder action performance inhaler disease asthma reduce impact provide full disclosure corporate responsibility report replace cfc gas continue research way minimise tenyear strategic plan target refresh greenhouse gas release product year update plan new implement climate change challenge target key target programme ambitious target emission energy pursue progress include use operation transport aim reduction unit sale energy use emission reduction unit sale cut operation transport achieve level emission energy consumption reduction energy use emission unit sale fall respectively reduction follow year limited progress mean need average material efficiency product transfer outstanding performance meet interim target research development current average energy reduction identify key objective annual reduction water use unit sale business result energy consumption include achieve reduction key business metric remuneration senior manager manufacturing link achievement energy reduction target create central fund finance energy saving project climate change team identify energy saving project helped year avoid tonne greenhouse gas emission ycneiciffe ssam stage stage stage stage transfer manufacture key average weight average gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp responsibility mitigate climate change impact aim identify way respond change disease pattern cause climate change gsk carbon footprint million tonne co equivalent key climate impact use inhaler patient climate impact operation energy climate impact travel transport climate impact environmental concern sustainability require holistic view especially relate optimal use resource water particularly important natural resource recognise business play positive role manage sustainably endorse united nations ceo water mandate water consumption fall unit sale exceed target target improve quality wastewater reduce waste disposal emission air exceed target area track completely eliminate ozonedeplete cfc end environmental audit score move close target packaging provide opportunity reduce resource use project reduce environmental impact packaging instance light toothpaste cap save tonne plastic year read environmental performance aspect sustainability corporate responsibility report view line wwwgskcom gsk annual report pp weiver ssenisub regulation regulation pharmaceutical regulation consumer healthcare region countryspecific law regulation define consumer healthcare industry subject national regulation information need safety efficacy comparable prescription medicine test pharmaceutical product govern testing approval manufacturing labelling marketing product approval manufacturing labelling market high standard technical appraisal frequently involve lengthy regulatory requirement major factor approval process new product launch determine marketable product january see historymake otc industry successfully develop approve european medicine agency grant centralised highly regulate environment increase approval weight loss medicine alli result cooperation exchange information major paneuropean launch alli licence weight loss regulatory authority consequently treatment available prescription eu transform structure regulatory affair department country additional national licence alli well match global regulatory environment grant approval country operate exist eu international group value money integrate department global regulatory affair change enable effectively formulate global payer world concern cost strategy obtain regulatory approval gsk product base healthcare pricing medicine requirement regional expertise new structure well satisfy healthcare purchaser value money position interact regulatory customer additional hurdle product acceptance dynamic globallyconnecte external environment regulatory test safety efficacy quality evaluation benefit risk continue price control paramount consideration approval new drug country price pharmaceutical product usa increase focus safety medicine control law government influence price fda amendments act mandate rigorous fda review control national healthcare organisation bear safety approval postmarkete phase large cost supply medicine consumer product fda examine well way identify recent government healthcare reform country france counterfeit medicine communicate new risk information spain germany restrict pricing reimbursement public remain engaged key area interest currently usa government price control europe new regulation aim strengthen safety private sector purchase federal law require pharmaceutical monitoring medicine improve citizen access reliable manufacturer pay prescribe rebate certain drug information medicine strengthen eu law protect eligible reimbursement state federal citizen well threat pose fake medicine healthcare programme president congress discussion eu legislator preparation continue dedicate year legislative process reform implementation new rule aim simplify americas healthcare system drive cost improve quality harmonise eu regulatory framework change increase access million americans health authorise medicinal product hope change insurance reform potential create positive minimise inefficiency procedure reduce overall change healthcare system expand access gsk administrative burden product potential increase prescribe regulatory environment emerge market asiapacific rebate governmentrun programme change continue evolve number country continue balance private public sector purchase pressure develop regulatory review system gsk actively participate control healthcare cost need health reform number specific regional national regulatory continue issue crossborder trade initiative provide opportunity meaningful scientific acceleration generic market comparative effectiveness regulatory dialogue industry agency research pharmaceutical pricing continue stakeholder gsk continue include broad set patient ongoing reform debate usa fortunately gsk position population number country medicine constructive contributor debate development programme order increase global patient access increase recognition chronic disease primary new innovative medicine optimise regulatory approval driver healthcare spend pharmaceutical product deliver important intervention help hold healthcare cost gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp world market economy outlook world market pharmaceutical world economy world economy deteriorate early global pharmaceutical sale billion compare international financial crisis deepen economy billion country contract year emerge market show growth world market value geographic region bn total aggressive cut official interest rate fiscal stimulus measure usa national initiative support international banking system europe lead improvement end year france economic recovery likely remain fragile uneven emerge market provide strong growth germany italy equity price strengthen ftse index uk increase dow jones industrial average rest world inflationary pressure remain control emerge market modest increase inflation expect asia pacific potential healthcare reform usa create japan uncertainty strategy design canada group position able deliver longterm sustainable total financial performance despite uncertainty market growth cer basis usa europe outlook rest world gsk return sale growth company strategy th september gsk world deliver confident prospect gsk believe pharmaceutical product seretideadvair valtrex move position deliver goal longterm sustainable financial performance world market value therapeutic class bn total central nervous system cardiovascular alimentary tract metabolic antineoplasticimmunomodulatory antiinfective bacterial viral fungal exclude vaccine respiratory note datum base month th september datum market share market growth rate gsk estimate base recent datum independent external source appropriate value sterle relevant exchange rate figure quote product market share reflect sale gsk licenseespp weiver ssenisub financial review pharmaceutical turnover cardiovascular urogenital growth rate include review turnover constant cardiovascular urogenital sale increase billion exchange rate cer state sterling growth continue strong growth key product arixtra rate find table pharmaceutical turnover million avodart million lovaza therapeutic area geographic region million partly offset generic competition pharmaceutical turnover grow billion pharmaceutical coreg growth help sale pandemic relate product metabolic include relenza hn vaccine product regional basis metabolic sale decrease billion usa decline reflect continued erosion product generic competition strong performance sale avandia million continue decline deliver europe emerge market asia region bonvivaboniva sale decline usa pacificjapan sales contribution stiefel grow europe rest world acquire nd july total million oncology emesis pharmaceutical turnover therapeutic area oncology emesis sale increase billion gsk turnover grow impact generic tyverbtykerb million grow strongly europe competition range gsk product low avandia sale rest world follow product approval gain decline hiv business offset strong growth zofran decline result generic competition key product seretideadvair avodart lovaza relenza vaccine franchise include hn pandemic vaccine vaccine vaccine sale increase billion respiratory respiratory sale increase billion pandemic vaccine sale million record year deliver fourth quarter gsk seretideadvair grow billion especially strong partner government respond hn pandemic growth emerge market million japan million ventolin sale grow sale gsk new synflorix vaccine total million reflect million drive performance usa sale launch market begin shipment double million veramyst sale rise brazilian government year billion agreement million sign august strong contributor growth year include boostrix million cervarix antiviral million rotarix million antiviral increase billion partially offset performance sale infanrixpediarix fall relenza sale million million million primarily result continued impact reflect successful capacity expansion meet government increase competition dtpa sector usa hepatitis order world strong retail performance japan vaccine sale fall million million sale valtrex decline billion competitor product return market result generic competition product usa begin november sale hiv medicine total billion year epzicom sale grow million offset decline rest portfolio viiv healthcare new specialist hiv company establish gsk pfizer officially launch rd november cns cns sale decrease billion majority gsk cns franchise impact generic competition usa wellbutrin decline primarily reflect sale wellbutrin xl usa biovail second quarter gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major product total cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarixflulaval flu pandemic hepatitis engerix fendrix havrix twinrix infanrix pediarix rotarix synflorix stiefel product cer represent growth constant exchange rate represent growth actual exchange rate turnover quarter give financial record page gsk annual report pp weiver ssenisub financial review regional analysis consumer healthcare turnover turnover report table represent sale invoice growth gsk local entity customer local market plus total cer copromotion income market overthecounter medicine growth alli cer breathe right usa cold sore franchise europe nicotine replacement therapy emerge market panadol franchise asia pacificjapan tums trade oral healthcare aquafresh franchise cer represent growth constant exchange rate represent growth biotene actual exchange rate denture care include stiefel sensodyne franchise usa nutritional healthcare sales usa decline billion principally reflect lucozade continue decline avandia competition horlick infanrixpediarix return market competitor ribena hepatitis franchise generic competition significant product lamictal imigran valtrex requip coreg addition wellbutrin xl sell biovail cer represent growth constant exchange rate represent growth q decline partly offset significant sale actual exchange rate turnover quarter give financial record page relenza pandemic vaccine double ventolin sale good growth lovaza contribution recently total consumer healthcare sale year rise launch product boostrix rotarix billion growth region category europe otc medicine sales europe increase billion continued otc product sale grow billion drive sale growth seretide relenza particularly strong vaccine panadol million alli growth drive pandemic vaccine offset impact double million result launch europe generic competition number product continue price begin april sale nicotine replacement therapy cut government region product decline emerge market oral healthcare sale emerge market increase billion sale oral healthcare product rise billion sensodyne strong growth region therapeutic area helped perform strongly sale million denture care acquisition ucb bms business different sale grow million sale aquafresh decline country region reduction white tray market offset growth aquafresh toothpaste brand help launch asia pacificjapan new isoactive product sale asia pacificjapan grow billion reflect continue seretideadvair growth strong relenza sale particularly nutritional healthcare retail market japan strong vaccine growth nutritional healthcare sale grow billion drive strong performance horlick million partly offset decline lucozade sale million impact low sale impulse market uk market gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review result major restructuring restructuring activity follow relate total result acquisition nature undertake operational excellence programme carry october board approve implementation follow detailed formal plan management consider detailed formal plan gsk announce significant new appropriate present cost restructuring activity operational excellence restructure programme second formal manner acquisition stiefel laboratories inc plan represent significant expansion operational july acquisition year meet excellence programme approve board criterion set acquisition year announce february conduct series cost incur direct result related restructuring business review gsk announce expansion programme include major restructure column restructure programme deliver billion incremental restructuring cost expect incur direct result pretax saving approximately saving acquisition estimate approximately million direct line enhance profitability million charge restructure remainder reinveste business charge cost incur direct result acquisition reliant incremental programme expect total billion pharmaceuticals inc acquisition october phase balance meet criterion set charge total approximately cash expenditure pay asset writedown cumulative saving new programme phase approximately follow group result cost operational excellence million million majority programme acquisitionrelate restructuring programme balance meeting criterion describe present separate column income statement describe restructure programme comprise detailed formal result major restructuring presentation plan cover area gsk business include manufacturing gsk intend apply consistently future major restructuring sell rd infrastructure estimate total cost programme material impact gsk operating result approximately billion expand programme expect manner gsk business conduct deliver annual pretax saving approximately billion adopt clearly group result time substantially complete approximately cost restructure programme management cost incur st december believe presentation assist shareholder gain approximately expect incur clear understanding group financial performance balance total approximately cost make projection future financial performance result expect cash expenditure expect include cost virtue size nature limited accounting writedown comparative value presentation consistent way uncertainty exist exact time cash management assess group financial performance outflow result potential future exchange rate restructuring cost incur solely direct result fluctuation element restructure operational excellence programme restructure programme subject employee consultation procedure programme follow reliant stiefel acquisition make difficult predict precision procedure report major restructuring column income complete majority remain cash statement restructuring cost principally arise payment expect give impairment property plant equipment termination extent cost operational excellence restructure employment contract staff redundant programme management believe material impact restructuring activity set note financial gsk operating result manner gsk statement major restructuring programme asset impairment business conduct gsk present restructure cost staff redundancy account million incur solely direct result operational excellence million restructuring cost incur report restructure programme amount major restructure column million tax million separate column income statement title major restructure remain cost million arise miscellaneous expenditure incur solely direct result addition restructuring cost operational excellence restructuring programme include termination programme major restructuring column income lease accelerate depreciation site closure cost consultancy statement include restructuring cost incur solely direct project management fee cost arise gsk result restructure programme follow relate ongoing operating activity report major material acquisition operation acquire business restructure column overlap extensively gsk exist operation gsk annual report pp weiver ssenisub financial review restructuring cost arise solely direct result sell general administration operational excellence programme restructuring sga cost percentage turnover increase programme follow relate acquisition meet percentage point include year legal charge criterion describe continue report operating million million charge relate expense result major restructuring cost major restructure programme million include restructuring cost relate minor acquisition million exclude legal restructuring million cost million relate cost sga cost turnover restructuring activity initiate commencement reflect investment growth market acquisition operational excellence programme restructure stiefel increase pension cost donation hn product activity material impact gsk operating result exchange loss intercompany transaction manner business conduct compare exchange gain year partially offset benefit current restructure programme anticipate duration operational excellence programme gsk currently expect incur material research development restructuring cost related programme rd expenditure total turnover acquisition meeting criterion describe include million intangible asset writeoff unanticipate material restructuring cost arise million partially offset low charge relate period gsk expect include major major restructure programme million restructuring column million provision release reassessment gsk operate profit profit taxation taxation receivable balance increase investment vaccine rd profit year discuss term total late stage pharmaceutical rd broadly offset saving result include major restructuring cost result restructure programme major restructuring operating income operating profit total result operate income million include gain asset disposal million million primarily total result include restructure cost relate operational reflect disposal wellbutrin xl asset aspen excellence programme acquisition reliant stiefel pharmacare royalty income million million growth royalty dispute settlement gain million onetime cer accounting gain million creation viiv healthcare turnover partially offset equity investment impairment million cost sale operating profit total result sell general total operating profit year million increase administration cer sterling term compare research operating profit margin increase percentage point reflect development high operating income broadly flat rd expenditure operating partially offset increase cost sale sga income profit taxation total result operate profit net finance cost cost sale finance income cost sale percentage turnover reduce marginally turnover principally reflect impact interest finance income generic competition high margin product usa unwind discount asset change product mix offset benefit restructure fair value adjustment hedge programme low restructuring cost million million finance cost interest cost unwind discount liability fair value adjustment hedges gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review profit disposal interest associate operating income profit disposal interest associate million operating income million include gain million share group hold quest diagnostic asset disposal million million inc sell quarter primarily reflect disposal wellbutrin xl asset aspen pharmacare royalty income million share tax profit associate joint venture million royalty dispute settlement gain share tax profit associate million million onetime accounting gain million million arise principally group hold creation viiv healthcare partially offset equity quest investment impairment million profit taxation total result operate income profit disposal take account net finance cost profit disposal associate amount million equivalent overall interest associate share profit associate income million expect total profit taxation million compare operate profit result major restructuring million cer increase sterling increase operate profit major restructuring year million cer decline sterling term operate profit result major compare operate profit margin restructuring compare margin decline margin result major restructuring set primarily generic competition usa impact cost good increase investment support growth group diversification strategy impact sga partly offset cer high level operate income turnover impact generic competition reduce sga cost sale investment level stabilise gsk operate profit margin sell general currently expect broadly similar exclude legal administration cost viiv healthcare accounting gain research information operate profit major restructuring development provide note segment information operate income profit taxation result major restructuring operating profit net finance cost cost sale cost sale increase turnover finance income principally reflect impact generic competition high interest income margin product usa change product mix partly unwind discount asset offset benefit restructure programme cost fair value adjustment hedge sale percentage turnover expect sell general administration sga cost percentage turnover increase finance cost percentage point include year legal charge interest cost million increase reflect investment growth market unwind discount liability acquisition stiefel increase pension cost donation fair value adjustment hedge hn product exchange losse intercompany transaction compare exchange gain year partially offset benefit current restructure programme sga cost exclude legal charge expect profit disposal interest associate turnover profit disposal interest associate million research development million quest share sell quarter rd expenditure total turnover include million intangible asset writeoff million partially offset provision release reassessment receivable balance increase investment vaccine rd latestage pharmaceutical rd broadly offset saving restructuring programme rd cost percentage turnover expect remain gsk annual report pp weiver ssenisub financial review share tax profit associate joint venture profit year share tax profit associate million million arise principally group hold growth cer quest diagnostics inc total profit taxation profit taxation result major restructuring year take account net finance cost profit disposal total profit attributable interest associate share profit associate profit shareholder tax major restructuring million compare basic earning share penny p p million cer decline increase basic earning ad sterling term result major restructure taxation profit taxation year result major restructuring profit attributable shareholder uk corporation tax adjust earning share penny p p overseas taxation adjust earning ad weight average number current taxation share millions defer taxation dilute total earning share penny p p taxation total profit dilute total earning ad charge taxation total profit amount million diluted weighted average number represent effective tax rate share millions charge taxation profit major restructuring charge total result include restructuring cost produce basic ep amount million represent effective tax rate p compare p growth gsk currently expect similar effective cer term growth sterle term exclude major tax rate group balance sheet st december restructuring cost ep p compare p include tax payable liability million tax growth cer increase sterle recoverable asset million term percentage point currency benefit arise th november irs concede asserted tax weakness sterle major currency year deficiency penalty arise reclassification dividend intercompany financing arrangement debt equity result additional tax cost gsk irs claim previously board declare fourth interim dividend penny estimate million gsk irs share result dividend year penny penny process finalise tax computation increase penny share equivalent tax year anticipate resolution issue year interim dividend receivable adr holder cent reflected closing agreement resolution ad base exchange rate exdividend issue impact group result date th february record date th february payment date th april gsk continue believe adequate provision liability likely arise open assessment ultimate critical accounting policy liability matter vary amount provide consolidated financial statement prepare accordance dependent outcome litigation proceeding ifrs adopt use european union negotiation relevant tax authority ifrs issue iasb follow accounting policy approve board described note financial statement accounting principle policy management require estimate assumption affect amount asset liability revenue expense report financial statement actual amount result differ estimate gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review critical accounting policy adopt relate follow area reconciliation gross turnover net turnover turnover pharmaceutical business follow taxation legal dispute property plant equipment gross turnover goodwill chargeback intangible asset manage care medicare gpo pension postemployment benefit rebate information judgement estimate area government give note financial statement key accounting state programme judgement estimate cash discount respect turnover accounting policy group large customer return business pharmaceutical market prior year adjustment complex arrangement rebate discount allowance item follow briefly describe nature arrangement total deduction existence group pharmaceutical business net turnover g sk arrangement certain indirect customer customer able buy product wholesaler sterling value increase approximately compare reduce price chargeback represent difference result average exchange rate movement invoice price wholesaler indirect chargeback increase result higher direct customer contractual discount price accrual estimate chargeback relenza sale manage care medicare chargeback calculate base term gpo rebate increase slightly result high contracting agreement historical experience product growth rate discount arise competitive pressure market place c ustomer rebate offer key manage care group purchasing organisation gpo direct total accrual rebate discount allowance return indirect customer arrangement require customer pharmaceutical business follow achieve certain performance target relate value st st product purchase formulary status predetermine market december december share relative competitor accrual customer rebate estimate base specific term agreement historical experience product growth rate chargeback manage care medicare medicaid programme stateadministere gpo rebate programme provide assistance certain poor vulnerable government state programme patient medicaid drug rebate program cash discount establish reduce state federal expenditure customer return prescription drug gsk participate provide rebate state accrual medicaid rebate calculate base specific term individual state agreement total combination historical experience product population growth anticipate price increase impact sterling value decrease largely result yearend contracting strategy exchange rate movement dollar term provision cash discount offer customer encourage prompt largely unchanged payment accrue time invoice monthly process operate monitor inventory level adjust subsequently reflect actual experience wholesaler abnormal movement process use gross historical experience customer return sale volume prescription volume base party datum gsk record accrual estimate sale return apply source information receive key wholesaler aim historical experience customer return amount maintain inventory consistent level year year invoice market relate information base pattern consumption stock level wholesaler anticipate price increase basis pharmaceutical inventory level wholesaler competitor activity distribution channel st december estimate approximately month turnover calculation use party information accuracy totally verify believe sufficiently reliable purpose gsk annual report pp weiver ssenisub financial position resource financial position property plant equipment gsk business sciencebase technologyintensive highly regulate governmental authority group allocate asset significant financial resource renewal maintenance noncurrent asset property plant equipment minimise risk interruption property plant equipment production achieve compliance regulatory standard goodwill number process use chemical hazardous material intangible asset total cost group property plant equipment investment associate joint venture st december million net book value investment million land building represent defer tax asset million plant equipment million asset derivative financial instrument construction million gsk invest noncurrent asset million new renewal property plant equipment mainly relate large number project renewal total noncurrent asset improvement expansion facility worldwide site current asset property mainly hold freehold new investment finance inventory group liquid resources st december gsk capital current tax recoverable contractual commitment future expenditure million trade receivables operating lease commitment million gsk believe derivative financial instrument facility adequate current need liquid investment group observe stringent procedure use specialist cash cash equivalent skill manage environmental risk activity asset hold sale environmental issue date operation total current asset modify discontinue report responsibility total asset environment note financial statement legal proceeding liability goodwill current liability shortterm borrowing goodwill increase year million trade payable st december million increase primarily reflect goodwill arise acquisition stiefel derivative financial instrument laboratory inc million pfizer hiv business current tax payable million certain business ucb sa million shortterm provision intangible asset total current liability intangible asset include cost intangible acquire noncurrent liability party computer software net book value longterm borrowing intangible asset st december million defer tax liability million increase reflect addition pension postemployment benefit million partly offset currency movement provision amortisation impairment exist intangible large element derivative financial instrument addition million relate acquisition stiefel noncurrent liability laboratory inc reflect brand acquire total noncurrent liability stiefel trade addition million relate fair value pfizer hiv intellectual property acquire follow creation total liability viiv healthcare business year million net asset arise acquisition certain business ucb sa equity share capital share premium account retain earning reserve shareholder equity minority interest total equity gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial position resource investment provision gsk hold investment include associate joint venture group carry defer tax provision shortterm carry value st december million noncurrent provision million st december million market value st december million respect estimate future liability million million large million relate legal dispute provision investment associate quest diagnostic inc legal dispute indemnify disposal book value st december million liability cost restructure programme extent million aspen pharmacare holding limit balance sheet date actual constructive obligation acquire year book value st december exist reasonably estimate million investment include equity stake pension postemployment benefit company group research collaboration group account pension postemployment provide access biotechnology development potential interest arrangement accordance ias deficit net interest company arise business divestment surplus allow deferred taxation million derivative financial instrument asset million pension arrangement gsk noncurrent current derivative financial million million unfunded post instrument hold fair value million million employment liability pension liability increase follow decrease primarily reflect low currency volatility euro weaken long term interest rate include reduction dollar yen market rate rate discount uk pension liability increase estimate long term inflation rate inventory uk partly offset positive impact exchange movement inventory million increase million high asset value year increase arise hn vaccine synflorix stock build follow regulatory approval key market acquisition net debt stiefel laboratory inc strategic stock building support growth emerge market japan offset weaken overseas currency improvement follow implementation cash cash equivalent work capital reduction programme liquid investment borrowing repayable year trade receivables borrowing repayable year trade receivables million increase reflect relatively high vaccine sale hn net debt quarter stiefel acquisition partly offset impact weaken overseas currency translation net debt decrease million primarily weaken foreign currency receivables sale long outstanding debt foreign currency group debt denominate certain european market taiwan reduction overdue total equity receivables certain european asian market summary movement equity set derivative financial instrument liability gsk hold current derivative financial instrument hold fair value million million current million total equity beginning year noncurrent relate primarily hedge exchange translation total comprehensive income year currency asset consolidation decrease reflect dividend shareholder low currency volatility euro dollar yen ordinary share issue trade payable ordinary share purchase cancel trade payable amount million change minority shareholding increase primarily reflect work capital option minority interest improvement initiative extend supplier term consideration receive share transfer group day term objective acquisition stiefel esop trust laboratory inc partly offset weakening yearend ordinary share acquire esop trust foreign exchange rate sharebase incentive plan tax sharebase incentive plan distribution minority interest total equity end year st december total equity increase million st december million increase arise principally retain profit year partly offset actuarial loss define benefit pension plan gsk annual report pp weiver ssenisub financial position resource share purchase contractual obligation commitment employee share ownership plan esop trust follow table set group contractual obligation acquire million share gsk plc million commitment st december fall payment share hold trust satisfy future exercise option award group share option award scheme total yr yrs yrs yrs proportion share hold trust respect loan award rule scheme require gsk satisfy interest loan exercise market purchase issue new finance lease obligation share share hold trust match option finance lease charge award grant operating lease st december esop trust hold million commitment million gsk share future exercise intangible asset share option share award carry value property plant equipment million million deduct investment reserve market value share purchase commitment million million pension gsk repurchase share cancellation commitment million share hold treasury share total nil order ensure gsk sufficient flexibility deliver strategic priority company expect commitment respect loan future interest payable significant repurchase exist share buyback loan disclose take account effect programme exact time future derivative group enter number purchase extent repurchase share hold research collaboration develop new compound treasury share cancel determined pharmaceutical company terms arrangement company dependent market condition include upfront fee equity investment loan commitment factor st december gsk hold million share fund specify level research addition group treasury share million share cost agree payment future milestone million million deduct achieve agreement relate compound retain earning early stage development milestone payment continue purchase st december number year compound successfully exist programme development process generally close product marketing approval great possibility success commitment contingent liability payment show intangible asset represent financial commitment summarise note financial maximum pay milestone achieve statement commitment contingent liability obligation respect short longterm debt set number new commitment note financial statement contingent liability license agreement include arrangement note financial statement net debt chroma therapeutic limit concert pharmaceuticals inc idenix pharmaceuticals inc prosensa bv seattle genetics inc amount provide pension postretirement benefit set note financial statement pension gsk reach agreement trustee uk postemployment benefit amount provide restructure pension scheme additional contribution year programme legal environmental dispute set period eliminate pension deficit identify note financial statement provisions st december actuarial funding valuation table show commitment exclude normal ongoing annual funding requirement approximately million information pension obligation note financial statement pension postemployment benefit gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial position resource contingent liability net cash outflow investing activity million increase million primarily reflect significant follow table set contingent liability comprise increase cost business purchase include discount bill performance guarantee letter credit stiefel laboratory inc million net cash acquire item arise normal course business million certain business ucb sa million net expect expire cash acquire million az tika million total yr yrs yrs yrs comparable acquisition comprise sirtris pharmaceutical million net cash acquire million egyptian guarantee business bms million net defer consideration contingent liabilitie million addition sale liquid investment realise cash million total free cash flow normal course business gsk provide indemnification guarantee respect business disposal legal dispute subsequently arise provision outflow resource consider probable reasonable estimate likely outcome dispute include note financial statement provision group policy provide settlement cost assert claim environmental dispute outflow resource consider probable reasonable estimate prior point liability record legal environmental cost discuss risk factor page note financial statement legal proceeding gsk continue believe adequate provision liability likely arise open taxation free cash flow cash generate business assessment ultimate liability matter vary meeting obligation interest tax dividend pay significantly amount provide dependent minority interest capital expenditure noncurrent outcome litigation proceeding negotiation tangible intangible asset free cash flow relevant tax authority discuss note million increase principally financial statement taxation reflect high operating profit noncash charge primarily major restructuring programme low cash flow expenditure intangible asset partly offset high summary consolidate cash flow set level net interest pay result debt issuance year billion emtn programme reduce interest income deposit net cash inflow operating activity free cash flow gsk management plan net cash outflow investing activity report purpose discussion presentations net cash outflow financing activity investment analyst rate agency gsk free cash flow measure define ifrs measure directly increase cash bank overdraft comparable similarly describe measure exchange adjustment company reconciliation net cash inflow operating cash bank overdraft begin year activity close equivalent ifrs measure free cash bank overdraft end year cash flow show reconciliation free cash flow cash bank overdraft end year comprise cash cash equivalent overdraft net cash inflow operating activity purchase property plant equipment purchase noncurrent intangible asset disposal property plant equipment net cash inflow operating activity taxation pay interest pay million increase million reflect high interest receive profit tax exclude impact significant increase dividend receive joint venture noncash charge year primarily major restructuring programme associate undertake dividend pay minority interest free cash flow gsk annual report pp weiver ssenisub financial position resource movement net debt payment policy group company responsible monitoring manage work capital term sale collection supplier payment reflect local commercial practice net debt begin year increase cash bank overdraft uk company uk subsidiarie cash inflow liquid investment policy ensure supplier pay time particular net increase longterm loan uk company seek net repayment shortterm loan settle term payment supplier agree debt subsidiary undertaking acquire term transaction exchange movement ensure supplier aware agree term movement payment net debt end year abide term payment investment appraisal policy permit arrangement accelerate payment small supplier gsk formal process assess potential investment proposal order ensure decision align payment performance group overall strategy process include analysis st december average number day payable impact project earning return invest outstanding represent trade payable parent company capital assessment return base discount nil nil respect company uk cash flow discount rate perform financial analysis subsidiary aggregate day day decide internally allow determination extent investment cover group cost capital specific treasury policy investment discount rate adjust gsk report sterling pay dividend sterling profit account country risk weighting role corporate treasury manage monitor external internal funding requirement financial risk capital expenditure financial investment support strategic objective treasury activity govern cash payment tangible intangible fix asset amount policy procedure approve board director million million million recently st october disposal realise million million million cash payment acquire equity investment treasury management group tmg chair chief million million million financial officer meet monthly basis review treasury year sale equity investment realise activity member receive management information relate million million million treasury activity future cash flow capital management group expect future operate cash flow gsk operate global basis primarily subsidiary sufficient fund operate debt service cost satisfy company establish market trade normal level capital expenditure meet obligation significant level patent trademark protection product exist licensing agreement meet expenditure arise compete largely product efficacy differentiation major restructuring programme precise timing price selling margin sufficient cover normal operate uncertain outlined note financial statement major cost operating subsidiary generally cash generative restructuring programme meet routine outflow operate cash flow fund investment research include tax dividend subject risk factor discuss development new product routine page gsk time time additional outflow capital expenditure tax dividend repayment demand finance acquisition access mature debt extent determine board source liquidity short longterm capital market share repurchase bank financial institution addition cash flow operation need policy borrow centrally variety capital market issue borrow facility meet anticipated funding requirement borrowing cash generate operation onlent contribute equity certain subsidiary pay dividend acquisition gsk share repurchase gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial position resource liquidity st december centrally available cash reserve st december cash liquid investment billion commit undrawn bank facility billion hold follow date shortterm debt bank overdraft loan repayable year billion manage net borrowing requirement portfolio longterm borrowing include bond short bank balance deposit term finance billion commercial paper programme treasury treasury repo commercial paper programme back billion money market fund commit facility facility renew october corporate debt instrument consider level commit facility adequate government security give current cash holding information facility note financial statement net debt benefit strong positive cash flow operating unit billion manage centrally available european medium term note programme month net debt st december billion st december billion billion table summarise cash gross debt note issue programme shelf effect hedge registration statement st december billion billion note issue programme tmg monitor cash flow forecast monthly basis cash liquid investment longterm borrowing mature date gross debt fix longterm debt rating remain stable float february currently rate stable outlook noninterest bear standard poor stable outlook moodys net debt shortterm debt rating p standard poor moodys respectively maturity profile gross debt show table maturity profile gross debt equivalent gbp bonds eur bond usd bond commercial paper borrowing leases gsk annual report pp weiver ssenisub financial position resource treasury operation use interest rate swap redenominate external objective treasury activity manage posttax net borrowing interest rate coupon require gsk cost income financial operation benefit earning duration swap match duration principal corporate treasury operate profit centre use instrument interest rate derivative instrument account variety financial instrument finance operation fair value cash flow hedge relevant asset liability derivative financial instrument manage market risk counterparty risk management operation derivative principally comprise forward policy counterparty risk management work foreign currency contract interest rate currency swap select group relationship bank global counterparty swap borrowing liquid asset require limit assign gsk banking investment currency manage exposure funding risk change counterpartie base longterm credit rating moodys foreign exchange interest rate standard poor corporate treasury usage hold issue derivative speculative purpose limit monitor daily corporate compliance officer cco treasury policy specifically prohibit activity transaction operate independently corporate treasury breach financial instrument undertake manage risk arise limit report cfo immediately cco underlie business activity speculation monitor credit rating counterpartie change rating occur notifie corporate treasury foreign exchange management change investment level authority limit foreign currency transaction exposure arise internal appropriate counterparty analysis present tmg external trade flow hedge exposure overseas annually approval operating subsidiary transaction risk minimised match local currency income local currency cost financial asset liabilitie analysis net debt give note financial purpose internal trading transaction match statement net debt analysis financial asset liability centrally manage intercompany payment term reduce carry value fair value give note financial foreign currency risk exceptional foreign currency cash flow statement financial instrument relate disclosure hedge selectively management corporate treasury continue benefit strong positive cash flow manage shortterm cash surplus borrow operating activity net debt decrease year requirement subsidiary company centrally forward st december despite gsk acquisition activity contract hedge future repayment period total approximately billion originating currency information activity note financial seek denominate borrowing currency statement acquisition disposal principal asset cash flow primarily denominate financial asset liability st december dollar euro sterle certain borrowing swap representative treasury policy strategy apply currency require july gsk raise approximately billion borrowing denominate swap foreign currency billion capital market match investment overseas asset treat share repurchase hedge relevant asset forward contract major currency reduce exposure investment overseas group asset net investment hedge section note detail tmg review ratio borrowing asset major currency interest rate risk management policy interest rate risk management limit float interest payment prescribe percentage trading profit gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp risk factor risks uncertaintie relevant group business patent infringement litigation financial condition result operation affect group patent common patent challenge group performance ability achieve objective time effort generic manufacturer involve challenge factor group think base validity enforceability patent assertion cet recent annual workshop identify generic product infringe group patent gsk significant risk face group cause actual result successful defend attack patent maintain differ materially expect historical result exclusive right market major product risk uncertainty currently know group particularly usa group high turnover deem immaterial margin group financial result materially adversely affect note financial statement legal risk describe group implement proceeding discussion patentrelate proceeding system internal control involve policy procedure group involve description communication training programme supervision resolution prior proceeding affect date monitor process escalate issue appropriate generic version group product introduce level senior management system help facilitate group ability respond appropriately risk achieve generic drug manufacturer seek market generic version group objective help ensure compliance applicable group important product prior law regulation internal policy possible expiration group patent exhibit readiness group implement control respond risk product future launch generic face assurance step product compete lamictal imitrex paxil cr requip group take address certain risk manage risk wellbutrin xl valtrex significant impact group effectively overall turnover earning group management risk discuss potential change intellectual property law page corporate governance regulation major risk affect gsk business proposal change exist patent datum exclusivity law regulation major market group sell product risk rd deliver commercially successful continue feature political process country new product include proposal effect make continue development commercially viable new product prosecution patent new product difficult time development additional use exist product critical consuming adversely affect exclusivity period group group ability replace sale old product decline product include biological product proposal expiration exclusive right increase overall sale enact materially adversely affect group develop new product costly lengthy uncertain process financial result new product candidate fail stage process weakness intellectual property protection late stage product candidate fail receive certain country regulatory approval country group operate patent protection significantly weak usa new product candidate appear promise development european union develop country reduce significant investment fail reach market threaten reduce effective patent protection limited commercial success example pharmaceutical product generally particular therapeutic result efficacy safety concern inability obtain area facilitate early competition market necessary regulatory approval difficulty manufacture generic manufacturer loss patent protection include excessive manufacturing cost erosion patent term result reduce scope patent right compulsory licensing lengthy development period infringement patent materially adversely affect group financial result intellectual property right inability differentiate national market expect material group product adequately compete overall absence adequate patent protection limit furthermore health authority fda european opportunity look market future sale growth medicine agency japan pharmaceuticals medicine device agency increase focus safety assess risk substantial adverse outcome litigation benefitrisk balance drug difficult government investigation pharmaceutical product gain regulatory approval note financial statement legal proceeding increase pressure healthcare budget discussion proceeding governmental investigation average age population develop market increase involve matter prove rise civil absolute population develop market grow payer criminal liability group currently involve increasingly demand great incremental benefit unfavourable resolution similar future proceeding drug agree reimburse supplier price supplier investigation material adverse effect group consider appropriate failure develop commercially successful financial condition result operation group product develop additional use exist product material provision prior year related legal reason materially adversely affect group proceeding investigation reduce earning financial result gsk annual report pp weiver ssenisub risk factor group additional significant provision relate sale marketing regulation legal proceeding investigation future group operate globally complex legal regulatory reduce earning case practice plaintiff bar environment vary jurisdiction failure claim damage amount bear relationship comply applicable law rule regulation underlie harm accordingly potentially mislead jurisdiction result civil criminal legal proceeding group quantify base damage claim rule regulation change governmental potential exposure claim proceeding investigation interpretation rule regulation evolve prior conduct type describe note financial statement call question legal proceeding usa example group respond federal recent insurance loss experience include pharmaceutical product state governmental investigation pricing marketing liability exposure increase cost narrow reimbursement prescription drug product coverage afford insurance pharmaceutical company investigation result related restitution civil false claim generally include group act litigation behalf federal state government relate proceeding initiate group behalf order contain insurance cost recent year group consumer private payer proceeding result continue adjust coverage profile accept great degree trebling damage award fine respect violation uninsured exposure addition claim law criminal proceeding initiate insurance policy insurer reserve right deny coverage group consequence materially adversely ground denial coverage ultimately uphold affect group financial result claim result additional charge materially adversely affect group financial result party competition product liability litigation group operate highly competitive market pharmaceutical business face competition preclinical clinical trial conduct development proprietary product large international manufacturer potential product determine safety efficacy producer generic pharmaceutical significant product product use human follow approval regulatory innovation technical advance intensification price body notwithstanding effort drug vaccine competition competitor materially adversely affect introduce marketplace unanticipated effect group financial result group predict timing evident impact competitive product potential impact instance party perform analysis publish sale group product continue consolidation clinical trial result necessarily accurate pharmaceutical industry adversely affect group meaningful raise question safety competitive position continue consolidation pharmaceutical product publicise medium group customer increase pricing pressure result product liability claim group currently group pharmaceutical product defendant number product liability lawsuit include million annual global sale product class action involve substantial claim damage relate augmentin ir es lamictal ir paxil valtrex group pharmaceutical product litigation particularly generic competition usa usa inherently unpredictable excessive verdict justify evidence occur class action sweep group major product subject person prescribe group product problem unplanne loss patent protection unexpected inflate potential liability force number claim effect regulatory proceeding publicity affect doctor pain suffer punitive damage frequently assert patient confidence pressure competitive product product liability action allow represent potentially new effective treatment introduce group open end exposure materially adversely financial result materially adversely affect affect group financial result particular group face intense competition antitrust litigation manufacturers generic pharmaceutical product usa increasingly common patent major market generic product enter market infringement action prompt claim antitrust law expiration patent datum exclusivity period group violate initial prosecution patent product introduction generic product typically lead litigation involve defence patent claim dramatic loss sale reduce group revenue direct indirect purchaser payer typically file margin proprietary product expiration date class action relief seek include treble damage patent group major product description restitution claim damage adverse antitrust verdict subject litigation settlement affect date generic automatic trebling usa similarly antitrust claim version group product introduced set bring follow settlement patent litigation allege legal proceeding involve patent challenge set settlement anticompetitive violation antitrust law note financial statement legal proceeding successful antitrust claim group materially governmental payer control adversely affect group financial result pharmaceutical product subject price control pressure restriction market include japan germany spain france italy government intervene directly set price gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp risk factor addition market major purchaser pharmaceutical risk interruption product supply product governmental agency private health care manufacture pharmaceutical product constituent provider economic power exert substantial pressure material require compliance good manufacturing practice price term access formulary regulation group manufacture site subject review approval fda regulatory agency group accurately predict exist control compliance failure supplier key service material pressure restriction increase new control group manufacture facility lead product pressure restriction introduce measure recall seizure interruption production delay materially adversely affect group ability introduce approval new product pende resolution manufacture new product profitably financial result issue noncompliance result fine disgorgement example usa group high margin profit interruption supply incurrence fine sale country pricing pressure disgorgement materially adversely affect group significantly increase experience continue develop financial result outpatient pharmaceutical programme cover medicare group undertake business continuity planning beneficiary begin change related single source certain component bulk active material enable legislation afford government direct role finish product create risk failure supply negotiating price medicare programme event regulatory noncompliance physical disruption addition congress consider comprehensive health manufacturing site care reform legislation significantly expand scope risk concentration sale wholesaler government health care program include specific price control mechanism increase group rebate usa line pharmaceutical company liability respect program group sell product small number wholesaler addition hospital pharmacie physician additionally number state propose implement group sale large wholesaler amount scheme control price lowincome senior approximately group pharmaceutical sale citizen programme include increase rebate liability st december group trade receivables pharmaceutical company importation country wholesaler total million bulk purchase drug growth number st december million group expose patient cover large manage care institution concentration credit risk respect wholesaler usa increase implementation medicare affect financial difficulty benefit increase pricing pressure group product materially adversely affect group financial result trend materially adversely affect group financial result global political economic condition describe world large economy regulatory control include major market group operate group comply broad range regulatory control financial institution recently face extreme financial difficulty test approval manufacturing marketing include decline asset price liquidity problem limit pharmaceutical consumer healthcare product particularly availability credit economy experience usa countries european union affect sharp recession economy show sign cost product development time require recovery rate recovery slow reach market uncertainty successfully health authority increase focus safety continue economic weakness material adverse effect assess benefit riskbalance drug context group sale result operation financial condition initial product approval context approval ability raise capital group business include additional indication review information consumer healthcare particularly sensitive decline market product strict regulatory control heighten consumer spending addition renew decline risk change product profile withdrawal regulator asset price result low return group financial basis postapproval concern product safety investment cause value group investment reduce revenue result product recall product pension plan decrease require group increase liability lawsuit great regulatory scrutiny especially fund pension plan usa advertising promotion particular group conduct substantial portion operation outside directtoconsumer advertising uk group management foreign exchange rate addition case group voluntarily cease discuss business review foreign exchange management marketing product face decline sale base concern fluctuation exchange rate sterle efficacy safety example decline sale currency especially dollar euro avandia beginning follow publicity question japanese yen materially adversely affect group risk associate product financial result scientifically justify absence regulatory action group control change inflation interest development postapproval adverse event profile rate foreign currency exchange rate control product product class materially adversely affect economic factor affect business possibility group financial result political unrest legal regulatory change nationalisation jurisdiction group operate gsk annual report pp weiver ssenisub risk factor taxation treasury failure manage properly environmental risk result group effective tax rate drive rate tax additional remedial cost materially adversely jurisdiction higher lower apply affect group financial result note financial uk addition jurisdiction uk belgium statement legal proceeding discussion environmental usa currently offer regime encourage innovation relate proceeding group involve new scientific endeavour provide tax incentive example accounting standard rd tax credit furthermore give scale international new revise accounting standard rule interpretation nature group business intragroup transfer pricing circulate time time international standard set inherent tax risk international business change board result change recognition income tax law application respect matter expense materially adversely affect group transfer pricing foreign dividend control company rd financial result tax credit restriction tax relief allow interest intragroup debt increase group effective tax rate international standard change market valuation certain materially adversely affect financial result financial instrument reflect group report result gain loss actually realise tax charge include financial statement group significant impact income statement give period good estimate tax liability time audits accounting defer taxation intercompany inventory tax authority conclude degree uncertainty rise volatility depend ownership final tax liability period group policy inventory submit tax return statutory time limit engage tax authority ensure group tax affair current regulator regularly review financial statement list possible difference interpretation tax company compliance account regulatory legislation regulation resolve quickly possible requirement exceptional case matter settle agreement group believe complie appropriate regulatory tax authority gsk resolve dispute requirement concern financial statement disclosure formal appeal proceeding group currently company experience investigation appeal court decision respect transfer pricing potential noncompliance accounting disclosure canadian tax authority discuss note financial requirement result restatement previously statement taxation report result significant penalty group deal high value transaction frequent basis materially adversely affect group financial result result increase risk financial loss failure party provider mismanagement cash enter high risk position unaffiliate thirdparty supplier provide number good hedge transaction materially adversely service group operation service affect group financial result example service provide clinical research organisation pandemic influenza support development key product important market pandemic influenza vaccine experience operation group business material provide significant volatility give change risk perception develop thirdparty supplier necessary commercial production epidemiology relative mild nature virus product include speciality chemical commodity anticipate government medical community component necessary manufacture fillfinish government place order pandemic package group pharmaceutical consumer vaccine announce change plan healthcare product group believe immunisation programme renegotiate contract thirdparty relationship individually significant government seek future seek context overall group failure thirdparty supplier renegotiate contract delivery pandemic vaccine fulfil contractual obligation timely manner result provide significant contribution group result delay service interruption materially adversely hn vaccine hn vaccine group expect affect group financial result level sale hn possibly stockpile agreement protection electronic information asset roughly assurance group rely critical sensitive datum personally sale influenza vaccine meet estimate contribute identifiable information trade secret intellectual property significantly group result corporate strategic plan security datum expose environmental liability increase threat group subject standard environmental law jurisdiction impose actual protection personally identifiable information failure potential obligation group remediate contaminated implement appropriate safeguard adequately protect site group identify potentially responsible unauthorised unintentional access acquisition party comprehensive environmental response use modification loss disclosure critical sensitive compensation liability act number site remediation datum adversely affect group operation cost relate group use ownership site gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp risk factor alliance acquisition example strategic priority grow diversified business group strategy diversify new product involve expand group business emerge market area market group grown expect group pharmaceutical sale emerge market grow continue grow acquisition business nearly billion represent group alliance intense competition alliance acquisition turnover guarantee group sale candidate pharmaceutical industry group emerge market continue grow market unable deal acceptable term continue experience relatively high growth rate acquire form alliance company group emerge market especially vulnerable aftereffect assume significant debt subject unknown recent global financial crisis limit contingent liability fail realise benefit expect resource spend healthcare competition market transaction example pharmaceutical company staff skill train suitable employment include group consider acquire enterprise group intense involve patent dispute product liability litigation government emerge market group require rely investigation legal proceeding outcome party agent group risk liability subject considerable uncertainty assumption debt emerge market lack sufficient protection crime unknown contingent liability failure realise counterfeiting failure continue expand business expect benefit materially adversely affect group emerge growth market materially adversely affect financial result group financial result process integrate company group acquire addition group undertake operational excellence result disruption ongoing business effort restructuring programme estimate cost integrate organisation different location approximately billion expect deliver annual pretax thing differ system corporate culture divert saving approximately billion time substantially attention resource result loss key employee complete assurance group adverse consequence materially able execute fully transformation business adversely affect group financial result furthermore change group structure operation revenue cost efficiency result restructure attraction retention activity strategic initiative result high group rely heavily recruit retain talented expect cost difficulty failure realise expect employee range skill meet objective group cost saving end restructure programme face intense competition qualified individual supply achieve maintain competitive cost base materially people specific skill specific geographic region adversely affect group financial result limit particularly give group plan expand operation emerge market biological consumer healthcare inability attract staff specific technical leadership skill retain key employee ensure effective succession plan critical position materially adversely affect group financial result implement group strategic priority group establish strategic priority grow diversified business deliver product value simplify operating model assurance group able implement strategic priority fully strategic priority deliver expect benefit gsk annual report pp weiver ssenisub financial review accordance sec disclosure requirement follow pharmaceutical turnover discussion compare result year st december growth rate include review turnover constant result year st december exchange rate cer state sterling growth exchange rate find table pharmaceutical turnover therapeutic area currency influence group result remain dollar euro japanese yen total pharmaceutical turnover decline year billion drive largely performance pound weaken dollar billion impact expect generic competition yearend addition pound weaken mature brand decline avandia sale euro yen new record sales asia pacific japan fall billion reflect low set december low government order relenza impact world market pharmaceutical pharmaceutical price cut japan decline partly offset growth europe billion emerge global pharmaceutical sale billion compare market billion sterling term pharmaceutical billion turnover grow reflect weakness sterle world market value major currency geographic region bn total pharmaceutical turnover therapeutic area usa gsk turnover decline impact low europe avandia sale generic competition range gsk product france low flu prepandemic sale partly offset strong germany growth key product advair valtrex epzicom avodart italy lovaza vaccines franchise uk rest world respiratory emerge market respiratory sale increase billion asia pacific sale seretideadvair asthma copd rise japan billion usa advair sale rise billion canada return volume growth second half year total fda grant advair indication copd prevention exacerbation helped grow copd th september gsk world sector advair business europe sale increase pharmaceutical product lamictal seretideadvair billion advair performance particularly strong valtrex emerge market million japan sale product double million follow world market value launch therapeutic class bn total antiviral central nervous system cardiovascular antiviral decrease billion alimentary tract metabolic gsk hiv business continue experience strong competition antineoplasticimmunomodulatory epzicomkivexa grow million antiinfective bacterial offset decline rest portfolio sale viral fungal exclude valtrex herpe rise billion sale vaccine fuel growth sale flu antiviral relenza fall respiratory million reflect few government order prepandemic stockpile note datum base month th september gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review pharmaceutical turnover therapeutic area total usa europe rest world therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent veramyst flixonaseflonase antiviral hiv epzicomkivexa combivir trizivir agenerase lexiva epivir ziagen valtrex zeffix relenza central nervous system lamictal imigranimitrex seroxatpaxil wellbutrin requip requip xl treximet cardiovascular urogenital avodart lovaza coreg coreg cr coreg ir fraxiparine arixtra vesicare levitra metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin altabax oncology emesis hycamtin zofran tykerb vaccine hepatitis infanrixpediarix fluarix flulaval flu pandemic cervarix rotarix boostrix cer represent growth constant exchange rate represent growth actual exchange rate gsk annual report pp weiver ssenisub financial review cns regional analysis cns sale decrease billion usa sales usa decline billion principally majority gsk cns franchise impact generic reflect year impact avandia generic competition usa generic competition lamictal imigran competition significant product lamictal remain presentation wellbutrin start imigran wellbutrin xl requip course positive news coreg ir decline partly offset treximet approve migraine fda april advair valtrex lovaza cardiovascular urogenital proforma basis cardiovascular urogenital sale increase billion europe strong growth portfolio product partly sale europe increase billion continued growth offset generic competition coreg ir lovaza high seretide particularly strong vaccine growth offset triglyceride acquire reliant pharmaceutical impact generic competition number product grow proforma basis million grow continue price cut government region market share avodart benign prostatic hyperplasia emerge market enlarge prostate grow million take percentage point market share arixtra deep vein thrombosis sale emerge market increase billion pulmonary embolism grow million coreg strong growth russia china latin cr grow million america growth fuel primarily vaccine billion respiratory franchise metabolic billion metabolic sale decrease billion asia pacificjapan strong growth bonvivaboniva postmenopausal increase sale seretideadvair million osteoporosis million offset offset low order relenza japan price cut year impact avandia sale start fall avandia product sale decline year consumer healthcare turnover million sale fall million growth european sale million emerge market total cer avandia product sale return growth second half overthecounter year q sale medicine oncology emesis panadol franchise oncology emesis sale decrease billion smoking cessation product tum tykerb breast cancer continue grow follow approval cold sore franchise usa year approval country achieve breathe right european approval achieve alli june oral healthcare vaccines aquafresh franchise vaccine sale increase billion sensodyne franchise vaccine portfolio strong performance dental care hepatitis vaccine million combination nutritional healthcare paediatric vaccine infanrixpediarix million lucozade rotarix rotavirus gastroenteritis rise million horlick largely drive government tender order latin america ribena launch product usa august new cervical cancer vaccine cervarix record sale million year follow tender win include national government cer represent growth constant exchange rate represent growth order uk netherland actual exchange rate total consumer healthcare sale year rise billion compare growth benefit launch stock new antiobesity treatment alli sales alli million exclude alli consumer healthcare sale rise gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review otc medicine cost arise gsk ongoing operating activity otc product sale decline billion sale report major restructuring column smoke cessation product million panadol sale restructuring cost arise solely direct result grow million twice global average operational excellence programme restructure oral healthcare programme follow relate acquisition meeting criterion describe report operating expense sale oral healthcare product rise billion result major restructuring cost include market grow strong performance restructure cost relate minor acquisition million sensodyne million aquafresh cost million related restructuring million sensodyne growth represent world activity initiate commencement operational toothpaste growth market gsk compete excellence programme restructure activity nutritional healthcare material impact gsk operating result manner nutritional horlick sale rise million business conduct lucozade sale rise million ribena sale flat gsk operate profit profit taxation taxation profit million sale lucozade ribena year discuss term total result second half year decline slightly largely result poor include major restructuring cost result weather uk major restructuring result major restructuring total operating profit total result result total result include restructure cost relate new october gsk announce significant new operational operational excellence programme commence excellence restructure programme second plan represent october reliant restructuring programme significant expansion operational excellence programme approve board announce february growth restructure programme cover area gsk business cer include manufacturing sell rd infrastructure turnover estimate total cost approximately billion expand cost sale programme expect deliver annual pretax saving sell general approximately billion time expect administration substantially complete approximately research cost incur st december give extent cost operational excellence programme gsk present development restructuring cost incur solely direct result operate operational excellence programme amount income million tax million separate operating profit column income statement title major restructuring cost sale addition restructuring cost column income statement include restructuring cost incur solely direct cost sale increase turnover result restructure programme follow relate constant exchange rate cost sale percentage turnover material acquisition operation acquire business increase percentage point reflect charge overlap extensively gsk exist operation relate major restructuring programme million million unfavourable product regional billion million acquisition reliant pharmaceutical mix compare partly offset savings inc december acquisition october restructuring programme meet criterion total restructuring cost incur direct result acquisition million sell general administration charge pay sga cost include legal charge turnover increase percentage point constant set note financial statement major exchange rate increase percentage point legal restructure programme asset impairment staff cost million million include million redundancy account million charge announce january relate investigation million restructuring cost incur report gsk market promotional practice originate major restructure column million colorado sga cost include charge million remain cost million arise million relate major restructuring programme miscellaneous expenditure incur solely direct result exclude legal cost sga decrease restructure programme include consultancy project management fee termination lease site closure cost respect recognition foreign exchange loss follow liquidation subsidiary puerto rico gsk annual report pp weiver ssenisub financial review research development profit taxation total result rd expenditure increase include charge relate take account net finance cost share profit major restructuring programme million associate total profit taxation million million exclude charge rd expenditure compare million cer decline increase cer term investment late stage pipeline sterling decline partly offset restructure saving operating profit result major operating income restructuring operating income million million result major restructuring set include strong growth royalty income million million product intellectual property equity growth investment disposal realise million compare cer million roche litigation settlement include turnover cost sale operating profit total result sell general total operating profit million decrease administration sterling term cer term compare research pharmaceutical operate profit million development consumer healthcare operating profit fall operate million income year gain asset disposal settlement operate profit million million cost legal matter million million fair value movement cost sale financial instrument result charge million cost sale increase percentage point income million charge relate previous turnover constant exchange rate increase restructure programme million million percentage point turnover principally reflect impact charge relate major restructuring programme generic competition high margin product usa low million million impact item avandia sale high proportion sale generate low total operating profit million charge margin vaccine brand sell emerge market consumer compare million charge healthcare product partly offset saving restructuring programme profit taxation total result net finance cost sell general administration sga cost include legal charge turnover finance income constant exchange rate sga cost increase interest finance income percentage point turnover legal cost fair value adjustment hedge million million include million charge announce january relate investigation gsk market promotional practice originate colorado exclude legal cost sga percentage turnover finance cost fall percentage point interest cost growth sterling term reduction constant unwind discount liability exchange rate reflect benefit restructure fair value adjustment hedge programme sell distribution fall advertising promotion general administration expenditure exclude legal charge share tax profit associate joint venture research development share tax profit associate million rd expenditure increase turnover million arise principally group hold investment late stage pipeline partly quest diagnostic inc offset restructure saving gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial review operating income taxation operate income million million include strong growth royalty income million million product intellectual property equity uk corporation tax investment disposal realise million compare overseas taxation million roche litigation settlement include current taxation defer taxation operate profit result major restructure taxation total profit operate profit major restructuring million year increase sterling term decrease charge taxation profit major restructuring cer term compare pharmaceutical charge amount million million operating profit million consumer represent effective tax rate healthcare operating profit flat cer term million charge taxation total profit amount exclude legal cost operating profit decrease million million represent great turnover decline primarily effective tax rate group balance high cost sale percentage turnover sheet st december include tax payable liability year gain asset disposal settlement million tax recoverable asset million million million cost legal matter group main open tax issue usa canada million million fair value movement japan financial instrument result charge million income million charge relate late position taxation taxation previous restructuring programme million financial review million impact item operating profit year profit major restructuring million charge million growth cer profit taxation result major total profit taxation restructuring year net finance cost total profit attributable shareholder finance income basic earning share penny p p interest income basic earning ad fair value adjustment hedge result major restructure profit taxation year result major restructuring finance cost profit attributable shareholder interest cost adjust earning share penny p p unwind discount liability adjust earning ad fair value adjustment hedge weight average number share millions diluted total earning share penny p p take account net finance cost share profit dilute total earning ad associate profit tax major restructuring dilute weight average number million compare million share millions cer decline flat sterling term total result include restructuring cost produce basic eps p compare p decline cer decline sterling term dividend board declare fourth interim dividend penny share result dividend year penny penny increase dividend penny share gsk annual report pp noitarenumer dna ecnanrevog board sir christopher gent professor sir roy anderson larry culp aged julian heslop age aged aged appoint st july appoint st april appoint st june appoint st october nonexecutive director chief financial officer chairman nonexecutive director mr culp president chief mr heslop join glaxo sir christopher nonexecutive professor anderson executive officer danaher wellcome financial controller director ferrari spa professor infectious disease corporation prior join april january chief executive officer epidemiology faculty danaher hold position appoint senior vice vodafone group plc medicine imperial college accenture previously andersen president operation controller retirement july london member consulting prior join group nonexecutive director international advisory board hold senior finance role lehman brothers holdings inc hakluyt co ltd grand metropolitan member kpmgs chairman fellow royal society advisory group senior adviser foreign associate member bain co member institute medicine advisory board reform national academy sciences french academy sciences position include rector imperial college chief scientific adviser ministry defence uk andrew witty aged dr stephanie burn sir crispin davis age sir deryck maughan appoint st january aged appoint st july aged chief executive officer appoint th february nonexecutive director appoint st june mr witty name chief nonexecutive director march sir crispin nonexecutive director executive officer designate dr burn chairman president chief executive officer sir deryck partner gsk october chief executive officer reed elsevi plc prior kohlberg kravis roberts co appoint chief executive dow corn corporation appointment chief nonexecutive director officer ceo st member executive aegis group plc thomson reuters blackrock join group american chemical society join guinness inc chairman hold senior sit executive committee plc member chief executive officer position asia africa society chemical main board group citigroup international usa immediately prior industry america section serve manage director united salomon brothers inc appoint ceo andrew board director distiller spend early president pharmaceutical american chemistry council career procter gamble europe position hold board director include president january member society womens company food division business council health research dr burns hold britain board member phd organic chemistry phrma president efpia iowa state university member singapore economic development board international advisory council adviser governor guangzhou china gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp board james murdoch aged dr moncef slaoui aged sir robert wilson appoint th appoint th aged nonexecutive director chairman research appoint st november mr murdoch chairman development nonexecutive director chief executive europe dr slaoui join gsk biological senior independent director asia news corporation engineer sir robert nonexecutive nonexecutive development chairman bg group plc chairman bskyb robust vaccines pipeline previously executive member board news subsequently lead worldwide chairman rio tinto plc corporation serve chief business development retirement october executive officer bskyb pharmaceuticals chairman economist appointment lead rd group previously chairman chief member board executive officer star tv agency science serve leadership technology research astar council climate group phd molecular biology immunology universit libre de bruxelles dr daniel podolsky tom de swaan aged director age appoint st january sir ian prosser dr ronaldo appoint st july nonexecutive director schmitz retire nonexecutive director mr de swaan chairman board th dr podolsky president supervisory board university texas southwestern vanlanschot bankiers medical center dallas hold member board director phillip obryan montgomery zurich financial services jr md distinguish presidential vice chairman chair academic administration supervisory board chairman doris bryan audit committee royal wildenthal distinguish chair ahold member medical science member supervisory board royal dsm institute medicine january national academy sciences member managing board chairman board chief financial officer scientific cofounder abn amro gi company gsk annual report pp noitarenumer dna ecnanrevog corporate executive team cet john clarke abbas hussain president consumer healthcare president emerge market john responsible abbas join gsk june consumer healthcare business eli lilly company produce oral healthcare spend year overthecounter nutritional oversee market healthcare product join europe africamiddle east beecham australasia andrew witty president future group eddie gray chief executive officer current appointment president andrew appoint chief january pharmaceuticals europe executive officer eddie responsible join glaxo uk group operation career europe january company hold role join beecham managing director south africa prior current vice president general appointment senior vice manager marketing president general manager usa senior vice president pharmaceutical uk duncan learmouth asia pacific appoint senior vice president president pharmaceuticals deirdre connelly global communications europe glaxosmithkline president north america duncan responsible january pharmaceutical group investor relation deirdre join gsk february internal external work eli lilly communications corporate company year responsibility partnership hold variety position community join include sale professional glaxo vice general manager puerto rico president global investor executive director human julian heslop relation appointment resource recently chief financial officer current position july president operations julian chief financial officer april head simon bicknell finance function senior vice president responsible activity company secretary corporate financial reporting control compliance officer tax treasury finance system simon ensure compliance insurance join glaxo risk management wellcome financial controller effectively embed april business oversee corporate marc dunoyer bill louv governance group president pharmaceutical chief information officer responsible asia pacificjapan bill appoint chief internal audit assurance marc appoint president information officer january simon join corporate pharmaceutical asia pacific responsible secretariat japan addition information technology appoint deputy company current role gsk bill join glaxo secretary glaxo wellcome appoint chairman gsk japan vice president medical data company secretary january february sciences prior current role glaxosmithkline plc lead rare disease bill senior vice president business gsk rd rd information technology commercialisation join group president pharmaceuticals japan january current appointment gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate executive team cet david redfern dan troy chief strategy officer senior vice president david responsible proactive general counsel exploration new business dan join gsk senior vice opportunity strategic president general counsel planning begin career september previously gsk corporate partner washington development law firm sidley austin llp dan phelan jean stphenne appoint finance director chief counsel fda chief staff president general europe pharmaceutical chair dan responsible corporate manager biological appoint area director america bar association section strategy development jean lead gsk global central europe administrative law hr real estate facility vaccine business northern europe previously adjunct scholar environmental health safety previously vice president american enterprise institute global security join human vaccine research washington dc smith kline french development previously hold role production join senior vice president human company head resource appointment bacterial viral vaccine chief staff production jean name baron king albert ii belgians recognition lead contribution moncef slaoui rd industry belgium chairman research development moncef lead group drug discovery development activity join group key player david pulman building gsk vaccine pipeline president global appoint manufacture supply senior vice president worldwide david responsible business development global manufacturing claire thomas current appointment supply organisation senior vice president june global procurement join human resource glaxo broad claire lead global human experience manufacturing resource hr function operation previously lead previously oversaw hr primary supply european pharmaceuticals international manufacturing north american pharmaceuticals europe manufacture global logistic claire join company manufacturing appoint strategy organisation director human resource uk pharmaceuticals claire honour outstanding european woman achievement gsk annual report pp noitarenumer dna ecnanrevog corporate governance governance policy chairman ceo section discuss gsk management structure sir christopher gent chair company st january governance procedure section chairman remuneration report page include detail mr witty chief executive officer ceo mr wittys company apply complie principle biographical detail find page provision combine code corporate governance chairman lead board represent board financial reporting council combined code laws ceo cet member necessary board regulation meeting ceo manage group implement board corporate executive team strategy policy adopt board chairman director list board page chairmen board committee communicate regularly ceo cet member division responsibility board responsible group system corporate role chairman ceo set governance ultimately accountable group activity write agree board appear strategy risk management financial performance company website independence ceo responsible executive management group board consider nonexecutive director assist cet cet meet time year independent character judgement necessary member responsibility list corporate executive team page dr schmitz serve board year retirement director th appoint senior independent director board glaxo wellcome plc st january sir robert wilson appoint senior independent director sid consideration annual review board effectiveness th follow sir ian prosser retirement meeting january board conclude board date sir ian hold role january dr schmitz remain independent notwithstanding length service opinion board dr schmitz continued board process demonstrate characteristic independence board authority accountable shareholder objectively challenge management take rigorous ensuring group appropriately manage debate time possess outstanding achieve strategic objective set board discharge knowledge company business affair responsibilitie annual programme meeting experience gain chairman audit committee include approval overall budgetary planning business long cycle investment business gsk consider strategy board review group internal control risk particularly important experienced member management policy approve governance structure board sir ian prosser consider independent code ethic accordance recommendation combine code board appraise approve major financing investment prior retirement board licensing decision excess define threshold addition sir christopher gent appoint board deputy board evaluate monitor performance group chairman determined board independent include take chairmanship board st january engage board meeting ceo executive accordance combine code exclude director member cet appropriate determination half board financial operating performance gsk external independent nonexecutive director sir christopher gent issue material group prospect member remuneration committee permit evaluate progress achievement group combine code light independence appointment financial business objective annual plan chairman monitoring report receive directly board consider professor sir roy anderson dr burns committees significant risk face group mr culp sir crispin davis sir deryck maughan mr murdoch dr podolsky mr de swaan sir robert wilson independent accordance recommendation combine code date publication majority board member exclude chairman independent nonexecutive director gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance board overall responsibility succession plan independent advice ceo executive director board give board recognise occasion ceo broad authority operate business group director feel necessary independent legal ceo accountable report board andor financial advice company expense performance business cet member regular agree procedure enable explain presentation board area responsibility governance section company website board meet cet member annual basis indemnification director discuss collectively group strategy qualify party indemnity provision define section primary element induction process new nonexecutive company act force benefit director undertake member cet non director director hold office executive director encourage separate informal discussion discretion cet member director conflict interest director duty avoid situation board meet time member attend direct indirect conflict interest possible conflict follow interest company duty apply particular number meeting exploitation property information opportunity hold whilst board number gsk advantage company article member meeting attend association include general power board authorise sir christopher gent conflicts breach duty relevant matter mr witty authorise advance mr j heslop board establish procedure handle situational dr slaoui conflict interest line good practice professor sir roy anderson guidance issue general counsel group dr burns accordance company article authorise mr l culp nominations committee grant review periodically event annually potential actual conflict authorisation sir crispin davis director count quorum authorisation sir deryck maughan actual potential conflict company secretary mr j murdoch minute consideration conflict authorisation grant dr podolsky record company secretary register conflict mr de swaan authorisation note board meeting sir robert wilson ongoing basis director responsible inform company secretary new actual potential conflict sir ian prosser arise change circumstance dr r schmitz affect authorisation previously give provide authorisation director absolve duty mr james murdoch appoint board th sir ian prosser dr ronaldo schmitz retired board th promote success company actual conflict arise post authorisation board choose exclude director relevant information debate suspend director addition schedule meeting board meet board resort require director resign quorate basis occasion company secretary business environment development company secretary responsible board ensure board keep uptodate important matter available individual director respect board procedure include legal governance regulatory development company secretary mr simon bicknell appoint presentation regular basis external barrister join group internal adviser secretary board committee remuneration addition nonexecutive director gain great insight committee deputy company secretary mrs victoria whyte understand business visit group operational appoint secretary remuneration committee facility attendance internal management meeting effect th january solicitor fellow include cet research development executive product institute charter secretary administrator marketing board meeting ad hoc basis board committee customise induction process conduct new board establish number committee nonexecutive director focus particular experience provide sufficient resource enable undertake take account different background process include duty executive director member audit meeting member cet senior executive risk remuneration nomination corporate responsibility visit particular operational facility group committee invite attend meeting director member corporate administration transaction finance committee gsk annual report pp noitarenumer dna ecnanrevog corporate governance corporate governance framework board chairman executive director independent nonexecutive director audit risk committee remuneration committee corporate responsibility chief executive independent independent nonexecutive independent nonexecutive officer nonexecutive director director chairman directors chairman nominations committee finance committee corporate administration independent nonexecutive executive nonexecutive transaction committee cet directors chairman director directors cet member key board committees management committee current membership committee show table corporate audit risk remuneration nomination responsibility sir christopher gent c c professor sir roy anderson dr burns mr l culp sir crispin davis c sir deryck maughan mr j murdoch dr podolsky mr de swaan c sir robert wilson key c chairman member gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance committee write term reference approve board follow summary role term reference committee current term reference committee obtain company secretary governance section company website meeting committee report committee role term reference membership comprise year audit risk review financial internal reporting independent non process system internal control executive director identification management risk external internal audit process committee propose shareholder appointment external auditor directly responsible remuneration oversight work remuneration determine term service remuneration independent non executive director member executive director cet assistance external chairman independent adviser evaluate make recommendation board overall executive remuneration policy chairman ceo responsible evaluating make recommendation board remuneration nonexecutive director nomination review structure size composition independent non board appointment member executive director board cet make recommendation chairman board appropriate committee monitor plan succession board senior management corporate provide boardlevel forum regular independent non responsibility review external issue potential executive director impact group business chairman reputation committee responsible oversight gsk worldwide donation community support finance review approve behalf board executive non necessary annual report form f convene executive director agm preliminary quarterly statement trading result approve certain major licensing capital transaction change group investment instrument counterparty limit corporate review approve matter connection executive non necessary administration administration group business executive director transaction certain corporate transaction cet member company secretary gsk annual report pp noitarenumer dna ecnanrevog corporate governance evaluation board board committee director dialogue shareholders board commission dr long boardroom review financial result announce quarterly act independent facilitator board evaluation process company report formally shareholder twice year action process form basis board halfyear fullyear result announce fullyear internal review process result include company annual report identify utilise time spend board committee publish shareholder meeting effectively facilitate contribution nonexecutive director broad range issue company produce annual summary send eek enhance nonexecutive director shareholder advise availability annual continue education process initial induction report notice meeting wwwgskcom ceo cfo presentation fullyear result institutional p rovide great visibility board gsk executive talent investor analyst medium management succession planning process normally webcast teleconference release senior independent director sir robert wilson conduct second quarter result institutional investor evaluation performance chairman analyst medium annual report summary board committee director collaboration quarterly result available company website committee chairman agm take place london formal notification send board evaluation process include onetoone interview shareholder month advance meeting director topic discuss include variety business presentation shareholder director able aspect associate board effectiveness include board attend available formally agm informally committee role responsibilitie culture dynamic question committee chairman ordinarily attend process support individual effectiveness feedback agm respond shareholder question entire board evaluation provide form write report attendance company agm save board discuss finding sir deryck maughan prevent attend chairman board committee undertake urgent business commitment arise shortly separate evaluation outcome report meeting resolution agm decide poll respective committee board require companys article association result poll announce london stock exchange post board review conclude high level company website detail agm set satisfaction way mr witty grown section annual general meeting notice ceo role openess dialogue executive agm publish company website director nonexecutive director board member meet separately chairman present discuss ensure nonexecutive director aware chairman performance contribution high understand view major shareholder company level confidence sir christopher chairmanship board board place process focus sectorspecific issue unanimous unequivocal support general shareholder preference director executive nonexecutive ceo cfo chairman maintain dialogue institutional board committee believe operate shareholder performance plan objective effectively high level programme regular meeting appointment ceo mr witty undertake extensive ongoing series board agree follow action discussion meeting gsk institutional shareholder evaluation report group investor relation department office london identify increase board time philadelphia act focal point contact investor devote strategic discussion indicator success year delivery rd pipeline chairman meet regularly institutional investor devote time focus consideration company hear view discuss issue mutual importance key risk ongoing basis communicate view investor board provide board regular update insight sid available shareholder newly enhance management succession chairman remuneration committee chairman planning process svp human resource meet annually major shareholder board take policy decision undertake externally discuss executive remuneration policy facilitate evaluation process year intervene nonexecutive director include new appointee available period review facilitate sid chairman meet major shareholder request company website provide access current financial business information group gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance share capital control bank new york mellon depositary company detail company authorise issue share capital ad list new york stock exchange ordinary number share hold treasury st december share represent company adr program find note financial statement share capital manage depositary register bny share premium account gsk share list london nominee limit detail number ordinary share hold stock exchange quote new york stock depositary find exchange nyse form american depositary share ad company acquire disposed interest ad represent ordinary share share period review detail share holder ordinary share entitle receive dividend purchase prior year cancel hold declare company report account attend treasury share disclose note financial statement speak general meeting company appoint proxy share capital share premium account exercise voting right director officer restriction transfer limitation hold interest director officer connect ordinary share requirement obtain prior approval person issue share capital company give transfer ordinary share carry special right remuneration report page regard control company restriction rule appointment replacement director vote right major shareholder voting right contain company article association company share shareholder know arrangement article approve shareholder accordance financial right hold person legislation force time time holder share know agreement restriction share transfer voting right article provide director appoint ordinary resolution member resolution director share acquire gsk share scheme plan rank provide instance director appoint equally share issue special right way retire agm follow appointment trustee companys employee share ownership plan esop trust waive right dividend share hold article provide director subject esop trust reelection agm interval year annually hold office continuous period year change control essential contract company member remove director pass company contract arrangement ordinary resolution special notice give individually essential business party pass special resolution director automatically significant agreement effect alter cease director terminate change control follow takeover bid bankrupt compound company agreement director creditor generally officer provide compensation loss office cease director virtue company act employment result takeover provision article company share plan cause option award grant plan vest takeover detail termination suffer mental ill health provision company framework contract executive miss director meeting continuous period director give month permission board resolve shall cease director interest voting right prohibit director law state far company aware person significant direct indirect holding resign company information provide company pursuant offer resign board accept offer financial service authoritys fsa disclosure transparency director number require rule dtrs publish regulatory information service resign company website th february company receive notification accordance fsa dtrs follow notifiable interest voting right company issue share capital percentage issue share capital blackrock inc legal general group plc percentage ordinary share issue exclude treasury share th february gsk annual report pp noitarenumer dna ecnanrevog corporate governance article association notwithstanding new policy company continue support power director determine uk legislation gsk political action committee pac employees usa companys articles association available gsk give political donation pac employee organisation website article amend special resolution allow employee contribute fund political member director exercise company power donation employee decide recipient pac provide article applicable legislation stipulate donation total power exercise member donate political organisation gsk pac director authorise issue allot ordinary agm shareholder authorise share current article power current article company donation eu political organisation authority company purchase incur eu political expenditure provision political share subject shareholder authority seek party election referendum act annual basis agm share purchase year authority renew annually law company cancel hold treasury share require company continue obtain shareholder approval share buyback programme donation eu political organisation incur eu political expenditure company billion programme share repurchase commence intend donation political party july share cost billion repurchase independent election candidate donation programme repurchase eu political organisation incur eu political expenditure company expect significant repurchase programme cover purchase definition political donation political expenditure company share cancellation hold treasury political organisation legislation wide share accordance authority renew shareholder particular definition eu political organisation agm company authorise extend body concern policy review law purchase maximum million share detail reform representation business community special share purchase prior year cancel hold interest group concern environment treasury share disclose note financial statement company subsidiary wish support share capital share premium account result definition cover legitimate business activity ordinary sense consider political donation exact time future purchase political expenditure activity design support extent repurchase share hold treasury share political party independent election candidate authority cancel determine company board seek annually precautionary measure dependent market condition factor ensure company subsidiary inadvertently donation political organisation political breach legislation expenditure effect st january ensure consistent approach political contribution group gsk introduce global policy stop voluntarily political contribution political donation eu political organisation noneu political organisation comprise usa canada prior introduction group new approach political contribution usa large recipient political donation line law corporate donation federal level candidate political party state local level gsk support candidate seek environment appropriately reward highrisk highinvestment industry situation similar canada rest world donation rare low value gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance annual general meeting internal control framework board recognise responsibility present balanced agm hold pm thursday th understandable assessment group position prospect queen elizabeth ii conference centre broad sanctuary westminster london swp ee business transact board accountability review approve meeting include adequacy effectiveness internal control operate group include financial operational compliance control receive adopt glaxosmithkline risk management board delegate responsibility annual report review audit risk committee receive approve remuneration report regular reporting align gsk assurance programme remuneration report page set responsibility management cet implement remuneration policy operate glaxosmithkline board policy risk control cet responsible disclosure director remuneration include identify approve monitoring enforce key policy require company act large heart group conduct business mediumsize company group account report internal control framework include central direction resource regulation resolution propose approve allocation risk management key activity research remuneration report development manufacturing marketing sale legal human resource information system financial practice retirement reelection director framework comprehensive planning system dr stephanie burn mr julian heslop sir deryck maughan annual budget approve board result operate dr daniel podolsky sir robert wilson retire unit report monthly compare budget offer reelection board current forecast prepare regularly year article company article association group place establish procedure identify reappointment remuneration auditor consolidate reporting entity group control activity include resolution propose authorise audit risk policy practice cover appropriate authorisation committee reappoint pricewaterhousecooper llp approval transaction application financial reporting standard auditor determine remuneration review significant judgement financial performance pecial business extensive financial regulatory operational control procedure company seek authority risk activity review group internal auditor donation eu political organisation incur responsibility clearly delegate local business unit eu political expenditure cap support regional management structure principle allot ordinary share company design provide environment central leadership director authority disapply preemption right couple local operating autonomy framework allot new share connection right issue exercise accountability control group maximum current group attach importance clear principle issue share capital purchase ordinary share procedure design achieve appropriate accountability maximum current issue control group policy risk management legal compliance share capital mandate business unit establish process manage exempt auditor state monitoring risk significant business group senior statutory auditor company gsk internal control framework rely follow annual report oversee report risk compliance issue reduce notice require general meeting clear day risk oversight compliance council rocc rocc council senior executive authorise board amend companys article association line assist audit risk committee oversee risk management company act shareholder right directive internal control activity group membership comprise include limit annual fee pay director cet member head departments shareholder entitle appoint proxy attend internal control risk management assurance audit agm speak vote behalf provide compliance responsibility event single shareholder appoint multiple proxy rocc meet regular basis review assess significant proxy appoint exercise right attach risk mitigation plan provide oversight internal different share share hold member control ensure compliance applicable law regulation detail appoint appoint corporate internal gsk policy rocc respond group policy representative proxy find notice refer provide business unit framework agm publish company website risk management upward report significant risk mitigation planning identification manager overall responsibility management give risk requirement gsk annual report pp noitarenumer dna ecnanrevog corporate governance risk oversight audit risk compliance committee council internal assurance business unit assertion audit assessment assessment independent external audit emerge business internal review business regulatory incident risk control audit business unit monitor agency outcome event management infrastructure activity internal audit activity gsk risk universe management internal assurance audit risk management compliance board rmcbs new alignment global audit function rmcbs establish major business unit strengthen gsk governance model afford internal membership comprise member senior executive audit group great independence reduce fragmentation team respective business unit augment specialist global audit function provide direct reporting line appropriate rmcbs oversee management internal audit group gsk company secretary corporate risk consider important respective business compliance officer chairman audit risk unit include risk designate significant committee ensure significant issue escalate timely glaxosmithkline increase number risk manner help eliminate overlap gap potential actively manage group overunder auditing exist previous structure business unit corporate function periodically review provide clear platform develop common significant risk face business review approach conduct internal audits helps ensure include identify operational risk legal compliance risk risk consistency audit activity perform achievement strategic goal objective review efficient effective way occur annually embed assurance reporting align annual planning process ensure significant assurance report audit risk committee follow risk identify change management direction structure programme integrating reporting business unit external environment assurance internal audit assurance business unit corporate function require present assurance programme implement report annually rocc audit risk committee enhance governance provide independent assessment detail risk management compliance approach provide governance risk management control process balanced assessment status internal control key risk organisation gsk comprise main element highlight significant compliance issue management internal audit oversee risk consider important respective business unit include risk designate significant gsk internal audit group responsibility independently group information control place manage assess adequacy effectiveness management risk provide assure audit risk committee significant risk area report audit risk risk adequately manage internal control committee line agree annual assurance plan framework gsk internal audit function undergo significant transformation global audit function group internal internal audit report audit risk committee audit manufacture internal audit rd internal audit time business unit provide independent assessment environment health safety sustainability internal audit adequate control place manage significant risk consolidate single organisation leadership head audit assurance head audit assurance report gsk company secretary corporate compliance officer separate reporting responsibility chairman audit risk committee gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance issue control deficiency identify internal audit area group business necessary recommend process improvement gsk manager develop risk achieve satisfactory return shareholder corrective action plan eliminate cause noncompliance investment rd acquire new product business address gap internal control internal audit track case group objective apply expertise plan completion report result senior management prudent management elimination risk audit risk committee director review relate company subsidiary extend material associate undertaking joint significant compliance issue internal audit result escalate venture investment audit risk committee early opportunity board audit risk committee review risk management assessment risk internal control framework group risk management programme extend operate glaxosmithkline consider effectiveness legal regulatory issue consider group overall system internal control operation group strategy change external environment furthermore year cover report date approval risk management principle embed management board process follow board review practice business strategy objective system internal control accord guidance internal setting process control issue turnbull committee detail risk affect group risk factor page committee report note financial statement legal proceeding board committee report regularly board performance strategic risk evaluation sre activity assign sre new approach deliver enterprisewide assurance audit risk committee report significant issue face gsk conduct assurance team partnership business approach design evaluate area incomplete understand risk enable development implementation appropriate mitigation plan sre sponsor cet member risk owner oversight sre provide rocc corporate ethic compliance cec rocc support cec department responsible support development implementation practice facilitate employee compliance law group policy department provide assistance help employee meet high ethical standard comply applicable law regulation corporate responsibility tom de swaan thrust group compliance effort diligence audit risk committee chairman prevent detect misconduct noncompliance law regulation promote ethical behaviour compliance attendance meeting law regulation corporate responsibility level members committee member effective compliance system mr de swaan st january cec department manage company secretary chairman corporate compliance officer report directly ceo st september company secretary corporate compliance officer chair professor sir roy th rocc provide summary report roccs activity anderson group significant risk cet audit risk committee regular basis corporate compliance officer sir deryck maughan st january direct reporting line audit risk committee provide dr podolsky st january mechanism bypass executive management sir robert wilson th december need arise sir ian prosser th december effectiveness control dr r schmitz th december internal control framework operation year review continue operate sir ian prosser dr schmitz retired board th date approval report system internal control addition schedule meeting committee meet design manage eliminate risk achieve quorate basis occasion business objective provide reasonable absolute assurance material misstatement loss audit risk committee receive report area significant risk group relate internal control follow consideration report receive assurance framework audit risk committee report annually board effectiveness control gsk annual report pp noitarenumer dna ecnanrevog corporate governance attendee committee meeting financial accounting experience ceo mr tom de swaan chief financial officer abn amro cfo st december chairman determine board audit general counsel committee financial expert define sarbane oxley act sarbanesoxley head audit assurance company secretary corporate compliance officer sir deryck maughan partner kohlberg kravis roberts co head global internal audit appropriate kkr chairman kkr japan external auditor chairman ceo citigroup committee main responsibility include international vice chairman citigroup inc r eviewe corporate accounting financial report chairman cochief executive process officer salomon smith barney monitor integrity financial statement chairman chief executive e valuating system internal control identify officer salomon brothers inc manage risk include relation financial reporting process preparation consolidated account sir robert wilson economist nonexecutive verseeing activity group compliance chairman economist group audit function oversee compliance law chairman bg group plc regulations ethical code practice retire rio tinto hold senior management position culminate committee oversight role require address regularly appointment executive chairman relationship management internal external auditor understand monitor report relationship tier accountability scientific expertise committee receive regular report member professor sir roy world renowned medical scientist cet senior manager cover key risk management anderson advance knowledge infectious disease compliance activity group include cover rd epidemiology manufacturing sale marketing corporate function professor infectious disease epidemiology detail report framework committee faculty medicine imperial college set page internal control framework london fellow royal society december committee term reference amend reflect role oversee identification foreign associate member institute management risk new assurancebase audit medicine national academy framework refer page time science audit committee change audit foreign associate member french risk committee academy sciences rector imperial college london qualification audit risk committee member chief scientific adviser ministry committee member exception professor sir roy defence uk anderson dr podolsky bring considerable financial accounting experience committee work member dr daniel podolsky world renowned researcher past employment experience finance accounting role advance knowledge underlie comparable experience corporate activity professor sir mechanism disease new therapy roy dr podolskys background world renowned medical gastrointestinal disorder scientist researcher enable bring scientific expertise president university texas committees deliberations southwestern medical centre professor internal medicine member institute medicalnational academy sciences mallinckrodt professor medicine harvard medical school chief academic officer partner healthcare gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance committee work structured programme committee primary responsibility make activity stand item committee require recommendation shareholder appointment consider meet matter focus reappointment removal external auditor annually coincide key event annual financial reporting cycle assess qualification expertise resource independence external auditor effectiveness audit process external auditor report critical accounting evaluate effectiveness audit process prior make policy significant judgement recommendation reappointment external auditor practice group alternative committee review effectiveness performance accounting treatment criterion agree conjunction management discuss management begin year audit process resultant conclusion material write committee consider feedback prior year external audit communication management gather survey facilitate auditor client service restriction access information review team independent engagement team undertake audit work survey seek feedback cfo report financial performance number source include certain member board company technical financial involve audit process financial management accounting matter team corporate business unit level general counsel report material litigation agree audit fee propose external auditor company secretary report corporate governance committee consider cost comparison ensure fair corporate activity undertake rocc appropriate gsk contractual obligation compliance officer restrict committee capacity recommend particular firm external auditor group pricewaterhousecooper llp head audit majority head group remain place auditor group inception assurance report audit scope annual december group compliance coverage audit resource audit group result audits conduct make assessment committee consider paper year detail relevant uk legislative regulatory professional requirement relate external auditor evaluate company secretary report matter affect report external auditor compliance chairman quality timely disclosure financial requirement safeguard establish disclosure material information internal quality control procedure consideration committee board public market give committee need include risk shareholder enable withdrawal external auditor market risk committee review clarity evaluation planning completeness disclosure publish annual financial statement external auditor provide nonaudit services interim report quarterly preliminary committee ensure auditor objectivity independence result announcement formal safeguard policy require preapproval announcement relate financial committee service service include audit performance prior approval service auditrelate service tax service service board preapproval detailed particular service category service subject specific budget audit risk committee management internal auditor external auditor management report regularly board work ensure quality company committee extent service provide accordance corporate accounting financial reporting committee preapproval fee services perform serve primary link board external committee preapprove additional service internal auditor facilitate necessary independence casebycase basis expenditure audit nonaudit service management encourage external internal auditor set note financial statement operating profit communicate freely regularly committee committee meet collectively separately guideline set company policy engage external auditor head audit assurance external auditor provide nonaudit service include ascertain corporate compliance officer member management skill experience external auditor present suitable supplier nonaudit service adequate safeguard place objectivity independence audit threaten compromise fee level relative annual audit fee limit set committee company wellestablishe policy include code ethic available website helpline facility report investigation unlawful conduct waiver code gsk annual report pp noitarenumer dna ecnanrevog corporate governance nominations committee report process continue committee place emphasis candidate current ceo financial expertise professional search agency engage specialise recruitment high calibre nonexecutive director dossier potential nonexecutive appointee provide committee candidate shortlist interview merit objective criterion consider relevant qualification appoint new executive director cet members committee consider skill knowledge experience require particular executive position committee consider potential external internal candidate recommend board approve new appointment new director offer election company agm appointment announce publicly ms deirdre connelly appoint president north america sir christopher gent pharmaceuticals th february member nomination committee chairman cet attendance meeting committee recommendation board approve members committee member follow change take effect retirement sir ian prosser dr schmitz board conclusion sir christopher gent th december agm sir robert wilson replace sir ian chairman sid sir crispin davis replace sir robert chairman st january remuneration committee professor sir roy anderson mr l culp th march member audit risk committee mr de swaan step sir crispin davis th july corporate responsibility committee sir deryck maughan th july member remuneration committee mr murdoch member corporate responsibility committee addition sir robert wilson th march committees recommendation board approve sir ian prosser th december appointment sir crispin sir deryck maughan members committee chairman nominations committee effect th july februarydecember committee recommend board approve appointment mr murdoch member remuneration dr r schmitz th committee effect st october sir ian prosser dr schmitz retired board th remuneration report attendee committee meeting remuneration report find page ceo chief staff head hr company secretary relevant appropriate external adviser committee main responsibility include propose appointment board committee member committee main focus recruitment new nonexecutive director refresh board appointment new head north american pharmaceutical recruit nonexecutive director committee consider particular skill knowledge experience benefit board significantly appointment broad selection criterion focus achieve balance representation european uk market individual ceo experience skill develop sector speciality particular focus place recruiting replacement sir ian prosser dr ronaldo schmitz retired agm committee recommend appointment mr james murdoch nonexecutive director gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp corporate governance corporate responsibility committee report year committee review area include pandemic flu include access vaccine antiviral medicine develop country access pricing medicine develop country rd disease develop world patent pool community partnership investment humanitarian donation sale marketing practice include harmonisation gsk code practice disclosure payment healthcare professional communication clinical trial result use animal research employment practice include diversity inclusion sir christopher gent corporate responsibility committee chairman employee wellbee employee relation include consultation arrangement attendance employment litigation usa meetings members committee member supply chain management sir christopher gent th december climate change energy use reduction chairman manufacturing efficiency st january data privacy dr burn th december corruption prevention mr j murdoch th gsk publish comprehensive corporate responsibility report dr podolsky st july available company website sir ian prosser th combine code mr de swaan st july company comply provision apply main principle section combine code sir ian prosser retired board th mr de swaan cease member committee date regard aspect follow provision attendee committee meeting include chairman arrange chairman audit remuneration nomination committee ceo available answer question agm director general counsel attend h ead corporate communication community entire board attendance company agm partnership save sir deryck maughan prevent head corporate responsibility attend urgent business commitment company secretary arose shortly meet need convey apology absence augment gsk engagement stakeholder opinion march ms sophia tickell appoint independent external law regulation adviser committee ms tickell director pharma number provision law regulation apply gsk future series aim align well societal shareholder company share quote nyse value chair international advisory group form ad medicine transparency alliance ms tickell attend meetings committee advise company capacity nyse rules general nyse rules permit company follow uk main responsibility corporate responsibility corporate governance practice instead applied usa committee set committee rolling provide company explain significant variation agenda receive report member cet explanation contain company form f file senior manager ensure progress meeting gsk access security exchange commission corporate responsibility principle review principle sec edgar database company website nyse rule access medicine standard ethical conduct research come effect require company file annual innovation employment practice global community interim write affirmation concern audit risk committee partnership review annually principle discuss company statement significant difference year committee review corporate governance approve corporate responsibility report gsk annual report pp noitarenumer dna ecnanrevog corporate governance sarbanesoxley act disclose base recent evaluation follow number corporate accounting scandal internal control financial reporting external usa congress pass sarbanesoxley act sarbane auditor audit risk committee significant oxley wide range piece legislation concern largely deficiencie material weakness design financial reporting corporate governance operation internal control financial reporting reasonably likely affect adversely company ability recommend sec gsk establish disclosure record process summarise report financial information committee committee report ceo cfo fraud regardless materiality involve person audit risk committee chair company secretary significant role company internal control member consist senior manager finance legal financial reporting compliance corporate communication investor relation group carry evaluation supervision external legal counsel external auditor invite attend participation group management include meeting periodically responsibility consider ceo cfo effectiveness design materiality information timely basis determine operation group disclosure control procedure disclosure information responsibility timely file st december report sec formal review annual report form f committee meet time inherent limitation effectiveness system disclosure control procedure include possibility sarbanesoxley require annual report contain statement human error circumvention override control member company audit risk committee procedure accordingly effective disclosure control audit committee financial expert define sarbanesoxley procedure provide reasonable assurance achieve summary board judgement matter refer control objective additional disclosure requirement arise section section sarbanesoxley respect disclosure ceo cfo expect complete certification control procedure internal control financial reporting report conclusion effectiveness disclosure control procedure st march follow section corporate responsibility financial report certificate file sec group sarbanesoxley introduce requirement ceo form f cfo complete formal certification confirm section management annual report internal review annual report form f control financial reporting b ased knowledge contain material accordance requirement section sarbane misstatement omission oxley follow report provide management respect b ase knowledge financial statement companys internal control financial report financial information fairly present material respect define rule af df securities financial condition result operation cash flow exchange act date period present annual report management responsible establish maintain form f adequate internal control financial reporting hey responsible establish maintain disclosure group internal control financial reporting design control procedure ensure material information provide reasonable assurance reliability know evaluated effectiveness financial reporting preparation financial statement control procedure yearend result external purpose accordance ifrs evaluation contain annual report management conduct evaluation effectiveness form f internal control financial reporting base hey responsible establish maintain internal framework internal control integrate framework control financial reporting provide reasonable issue committee sponsor organisation assurance reliability financial reporting treadway commission preparation financial statement external purpose change group internal control accordance generally accept accounting principle financial reporting materially hey disclose annual report form f affect reasonably likely affect materially change internal control financial reporting group internal control financial reporting period cover annual report form f management assess effectiveness internal control materially affect reasonably likely affect materially financial reporting st december company internal control financial reporting conclusion file group form f pricewaterhousecooper llp audit consolidated financial statement group year end st december assess effectiveness group internal control financial reporting auditing standard public company accounting oversight board united states audit report file group form f gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report sir crispin davis remuneration committee chairman dear shareholder new chairman gsk remuneration committee please present committee remuneration report seek approval shareholder agm know important change gsk remuneration policy uk executive director year deliver appropriately structure pay alignment market gsk key strategic priority high level shareholder engagement relation change please receive strong vote favour year remuneration report agm senior management alignment competitiveness progress simplify align remuneration structure corporate executive team cet result primary pay benchmark base nature individual role industry benchmark previously share option normally long grant instead cet member receive performance share plan award eligible participate gsk defer annual bonus plan standardise pay mix cet role executive director committee want reward failure consider severance term limit determine contract new cet appointee normally include severance term year base salary bonus entitlement addition please report ceo agree remove contractual entitlement bonus event termination employment note increase hold gsk share strategic alignment introduction second performance measure performance share plan provide clear focus cash generation business continue develop measure align remuneration ongoing work transform gsk give importance long term organic growth rd productivity future gsk assess meaningful way measure success area consider performance measure future award good governance number corporate governance development past year response economic turmoil likely come review arrangement year want ensure motivate excessive risk take introduce new defer annual bonus plan company introduce clawback mechanism annual bonus problem arise year bonus award continue monitor good practice governance development commit regular review remuneration arrangement ensure continue encourage right behaviour leadership team follow report provide detail gsk current remuneration arrangement include change implement committee believe change support future business good interest shareholder sir crispin davis remuneration committee chairman th february gsk annual report pp noitarenumer dna ecnanrevog remuneration report remuneration committee quorate meeting hold year approve role committee formal grant longterm incentive lti awards accordance gsk remuneration policy role committee set company remuneration policy executive director cet member exception mrs whyte deputy company secretary executive ensure consistent company secretary committee employee company scale scope operation support business strategy involve conduct committee meeting mr witty ceo growth plan help drive creation shareholder value mr heslop cfo mr bicknell senior vice president company set remuneration policy level senior secretary corporate compliance officer mr phelan chief executive committee give consideration remuneration staff ms thomas senior vice president human resource policy level wide employee population mr powley senior vice president corporate compensation invite attend meeting committee term reference require attend individual remuneration committee term reference conform discuss director involve decide requirement combine code available company remuneration website obtain company secretary committee access external advice require deloitte governance llp appoint committee provide board consider member committee independent advice executive remuneration year independent nonexecutive director accordance deloitte llp provide independent commentary matter combine code exception chairman consideration committee provide update good company sir christopher gent independent practice legislative requirement market practice appointment company deloitte llp provide tax consulting service committee meet time member gsk year provide advice executive attending follow remuneration matter committee tower number number watson provide additional market datum committee meeting meeting hold attend commitment shareholder committee member whilst whilst member member member committee engage regular dialogue shareholder sir crispin davis st july hold annual meeting gsk large investor chairman discuss feedback remuneration policy th key development year particular committee discuss significant change policy measure sir robert wilson st january assess performance chairman th th summary policy result remuneration review change mr l culp st january remuneration package ceo cfo sir christopher gent st january mr j murdoch st october remuneration structure cet member include mr de swaan th chairman research development harmonise dr ronaldo schmitz th ceo cfo result effect share option normally long grant mr de swaan chairman audit risk committee cet member instead cet member receive additional dr schmitz retired board th performance share award eligible participate member committee prior date gsk defer annual bonus plan gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report key element remuneration policy onwards salary salary level review annually influence executive role experience benchmarke relevant comparator group annual bonus majority bonus base achievement financial target base group profit interest tax business unit operate profit individual performance predetermine personal objective take account determine individual bonus payment rd specific key performance indicator rd employee achievement additional operational efficiency goal take account determine annual bonus respect individual include ceo maximum bonus opportunity salary committee review ongoing financial impact prior year activity executive role appropriate adjustment individual bonus award reflect circumstance defer individual elect defer bonus earn annual respect ceo cfo eligible participate bonus plan executive participate deferred bonus match oneforone subject relative total shareholder return tsr performance year tsr vest psp performance vest base relative tsr comparator group currently comprise pharmaceutical share company plan psp half tsr component measure year half year vest median vest upper quartile performance twelvemonth averaging period tsr vest base adjust free cash flow measure year vest threshold rise stretching performance exceed set threshold specify margin operate maximum face value annual performance share award follow salary ceo chairman research development cfo share option option long normally grant executive plan pension uk executive define contribution plan legacy final salary plan close new entrant executive participate define contribution plan benefit company contribution base salary plus match contribution base salary executive gsk operate cash balance plan executive benefit contribution salary gsk annual report pp noitarenumer dna ecnanrevog remuneration report total remuneration benchmarking ceo committee review gsk total remuneration comparable company regular basis ensure salary remuneration arrangement structure appropriately deliver cash bonus value money shareholder long term defer bonus include match competitive relevant comparator group determine performance share individual executive benchmarking purpose total remuneration incorporate base salary bonus ltis set pay committee consider pension arrangement cfo uk crossindustry comparator group global pharmaceutical comparator group salary angloamerican france sanofiaventis cash bonus astrazeneca switzerland novartis defer bonus include match barclay roche holding performance share bg group uk astrazeneca bhp billiton usa abbott laboratories bp amgen british american tobacco bristolmyers squibb chairman rd diageo eli lilly hsbc johnson johnson salary reckitt benckiser merck cash bonus royal dutch shell pfizer rio tinto deferred bonus include match performance share standard charter tesco unilever vodafone committee consider current economic revise reflect delist scheringplough wyeth condition new gsk harmonise pay philosophy amgen include benchmarke current accordingly agree ceo cfo pay tsr comparator group hold level alignment pay structure cet dr slaouis base salary adjust reflect individual element remuneration new balance market rate pay responsibility balance fix base salary variable annual table immediately follow set current base salary bonus lti element remuneration vary depend propose performance chart right anticipate mix salary increase typically effect st april year fix variable pay expect value basis new remuneration policy actual mix high base effective date base effective date low depend performance gsk individual salary salary salary salary change typically significant portion approximately mr witty st april st april executive director package variable mr heslop st april st april base salary dr slaoui st april st april base salary set reference relevant comparator group level consider appropriate secure talent need deliver gsk strategic priority gsk remuneration policy base principle achieve competitiveness global pharmaceutical industry primary pay comparator committee decide individual executive basis primary pay comparator global pharmaceutical sector ukbase large crossindustry multinational andor comparator group primary comparator group uk crossindustry global pharmaceutical mr witty ceo mr heslop cfo dr slaoui chairman rd salary level review annually influence executive role experience pay environment gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report annual bonus bonus target ceo set board set objective ceo board focus strategy annual bonus design drive achievement develop company set page gsk annual financial strategic business target personal objective annual report reason commercial sensitivity specific objective keep confidential follow end ontarget bonus executive director give financial year board review ceo performance table generally set objective committee determine bonus payable ontarget bonus base salary ceo executive ceo make recommendation cfo committee performance objective chairman rd recommendation consider committee determine level bonus payable maximum bonus set reference individual ontarget year committee review ongoing financial impact bonus level cap bonus payment prior year activity role individual executive salary cap remain unchanged annual bonus activity committee appropriate adjustment pensionable individual bonus award reflect circumstance year committee revise annual bonus plan chairman audit risk committee member strengthen alignment new business strategy detail committee provide input audit risk committee set page budgeting process review group performance adjustment respect bonus bonus measure rd employee include dr slaoui link group profit interest pipeline robust governance structure establish tax ensure bonus payable fairly reflect rd productivity performance performance profit target stretching process require review progress target rd financial bonus compensation review committee include ceo annual target business unit company nonexecutive director designate bonus operating profit scientific expert professor sir roy anderson dr podolsky targets committee review plan operation year decide continue annual bonus rd committee continue operation review future consider extend executive include ceo individual objective bonus award objective set company focus particular continued development launch late stage pipeline asset delivery commercial target execution restructure majority annual bonus opportunity base formal programme simplify operating model review performance stretch financial target base group profit interest tax business unit operating committee take account gsk success achieve profit target remainder base achievement objective individual performance specific individual objective annual bonus calibrate determine bonus award actual bonus payment reflect stretch target establish executive director shown range drive significant change gsk business model bonus base salary st december threshold target maximum payable bonus set committee reflect gsk increase sale achievement target bonus threshold profit cash flow performance year challenging reflect stretch nature bonus target market condition significant loss sale generics usa include achievement key strategic individual objective include deliver continue growth vaccine portfolio geographic diversification particularly emerge market consumer healthcare achieve key milestone transformation rd productivity particularly relation late stage rd pipeline product simplification gsk business model achievement operational efficiency gsk annual report pp noitarenumer dna ecnanrevog remuneration report defer annual bonus plan performance share new defer annual bonus plan introduce performance share plan ensure focus gsk encourage longterm shareholding discourage longterm shareholder return relative excessive risk take help drive longterm shareholder pharmaceutical company delivery gsk return relative global pharmaceutical company strategic priority eligibility bonus year restrict ceo plan measurement performance broaden cfo cet member invite participate senior team incentivise operational bonus year onwards simplification cet measure align gsk business strategy tsr remuneration structure tsr remain appropriate comparative measure focus return shareholder wellunderstood test annual bonus earn defer mechanism measure performance allow comparison year company match share oneforone depend company operate different country company relative tsr period performance typically proportion award executive measure vest schedule consistent threeyear continue subject relative tsr balance base tsr component performance share plan describe strategic operational measure support business strategy ceo elect participate gsk defer annual bonus emphasis work plan respect bonus result capital cash management ceo bonus defer share company reteste performance matching award number share vest february subject company award relative tsr performance continue employment performance share award executive february dividend equivalent accrue deliver respect defer share matching share vest tsr measure award award base longterm incentive plan relative tsr comparator group currently comprise new lti plan approve shareholder agm global pharmaceutical company tsr element provide well alignment uk market practice percentage vest median vest upper ceo cfo receive share option grant instead quartile tsr performance graph show tsr vest ltis form performance share schedule award grant opportunity defer bonus earn share proportion vest outline eligible receive matching share subject achievement additional performance condition chairman research development continue receive share option eligible participate new defer annual bonus arrangement onwards remuneration arrangement cet member include chairman research development align ceo cfo result share option normally long grant instead cet member receive performance share awards new lti plan committee reduce grant vest level determine participant engage conduct contrary legitimate expectation company employee participant position typically award deliver resident executive form ad award deliver form ordinary share executive resident uk country awards tsr rank position plan incorporate dilution limit consistent guideline provide association british insurer provide focus sustain longerterm performance current estimate dilution exist award gsk performance period extend award employee share scheme merger approximately half tsr element award measure company share capital st december year half year lti plan summarise relevant section measure performance stable basis reflect well basis award longterm nature pharmaceutical industry tsr average executive period month award onwards gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report ensure focus award base return relative tsr available shareholder end year global pharmaceutical phasing drive psp company sustain long award term performance pay share vary base performance award base adjusted free cash flow adjust free cash flow measure vest award recognise importance effective work capital committee review performance performance share cash management remain vest subject award grant executive director february achievement adjust free cash flow target target threeyear performance period start st january adjust material factor distort free cash flow end st december company rank performance measure typically include exchange median revise comparator group rate movement include legal major taxation award vested award senior executive settlement special pension contribution dependent tsr performance materially distort calculation impact acquisition ep performance ep portion awards vest divestment quantify adjust vest table recent performance share award event major adjustment calculation disclose share option award show shareholder award target b share option adjust free cash flow target vest remuneration review undertake threshold vest billion decide share option long grant billion ceo cfo align package well uk billion market outline decide simplify maximum vest billion remuneration structure cet member share option normally long grant cet member point vest calculate straight onwards line basis element base adjust free cash flow measure year detail subsist option performance condition attach grant provide audit section award value report individual award limit maximum initial value performance share grant individual vest award year exceptional circumstance maximum performance condition share option award grant face value performance share grant meet result award lapse individual year time salary value c historical vest gsk ltis performance share award grant executive director show table gsk lti performance condition continue challenge demonstrate table tsr important base salary award lti measure year measure retain current policy ceo share cfo share chairman rd ad adjust reflect removal share option provide close link shareholder return payment executive notional dividend reinveste pay proportion vest award value reinveste dividend incorporate benchmarking award level gsk annual report year year year year available end year recognise importance available effective work end year capital management cashpp noitarenumer dna ecnanrevog remuneration report follow table show vest level gsk performance b pension arrangement share share option award executive usa gsk operate cash balance plan provide remuneration review tsr vest percentage annual contribution interest sum accumulate indicate gsk tsr performance median cash balance plan contractual promise provide comparator group performance period specific level retirement income plan incorporate performance share share option executive pension credit senior executive contribution plan plan rate plan range base salary vest vest depend grade current senior executive eligible tsr eps performance period measure measure executive pension credit cap employee usa benefit cap provide unfunded nonqualified plan share ownership requirement align interest executive average annual vest shareholder executive require build maintain significant holding share gsk time award change award cycle current share ownership requirement sor set table pension share ownership requirement pension provide important tool create longterm ceo x base salary culture loyalty executive director x base salary executive participate gsk senior executive pension plan cet member x base salary pension arrangement structure accordance year mr witty building shareholding plan operate executive country actively purchase share market spend total likely retire detail individual arrangement executive tax earning publication director set annual report help build sor addition new executive gsk eligible define acquisition share dividend reinvestment contribution scheme cash balance plan exist obligation elect participate gsk defer annual bonus plan define benefit scheme uk continue respect pretax bonus resultant honour award defer share include mr wittys sor table uk pension arrangement company currently operate define contribution plan shareholding purpose sor th february legacy final salary plan close new entrant newly hire executive uk participate define hold hold contribution plan sor purpose sor purpose increase shareholde uk government announce series change mr witty pension impact pension approximately ordinary share ordinary share executive gsk propose pension legislation mr heslop implement significant negative consequence ordinary share ordinary share uk executive effectiveness pension dr slaoui significantly reduce pension continue ordinary share ordinary share important tool create longterm culture promote employee retention gsk keep situation executive require continue satisfy shareholde active review requirement minimum month follow executive participate define contribution plan receive retirement company support longterm nature company contribution base salary depend business grade opportunity receive remuneration element match contribution line policy executive participate allemployee share plan member pension plan uk usa legacy final salary plan provide twothird final sharesave plan sharereward plan uk hm salary age employee subject cap benefit revenue custom approve plan open uk employee excess cap currently provide unfunded term arrangement legacy final salary plan actuarial reduction factor apply participant leave employment mr witty mr heslop member sharesave plan hisher accord age mr witty mr heslop contribute month plan provide option buy share end employment terminate company cause threeyear saving period line opportunity available way member legacy final uk employee salary plan reduction factor apply gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report mr witty mr heslop contribute month buy case outstanding awards glaxosmithkline share sharereward plan company match annual investment plan close new deferral number share buy month effect quarter provide agreement terminate cause defer executive receive benefit include healthcare income gain automatically medical dental personal financial advice life assurance distribute soon administratively practicable cash value benefit receive executive director termination show line policy applicable senior executive executive director term condition dr slaoui eligible future date receive executive director contract continue medical dental insurance retirement policy set provide framework contract follow merger participant legacy share option executive director scheme elect exchange legacy option option glaxosmithkline share receive additional cash notice period calendar month benefit equal grant price original option termination additional benefit trigger option exercise employ company lapse qualify additional cash benefit participant executive retain option second anniversary termination payment x annual salary effective date merger x annual ontarget bonus outside appointment executive director mitigation require outside appointment approve chairman vest ltis rule relevant incentive plan behalf board company policy remuneration approve shareholder earn appointment keep individual executive director pension base exist arrangement term relevant pension plan nonexecutive director term condition nonexecutive director glaxosmithkline service noncompete clause month termination contract instead letter appointment notice date agree serve company nonexecutive director ceo agree amendment contract remove contractual conclusion agm follow anniversary entitlement bonus termination package contract appointment case extend new executive normally include bonus element termination term year mutual agreement director serve payment extent company impose noncompete term long year offer provision restrict individual work compensatory reelection shareholder payment nonexecutive director entitle compensation ability impose month noncompete period nonsolicitation restriction executive consider important company order appointment terminate ability protect group intellectual property staff light follow table show date initial letter committee believe appropriate provide appointment nonexecutive director mitigation contract follow table set detail executive director nonexecutive director date letter appointment service contract professor sir roy anderson current director date contract effective date expiry date dr burns mr l culp mr witty sir crispin davis mr j heslop sir deryck maughan dr slaoui mr j murdoch mr wittys contract renew june follow appointment dr podolsky ceo supplement th february reflect change mr de swaan severance term outline sir robert wilson termination payment respect sir ian prosser notice period extend contract expiry date dr r schmitz entitlements sir ian prosser dr ronaldo schmitz retired board conclusion addition contractual provision outline agm th event executive director service agreement terminate employ company follow apply gsk annual report pp noitarenumer dna ecnanrevog remuneration report nonexecutive director fee share ad notionally award company aim provide nonexecutive director fee nonexecutive director allocate interest account competitive pay company include director interest table equivalent size complexity fee apply st december accumulate balance share ad follow notional dividend subsequently reinveste pay nonexecutive director retirement board annum retirement nonexecutive director receive standard annual cash retainer fee share ad cash equal value share supplemental fee ad date retirement chairman chairman audit risk committee sir christopher gents letter appointment board senior independent director date th agree scientificmedical expert serve company deputy chairman st december st january chairman conclusion chairman remuneration corporate agm follow anniversary appointment responsibility committee extend term year mutual agreement nonexecutive director undertake effect reelection director agm hold intercontinental travel meeting meeting st chairman fee currently annum plus chairman current chairman corporate allocation share value annum responsibility committee receive additional fee list tsr performance graph reflect increase focus company follow graph set performance company compliance risk gsk significantly enlarge remit relative ftse index company responsibilitie audit risk committee constituent pharmaceutical performance comparator commitment require chairman company agree group st january st december graph time requirement role committee chairman prepare accordance regulation move approximately day approximately day indication likely vest award grant annum reflect increase fee company incentive plan payable detail change committee term tsr performance reference new audit assurance model give page follow independent review supplemental fee chairman audit risk committee increase annum annum effect st october exchange rate fee pay dollar convert follow exchange rate exchange rate date approval period rate apply glaxosmithkline total return index give recent fluctuation dollar exchange rate agree glaxosmithkline pharma peer return index effect st october exchange rate set ftse total return index annually base average daily rate quarter year prior payment rate review exchange rate move significantly director senior management remuneration year follow table set director glaxosmithkline nonexecutive director share allocation plan plc remuneration earn interest share enhance link directors shareholders gsk glaxosmithkline plc interest share option incentive require nonexecutive director receive significant plan pension benefit member cet fee form share nonexecutive participate remuneration plan executive director total fee exclude chairman pay form director aggregate remuneration interest share ad allocate share account non director senior management provide executive director opportunity invest balance fee share account gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report annual remuneration total total fee annual annual fee annual annual salary benefit bonus remuneration salary benefit bonus remuneration footnote executive director mr witty abc mr j heslop b dr slaoui bd nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch e mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky director dr barzach mr j coombe sir ian prosser h dr r schmitz h dr jp garnier b dr l shapiro f mr c viehbacher bg dr yamada b total remuneration analyse executive director nonexecutive director director total remuneration remuneration director payroll report dollar dollar amount include total base conversion sterling average exchange rate year mr witty join board st january remuneration disclose date b follow merger order encourage employee convert nonsaving relate option hold legacy share ad option glaxosmithkline share ad employee grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse underwater qualify additional cash benefit participant retain option second anniversary effective date merger year mr witty receive mr heslop receive dr slaoui receive result option grant lapse dr garnier receive mr viehbacher receive nil dr yamada receive nil result option grant lapsing c mr witty elect participate gsk defer annual bonus plan respect bonus describe dr slaoui nonexecutive director agency science technology research astar respect receive include e mr murdoch appoint board effect th f dr shapiro retired board th step member gsk scientific advisory board st july receive fee form ad include fee salary g mr viehbacher appoint board st january remuneration disclose date resign board th september leave company st december h sir ian prosser dr r schmitz retire nonexecutive director company th leave board sir ian prosser dr r schmitz receive accumulate balance share previously award nonexecutive director share arrangement base current share price differ value date allocation set table include fee salary dr barzach receive fee glaxosmithkline france healthcare consultancy provide include fee salary director receive reimbursement expense year require separate disclosure require regulation gsk annual report pp noitarenumer dna ecnanrevog remuneration report nonexecutive director remuneration total cash sharesad total cash sharesad fee current nonexecutive director professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch mr de swaan sir robert wilson dr burns mr l culp sir deryck maughan dr podolsky nonexecutive director sir ian prosser dr r schmitz total remuneration table set remuneration receive nonexecutive director company nonexecutive director require total fee form share allocate share account pay retirement board detail total value share ad date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share ad table set accumulate number share ad hold nonexecutive director relation fee receive board member st december movement account year number share ad allocate dividend nonexecutive director share arrangement footnote elect reinveste pay current nonexecutive director share professor sir roy anderson sir crispin davis sir christopher gent mr j murdoch b mr de swaan sir robert wilson ads dr burns mr l culp sir deryck maughan dr podolsky nonexecutive director sir ian prosser dr r schmitz chairman receive allocation share value annum b mr murdoch appoint board effect th gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report table set settlement nonexecutive director share arrangement leave board value value date awards award payment footnote leave allocation leave sir ian prosser ab dr r schmitz ac change value award allocation leave attributable dividend reinveste change share price date award date leave b award sir ian prosser nonexecutive director share arrangement partially settle share balance share settle c awards dr r schmitz nonexecutive director share arrangement settle cash director interest follow interest director company connected person show accordance fsa listing rule share ad st january th february st december date th february st december st january footnote appointment executive director mr witty mr j heslop dr slaoui b nonexecutive director professor sir roy anderson c dr burns c mr l culp c sir crispin davis c sir christopher gent c sir deryck maughan c mr j murdoch cd dr podolsky c mr de swaan c sir robert wilson c glaxosmithkline ad represent glaxosmithkline share interest abovementione director th february reflect change yearend date include share purchase glaxosmithkline sharereward plan mr witty totalling st december st december share th february mr heslop totalling st december st december share th february b include ad purchase glaxosmithkline stock fund retirement saving plan executive supplemental saving plan c include share ad receive fee describe nonexecutive director share allocation plan dividend receive share ad convert share ad st december mr murdoch appoint board effect th holding show date gsk annual report pp noitarenumer dna ecnanrevog remuneration report incentive plan share option option share grant footnote date grant exercise period grant price number lapse mr witty mr j heslop dr slaoui b option ad grant date grant exercise period grant price number lapse dr slaoui b grant share option mr heslop respect participation sharesave plan b detail include interest dr slaouis connect person employee gsk option outstanding st december early late vesting lapse date option market price glaxosmithkline share yearend give table weight average vest date lapse date mr witty grant price number early latest early late option market price yearend vest unvested option market price yearend vest unvested total share option st december weight average vest date lapse date mr j heslop grant price number early latest early late option market price yearend vest unvested option market price yearend vest unvested total share option st december weight average vest date lapse date dr slaoui grant price number early latest early late option market price yearend vest option market price yearend vest total share option st december option market price yearend unvested option market price yearend unvested total ad option st december include share option hold dr slaouis connect person employee gsk gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report gsk grant share option executive director annual basis director hold option share option plan refer note financial statement employee share scheme nonexecutive director interest option company share table set share option grant respect performance period performance target option vest st december performance target vest status annualise growth percentage grant footnote performance period ep award vest february unvested rpi february unveste rpi rpi rpi rpi performance target share option meet result lapse anniversary date grant table set share option grant respect performance period target performance target vest status annualise growth percentage grant performance period ep award vest february award unvested rpi february award unvested rpi rpi rpi rpi highest low closing price year end st december glaxosmithkline share respectively high low price glaxosmithkline ad year end st december respectively market price glaxosmithkline share st december st december glaxosmithkline ad st december price th february glaxosmithkline share glaxosmithkline ad performance share plan psp award performance share award executive director annual basis director hold option psp plan refer note financial statement market additional mr witty share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste market additional mr j heslop share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste gsk annual report pp noitarenumer dna ecnanrevog remuneration report market additional dr slaoui share number price vest share unveste grant date market dividend unvested performance period grant number price gain lapse reinveste market additional dr slaoui ad number price vest ad unveste grant date market dividend unvested performance period grant number price gain lapse reinveste include performance share hold dr slaouis connect person employee gsk term psp number share actually vest determined follow end relevant measurement period dependent gsk performance period describe page committee adjust comparator group remove scheringplough wyeth follow delist revised vest schedule accordingly outstanding future awards tsr performance measure revise comparator group include gsk set dividend reinveste performance share award executive performance period date final award dividend reinvestment calculate dividend payment date term psp participant defer receipt vested award total gain vest psp award executive director connect person follow vest schedule apply psp award tsr vest schedule award award performance period tsr rank company percentage award vest median median follow vest schedule apply psp award tsr vest schedule award award performance period tsr rank company percentage award vest median median adjust free cash flow vest schedule cash flow target award award performance period bn percentage award vest gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp remuneration report share value plan award market dr slaoui share ad number price vest defer unvested grant date market unvested plan year grant number price gain share ad ad ad ad executive director dr slaoui eligible receive award share value plan award show reflect holding dr slaouis connect person employee gsk award subject threeyear vest period vest contingent continue employment gsk pension benefit accrue annual pension benefit transfer value executive director office st december retirement set company act require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value change pension executive director disclose currency pension payable change change personal accrue transfer value accrue accrue accrue contribution transfer transfer change benefit change benefit benefit benefit value value transfer year net accrue year year value inflation benefit executive director mr witty mr j heslop dr slaoui dr slaoui show net contribution individual mr witty mr heslop participate glaxo wellcome define benefit plan accrual rate th final pensionable salary annum benefit accrue glaxo wellcome uk pension arrangement augment trustee plan reflect distribution surplus augmentation apply element mr witty mr heslops pension earning st march mr wittys mr heslops transfer value calculate basis actuarial advice accordance pension regulation transfer value represent present value future payment pension plan mr wittys annual accrue benefit increase exclude effect inflation transfer value personal contribution increase year mr heslops annual accrue benefit increase exclude effect inflation transfer value personal contribution increase year gsk annual report pp noitarenumer dna ecnanrevog remuneration report dr slaoui member executive cash balance pension th february group comprise person own plan plan provide executive pension credit share ad constitute gsk make annual contribution calculate percentage issue share capital company group hold executive base salary gsk make contribution date option purchase share base pay fund increase interest rate set annually ad share ad award advance base year treasury bond rate provide performance share plan include share ad cash sum retirement plan entitlement spouse vest defer vested defer ad pension pension increase legacy smithkline beecham midterm incentive plan share ad award share value plan transfer value cash sum increase notional share award deferred investment award dr slaoui year result accumulation plan holding issue executive share interest contribution pay company option plan describe note financial statement dr slaoui active participant belgium fortis plan employee share scheme st plan define benefit plan director interest contract lump sum payable normal retirement age describe note financial statement relate plan transfer value cash sum dr slaouis plan party transaction end financial year increase year result director connect person material interest accumulation interest contract significance relation group business dr slaoui member retirement saving plan k group company saving scheme open employee executive basis preparation supplemental saving plan saving scheme open executive accrue benefit government limit impose director remuneration report prepare retirement saving plan contribution plan invest accordance company act large range fund value accumulate fund pay mediumsize company group account report retirement regulation regulation meet relevant requirement fsa list rule accordance contribution pay regulation follow section remuneration report scheme gsk respect dr slaoui subject audit annual remuneration nonexecutive director director senior management remuneration incentive plan share option performance share plan award vest criterion share value plan award information provide compensation interest pension benefit opinion thereon express director senior management group group remain section subject audit purpose group define executive page refer audit section nonexecutive director member cet financial remuneration report approve board year total compensation pay member group director sign behalf period serve capacity aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme sir christopher gent members group grant chairman share option ad option share option th february plan award share ad performance share plan award share ad share value plan notional share ad grant defer investment award plan member group award reinvestment dividend share ad performance share plan notional share defer investment award plan gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp financial statement financial statement provide summary director statement responsibility independent auditor report group financial performance financial statement position consolidate income statement st december consolidate statement comprehensive income consolidate financial consolidated balance sheet statement prepare consolidated statement change equity accordance ifrs consolidated cash flow statement adopt european union note financial statement ifrs issue presentation financial statement international accounting accounting principle policy key accounting judgement estimate standard board new accounting requirement exchange rate segment information major restructuring programme operate income operating profit employee cost finance income financial statement finance cost consolidated financial statement present associate joint venture profit cash flow year balance taxation sheet position end year earning share dividend property plant equipment note financial statement goodwill note financial statement provide intangible asset support analysis primary statement investment associate joint venture investment noncurrent asset financial statement glaxosmithkline plc inventory financial statement glaxosmithkline plc trade receivables provide information company cash cash equivalent prepare uk gaap asset hold sale trade payable pension postemployment benefit provision noncurrent liability contingent liability net debt share capital share premium account movement equity relate party transaction adjustment reconcile profit tax operating cash flow reconciliation net cash flow movement net debt acquisition disposal commitment post balance sheet event financial instrument relate disclosure employee share scheme principal group company legal proceeding financial statement glaxosmithkline plc prepare uk gaap gsk annual report pp stnemetat laicnanif director statement responsibility director statement responsibility relation business review section contain annual report group financial statement include fair review development performance business position group director responsible prepare annual report description principal risk uncertainty face remuneration report group financial statement accordance applicable law regulation disclosure information auditor company law require director prepare financial statement director office date report financial year law director elect confirm prepare group financial statement accordance far aware relevant audit international financial reporting standard ifrs adopt information company auditor unaware european union prepare group financial statement director elect comply ifrs issue take step ought international accounting standard board iasb company take director aware law director approve group financial statement relevant audit information establish company satisfied true fair view auditor aware information state affair group profit loss group period confirmation give interpret accordance provision section company act prepare financial statement director require go concern basis select suitable accounting policy apply consistently business review page contain information performance group financial position cash flow judgement accounting estimate net debt position borrowing facility information reasonable prudent include treasury risk management policy exposure market state group financial statement comply ifrs credit risk hedging activity give note adopt european union ifrs issue financial statement financial instrument relate disclosure iasb subject material departure disclose explain financial statement make enquiry director reasonable expectation group adequate resource continue director responsible keep adequate accounting operational existence foreseeable future reason record sufficient explain company continue adopt go concern basis prepare transaction disclose reasonable accuracy time financial statement financial position group enable ensure group financial statement director remuneration internal control report comply company act article board audit risk committee review ias regulation responsible safeguarding assessment risk internal control framework operate asset group take reasonable step gsk consider effectiveness system internal prevention detection fraud irregularity control operation group year cover report date approval board director group financial statement year end st december comprise principal statement support note combine code set financial statement page board consider glaxosmithkline plc apply main report principle combine code corporate governance responsibilitie auditor relation group financial financial reporting council describe corporate statement set independent auditor report governance page comply provision describe group financial statement year end st december require listing rule financial service authority include annual report publish auditor consider director statement hardcopy print form available company compliance relation point combine code website director responsible maintenance specify review integrity annual report website accordance annual report uk legislation govern preparation dissemination annual report year end st december financial statement access website available comprise report director remuneration report outside uk comparable legislation different financial statement additional information investor current director name function list approve board director sign corporate governance section annual report behalf confirm good knowledge sir christopher gent group financial statement prepare chairman accordance ifrs adopt eu ifrs issue th february iasb true fair view asset liability financial position profit group gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp independent auditor report members glaxosmithkline plc audit group financial statement opinion matter prescribed glaxosmithkline plc year end st december company act comprise consolidated income statement consolidate opinion information give director report statement comprehensive income consolidate balance financial year group financial statement sheet consolidate statement change equity prepare consistent group financial statement consolidate cash flow statement relate note financial reporting framework apply matter require report preparation applicable law international financial reporting exception standard ifrss adopt european union report respect follow respective responsibility director company act require report auditor opinion explain fully director statement certain disclosure director remuneration specify law responsibility set director responsible preparation group financial statement receive information explanation satisfy true fair view responsibility require audit audit group financial statement accordance applicable law international standard audit uk ireland list rule require review standard require comply auditing practice director statement set relation board ethical standard auditor go concern report include opinion prepare corporate governance statement relate company member body accordance company compliance provision june chapter company act combine code specify review purpose give opinion accept assume matter responsibility purpose person report show hand come save report separately parent company financial expressly agree prior consent writing statement glaxosmithkline plc year end st december information director scope audit financial statement remuneration report describe audit audit involve obtain evidence amount company pass resolution accordance section disclosure financial statement sufficient reasonable company act senior statutory auditor assurance financial statement free material state misstatement cause fraud error include assessment accounting policy appropriate group circumstance consistently apply adequately disclose reasonableness significant accounting pricewaterhousecooper llp estimate director overall presentation charter accountant statutory auditor financial statement london opinion financial statement th february opinion group financial statement g ve true fair view state group affairs st december profit cash flow year end properly prepared accordance ifrss adopt european union prepare accordance requirement company act article las regulation separate opinion relation ifrss issue iasb explain note group financial statement group addition comply legal obligation apply ifrss adopt european union apply ifrss issue international accounting standard board iasb opinion group financial statement comply ifrss issue iasb gsk annual report pp stnemetat laicnanif consolidated income statement year end st december result major major restructuring restructure total note turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p dilute earning share penny p calculation result major restructuring describe note presentation financial statement consolidate statement comprehensive income year end st december profit year exchange movement overseas net asset net investment hedge reclassification exchange liquidation overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment actuarial lossesgain define benefit plan defer tax actuarial movement define benefit plan fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income expense fair value movement subsidiary acquisition comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder minority interest total comprehensive income year gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp result result result major major major major major major restructuring restructure total restructuring restructure total restructure restructure total note turnover cost sale gross profit sell general administration research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p calculation result major restructuring describe note presentation financial statement consolidate statement comprehensive income year end st december profit year exchange movement overseas net asset net investment hedge reclassification exchange liquidation overseas subsidiary tax exchange movement fair value movement availableforsale investment defer tax fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment actuarial lossesgain define benefit plan defer tax actuarial movement define benefit plan fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income expense fair value movement subsidiary acquisition comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder minority interest total comprehensive income year gsk annual report pp stnemetat laicnanif consolidated balance sheet st december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax liability pension postemployment benefit provision derivative financial instrument noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest total equity approve board th february sir christopher gent chairman gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp consolidate statement change equity year end st december shareholder equity share share retain minority total capital premium earning reserve total interest equity st january profit year comprehensive income year distribution minority interest dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share purchase held treasury share ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan st december profit year comprehensive income year distribution minority interest dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan st december profit year comprehensive expense year distribution minority interest change minority shareholding option minority interest dividend shareholder ordinary share issue ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan st december gsk annual report pp stnemetat laicnanif consolidated cash flow statement year end st december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment purchase business net cash acquire investment associate joint venture decreaseincrease liquid investment interest receive dividend associate joint venture proceed disposal associate net cash outflow investing activity cash flow financing activity proceed share employee share option share acquire esop trust issue share capital purchase share cancellation purchase treasury share increase longterm loan repayment longterm loan increase shortterm loan repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder dividend pay minority interest finance cash flow net cash outflow financing activity increase cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement presentation financial statement estimate total cost approximately billion description business expand programme expect deliver annual pretax saving approximately billion time substantially glaxosmithkline major global healthcare group complete give extent cost operational engaged creation discovery development manufacture excellence programme management believe material marketing pharmaceutical product include vaccine impact gsk operating result manner overthecounter otc medicine healthrelate consumer gsk business conduct gsk present restructuring cost product gsk principal pharmaceutical product include incur solely direct result operational excellence medicine follow therapeutic area respiratory antiviral programme separate column income statement title central nervous system cardiovascular urogenital metabolic major restructuring antibacterial oncology emesis dermatalogical vaccine addition restructuring cost operational excellence compliance applicable law ifrs programme major restructuring column income financial statement prepare accordance statement include restructuring cost incur solely direct company act article ias regulation result restructure programme follow relate international accounting standard ias international financial material acquisition operation acquire business reporting standard ifrs relate interpretation adopt overlap extensively gsk exist operation european union restructuring activity follow relate financial statement compliance ifrs issue acquisition nature undertake international accounting standard board operational excellence programme carry follow detailed formal plan management consider composition financial statement appropriate present cost restructuring activity consolidate financial statement draw sterling manner billion million acquisition functional currency glaxosmithkline plc accordance reliant pharmaceutical december billion ifrs accounting presentation financial statement comprise billion acquisition stiefel laboratory july consolidated income statement acquisition october meet criterion set acquisition cost incur consolidated statement comprehensive income direct result related restructure programme consolidated balance sheet include major restructuring column consolidate statement change equity group result cost operational excellence consolidated cash flow statement programme acquisitionrelate restructuring programme note financial statement meeting criterion describe present separate column income statement describe accounting convention result major restructuring presentation financial statement prepare historical gsk intend apply consistently future major restructuring cost convention modify revaluation certain item programme material impact gsk operating result state accounting policy manner gsk business conduct financial period adopt clearly group result financial statement cover financial year st january cost restructure programme management st december comparative figure financial believe presentation assist investor gain clear year st january st december understand group financial performance appropriate st january st december make projection future financial performance result include cost virtue size nature limited composition group comparative value presentation consistent way list subsidiary associate undertaking management assess group financial performance opinion director principally affect profit restructuring cost arise solely direct result net asset group give note principal group operational excellence programme restructure company programme follow relate acquisition meet presentation restructuring cost criterion describe continue report operate october board approve implementation expense result major restructuring detail formal plan gsk announce significant new operational excellence restructure programme second formal plan represent significant expansion operational excellence programme approve board announce february expansion approve board announce february restructure programme comprise detailed formal plan cover area gsk business include manufacturing sell rd infrastructure gsk annual report pp stnemetats laicnanif note financial statement presentation financial statement accounting principle policy continue consolidation consolidated financial statement include accounting principle policy preparation financial statement conformity asset liability result cash flow generally accept accounting principle require management company subsidiary include esop trust estimate assumption affect report amount group share result net asset associate asset liability disclosure contingent asset joint venture liabilitie date financial statement report amount revenue expense report period financial statement entity consolidate actual result differ estimate st december year financial statement prepare accordance entity group power govern group accounting policy approve board financial operating policy account subsidiary describe note accounting principle policy group ability exercise joint control information application accounting policy entity account joint venture group include area estimation judgement give note ability exercise significant influence account key accounting judgement estimate appropriate associate result asset liability associate comparative figure reclassify ensure consistent joint venture incorporate consolidated financial presentation current year information statement equity method accounting implementation new accounting standard interest acquire entity consolidated date effect st january gsk implement ifrs group acquire control interest sell deconsolidate operate segment ias revise presentation financial date control cease statement ias revise borrowing cost minor transaction balance subsidiary eliminate amendment number accounting standard profit tax take sale subsidiary implementation ifrs result change product sell customer outside group segmental information report gsk comparative information relevant proportion profit transaction joint present consistent basis information venture associate defer product sell give note segment information party defer tax relief unrealise intragroup profit parent company financial statement account extent consider recoverable financial statement parent company glaxosmithkline goodwill arise acquisition interest subsidiary joint plc prepare accordance uk gaap uk ventures associate represent excess acquisition accounting presentation company balance sheet present cost group share fair value identifiable accounting policy give asset liability contingent liability acquire capitalise separate item case subsidiarie cost investment case joint ventures associate goodwill denominate currency operation acquire cost acquisition fair value net asset acquire difference recognise directly income statement gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement accounting principle policy continue expenditure expenditure recognise respect good service receive foreign currency translation supply accordance contractual term provision foreign currency transaction book functional currency obligation exist future liability respect group company exchange rate ruling date past event obligation reliably transaction foreign currency monetary asset liability estimate manufacturing startup cost validation retranslate functional currency rate exchange rule achievement normal production expense incur balance sheet date exchange difference include advertising promotion expenditure charge income income statement statement incur shipment cost intercompany transfer consolidation asset liability include related goodwill charge cost sale distribution cost sale customer overseas subsidiary associate joint venture include sell general administrative expenditure translate sterling rate exchange rule balance restructuring cost recognise provide sheet date result cash flow overseas subsidiary appropriate respect direct expenditure business associate joint venture translate sterling reorganisation plan sufficiently detail average rate exchange advance appropriate communication exchange adjustment arise open net asset affect undertaken profit year retain overseas subsidiary associate research development joint venture translate sterling exchange difference research development expenditure charge income arise relate foreign currency borrowing hedge statement period incur development group net investment operation take separate expenditure capitalise criterion recognise asset component equity meet usually regulatory filing major translating sterling asset liability result market approval consider highly probable property plant cash flow overseas subsidiary associate joint venture equipment research development depreciate report currency hyperinflationary economy accordance group policy adjustment material reflect current price level environmental expenditure loss net monetary asset charge consolidated environmental expenditure relate exist condition result income statement past current operation current revenue future benefit discernible charge income statement revenue recognise income statement good group recognise liability sitebysite basis service supply available external customer reliably estimate liability include group portion order receive title risk loss pass total cost portion potentially responsible customer reliable estimate relevant party cost probable able deduction turnover represent net invoice value satisfy respective share cleanup obligation recovery deduction discount allowance give accrual reimbursement record asset virtually certain estimate future rebate return methodology legal dispute assumption estimate rebate return monitor provision anticipated settlement cost legal adjust regularly light contractual legal dispute group outflow resource obligation historical trend past experience project market consider probable reasonable estimate condition market condition evaluate wholesaler likely outcome addition provision legal thirdparty analysis market research datum internally expense arise claim receive dispute generate information value add tax sale taxis respect product liability claim relate product exclude revenue sufficient history claim settlement incur group copromote product party report ibnr actuarial technique determine record sale group record share revenue reasonable estimate group exposure unasserted claim copromotion income turnover nature copromotion product provision basis activity group record cost sale provision unasserted claim respect pharmaceutical turnover include copromotion revenue number legal proceeding group involve million million million possible reasonable estimate expect royalty income recognise operating income financial effect result ultimate resolution accrual basis accordance term relevant proceeding case group disclose licensing agreement information respect nature fact case provision typically cost associate claim group party charge income statement incur gsk annual report pp stnemetat laicnanif note financial statement accounting principle policy continue lease lease agreement transfer group substantially pension postemployment benefit benefit risk ownership asset treat cost provide pension define benefit scheme finance lease asset purchase outright calculate project unit credit method spread asset include ppe computer software period benefit expect derive capital element leasing commitment show employee service consistent advice qualified obligation finance lease asset hold finance lease actuary pension obligation measure present value depreciate basis consistent similar own asset estimate future cash flow discount rate reflect yield lease term short interest element lease rental high quality corporate bond include income statement lease operate pension scheme asset measure fair value balance lease rental cost charge income statement sheet date actuarial gain loss difference straightline basis lease term expect actual return asset effect change goodwill actuarial assumption recognise statement goodwill state cost impairment goodwill deem comprehensive income year arise group indefinite useful life test impairment annually contribution define contribution plan charge income statement incur cost postemployment fair value interest acquire entitys asset liability calculate similar way define benefit pension liability contingent liability exceed consideration pay scheme spread period benefit excess recognise immediately gain income expect derive employee service accordance statement advice qualified actuary intangible asset employee share plan intangible asset state cost provision amortisation incentive form share provide employee impairment share option share award scheme licence patent knowhow marketing right separately fair value option award calculate acquire acquire business combination grant date blackschole option pricing model amortise estimate useful life generally charge income statement relevant vesting period exceed year straightline basis time available use estimate useful life group provide finance esop trust purchase company determine amortisation charge account patent share open market meet obligation provide share live applicable value obtain period employee exercise option award cost run nonexclusivity asset life review appropriate esop trust charge income statement share hold adjust annually contingent milestone payment recognise esop trust deduct reserve transfer point contingent event certain reserve retain earning development cost incur group associate vest period relate share option award reflect acquire licence patent knowhow marketing right ultimate proceed receivable employee exercise write income statement incur property plant equipment criterion recognition internally generate intangible property plant equipment ppe state cost asset meet usually regulatory filing purchase construction provision depreciation major market approval consider highly probable impairment financing cost capitalise cost acquire brand value independently fair value qualify asset construction business acquire party brand depreciation calculate write cost residual value value substantial longterm brand ppe exclude freehold land straightline basis contractual legal nature sell separately expect useful life residual value life review rest business acquire brand amortise appropriate adjust annually normal expect useful estimate useful life year live major category ppe consider useful economic life indefinite cost acquire develop computer software freehold building year internal use internet site external use capitalise leasehold land intangible fix asset software site support building lease term year significant business system expenditure lead plant machinery year creation durable asset erp system software amortise fixture equipment year seven year computer software year disposal ppe cost relate accumulate depreciation impairment remove financial statement net proceed take income statement gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement accounting principle policy continue trade receivable trade receivables carry original invoice impairment noncurrent asset provision doubtful debt provision carry value noncurrent asset review evidence risk nonpayment take account age impairment indication asset previous experience general economic condition trade impair additionally goodwill intangible asset indefinite receivable determine uncollectable write firstly useful life intangible asset available use provision available income statement test impairment annually provision impairment charge income statement year concern subsequent recovery amount previously provide credit income statement longterm receivables impairment goodwill reverse impairment loss discount effect material noncurrent asset reverse change estimate determine recoverable amount trade payable extent revise recoverable amount trade payable hold amortise cost equate exceed carry value exist net nominal value longterm payable discount depreciation amortisation impairment recognise effect material investment associate joint venture cash cash equivalent investment associate joint venture carry cash cash equivalent comprise cash hand current balance consolidate balance sheet group share net asset bank similar institution highly liquid investment date acquisition postacquisition retain profit original maturity month readily loss goodwill arise acquisition convertible know amount cash insignificant risk change value availableforsale investment liquid investment investment classify available borrowing forsale investment initially record fair value plus borrowing initially record proceed transaction cost remeasure subsequent reporting receive net transaction cost borrowing subsequently date fair value unrealised gain loss availableforsale carry amortise cost difference investment recognise directly comprehensive income proceed net transaction cost impairment arise significant prolong decline fair redemption recognise charge income statement value equity investment reduce carry period relevant borrowing asset directly charge income statement taxation disposal impairment investment gain current tax provide amount expect pay loss defer comprehensive income apply tax rate enact substantively enact reclassified income statement dividend equity balance sheet date investment recognise income statement defer tax provide liability method group right receive payment establish equity investment temporary difference arise tax basis asset record noncurrent asset expect liability carry amount financial statement sell year defer tax asset recognise extent probable purchase sale equity investment account future taxable profit available trade date purchase sale availableforsale temporary difference utilise defer tax provide investment account settlement date temporary difference arise investment subsidiary associate joint venture time inventory reversal temporary difference control inventory include financial statement low probable temporary difference reverse cost include raw material direct labour direct cost foreseeable future defer tax provide rate tax relate production overhead net realisable value enact substantively enact balance sheet cost generally determine basis prelaunch date defer tax liability asset discount inventory hold asset high probability regulatory approval product point provision carry value recoverable provision reverse point high probability regulatory approval determined gsk annual report pp stnemetat laicnanif note financial statement accounting principle policy continue key accounting judgement estimate prepare financial statement management require derivative financial instrument hedge estimate assumption affect amount derivative financial instrument manage exposure asset liability revenue expense report financial market risk treasury operation principal derivative statement actual amount result differ instrument glaxosmithkline foreign currency swap estimate follow consider key accounting interest rate swap forward foreign exchange contract judgement estimate group hold issue derivative financial instrument trade speculative purpose turnover revenue recognise title risk loss pass derivative financial instrument classify heldfortrade customer reliable estimate relevant carry balance sheet fair value derivative deduction gross turnover reduce rebate discount designate hedge instrument classify inception allowance product return give expect give cash flow hedge net investment hedge fair value hedge vary product arrangement buy group change fair value derivative designate cash flow arrangement purchase organisation dependent hedge recognise comprehensive income submission claim time initial extent hedge effective ineffective portion recognition sale accrual time sale recognise profit loss immediately amount defer estimate rebate discount allowance payable return comprehensive income reclassify income statement base available market information hedge item affect profit loss historical experience net investment hedge account similar way cash amount estimate fully reflect flow hedge final outcome amount subject change dependent thing type buy group change fair value derivative designate fair value product sale mix hedge record income statement change fair value hedge asset liability level accrual review adjust regularly light contractual legal obligation historical trend past change fair value derivative instrument experience project market condition market condition qualify hedge accounting recognise immediately evaluate wholesaler thirdparty analysis market income statement research datum internally generate information future event discount cause assumption accrual base time effect money material balance discount change affect future result group current value appropriate rate interest unwind taxation discount record finance income finance cost current tax provide amount expect pay defer tax provide temporary difference tax basis asset liability carry amount rate enact substantively enact balance sheet date group open tax issue number revenue authority gsk continue believe adequate provision liability likely arise open assessment open issue exist ultimate liability matter vary amount provide dependent outcome negotiation relevant tax authority necessary litigation proceeding gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement key accounting judgement estimate intangible asset continue intangible asset acquire gsk party cost acquisition capitalise licence compound legal dispute development amortise point gsk provide anticipate settlement cost outflow available use estimate useful life resource consider probable reasonable estimate include period nonexclusivity estimate useful life likely outcome dispute legal review annually impairment test undertake event expense arise claim group occur question carry value asset company director take legal advice brand acquire business capitalise independently establish provision take account relevant separable expect life fact circumstance matter accordance year brand amortise straightline basis accounting requirement provision product liability claim estimate useful life exceed year certain product incur report end useful economic life foresee brand basis sufficient history claim settlement amortise subject annual impairment test available provision unasserted initial valuation valuation subsequent impairment claim respect number legal proceeding test base established market multiple riskadjuste group involve possible reasonable estimate future cash flow discount appropriate interest rate expect financial effect result ultimate future cash flow base business forecast resolution proceeding case group inherently judgemental future event cause disclose information respect nature fact assumption impairment review change case provision typically st december consequent adverse effect future result group provision legal dispute amount million million pension postemployment benefit cost provide pension postemployment ultimate liability legal claim vary amount benefit charge income statement accordance provide dependent outcome litigation ias period benefit derive proceeding investigation possible settlement negotiation employee service cost assess basis position change time assumption select management assumption assurance loss result outcome include future earning pension increase discount rate legal proceeding exceed provision expect long term rate return asset mortality report group financial statement rate disclose note pension post property plant equipment employment benefit carry value property plant equipment test expect long term rate return bond determine impairment indication value base portfolio mix indexlinke government asset impaired impairment determine reference corporate bond equity risk premium add high fair value cost sell value use equity measure assess riskadjuste future cash flow discount appropriate interest rate future cash flow base discount rate derive aa rate corporate bond yield business forecast inherently judgemental country deep market corporate future event cause assumption bond government bond yield sensitivity analysis impairment test set note property plant provide note pension postemployment equipment change consequent adverse effect benefit reduction discount rate lead future result group increase net pension deficit approximately million increase annual pension cost goodwill approximately million selection different assumption goodwill arise business combination capitalise affect future result group allocate appropriate cash generating unit deem indefinite life amortise annual impairment test relevant cash generating unit perform impairment test base established market multiple riskadjuste future cash flow discount appropriate interest rate future cash flow base business forecast inherently judgemental future event cause assumption impairment test set note goodwill change consequent adverse effect future result group gsk annual report pp stnemetat laicnanif note financial statement new accounting requirement follow new standard interpretation follow new amend accounting standard ifric endorse eu interpretation issue iasb likely iasbs annual improvement project publish april affect future annual report expect change effective st january material impact result financial position group project make minor amendment number standard ifrs revise business combination issue january area include operate segment sharebase payment lease apply business combination arise intangible asset financial instrument st january change new standard amendment ifrs sharebase payment group cash require recognition subsequent change fair value settle sharebased payment transaction issue june contingent consideration income statement implement gsk st january goodwill transaction cost recognise amendment clarifie scope ifrs accounting immediately income statement fair value gain group cashsettle sharebased payment transaction loss exist investment acquire company financial statement individual group entity recognise income statement date acquisition ias revise relate party disclosure issue november ias revise consolidated separate financial statement implement gsk st january issue january implement revise standard clarifie definition relate party time ifrs revise respect transaction provide exemption government relate entity noncontrolle interest group entity result change control revise standard require ifrs financial instrument issue november difference consideration pay receive implement gsk st january record noncontrolle interest recognise equity standard step project replace ias case divestment subsidiary retain interest cover classification measurement financial asset remeasure fair value difference fair value iasb intends expand ifrs add new requirement previous carrying value recognise immediately classification measurement financial liability derecognition income statement financial instrument impairment hedge accounting complete replacement ias end ifrs revise ia revise apply prospectively transaction occur st january ifric extinguish financial liability equity instrument issue november implement amendment ias financial instrument recognition gsk st january interpretation address measurement eligible hedge item issue july accounting entity issue equity instrument order implement gsk st january settle financial liability amendment clarify aspect hedge accounting relate hedge option identification inflation amendment ifric prepayment minimum hedge risk funding requirement issue november implement gsk st january amendment amendment ia financial instrument presentation permit voluntary prepayment minimum funding requirement classification right issue issue october recognise asset implement gsk st january amendment require issue exist shareholder right acquire exchange rate additional share recognise equity regardless group use average exchange rate prevail currency share period translate result cash flow overseas subsidiary joint venture associate undertaking ifric distribution noncash asset owner publish sterling period end rate translate net asset november implement gsk undertaking currency influence st january interpretation specify entity translation relevant exchange rate account distribution noncash asset owner average rate euro yen period end rate euro yen gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement segment information gsk implement ifrs operating segment effect st january result change segmental information report gsk comparative information present consistent basis gsk operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet individual member cet responsible geographic region pharmaceutical business consumer healthcare business respectively major restructuring rd investment essential sustainability pharmaceutical business segment report usa europe emerge markets asia pacificjapan regional pharmaceutical operating profit exclude allocation globally fund rd central cost principally corporate function unallocate manufacturing cost gsk management reporting process allocate intragroup profit product sale market sale record profit analysis present basis trading pharmaceutical segment include canada puerto rico stiefel central vaccine tender sale contract manufacturing sale stiefel business integrate gsk effect st january result report relevant geographical pharmaceutical segment line way business manage gsk acquire hiv business pfizer effect th october return minority stake combine hiv business call viiv healthcare limited line way viiv healthcare business manage report separate segment st january gsk hiv business report relevant pharmaceutical segment incremental income cost creation viiv healthcare report trading pharmaceutical pharmaceutical rd segment responsibility chairman research development report separate segment unallocated pharmaceutical cost include cost vaccine rd central manufacturing cost attribute segment corporate unallocated cost disposal profit include corporate function cost legal matter fair value movement financial instrument investment unallocate profit asset disposal restate restate turnover segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical turnover consumer healthcare turnover pharmaceutical turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine consumer healthcare turnover category otc medicine oral healthcare nutritional healthcare gsk annual report pp stnemetat laicnanif note financial statement segment information continue pharmaceutical business sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler segment profit restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical rd unallocated pharmaceutical cost pharmaceutical operating profit consumer healthcare operate profit segment profit corporate unallocated cost disposal profit operate profit major restructure major restructuring total operating profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year depreciation amortisation segment restate restate pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical rd unallocated pharmaceutical pharmaceutical depreciation amortisation consumer healthcare depreciation amortisation segment depreciation amortisation corporate unallocated depreciation amortisation depreciation amortisation major restructure major restructure total depreciation amortisation gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement segment information continue ppe intangible asset impairment segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical rd unallocated pharmaceutical pharmaceutical impairment consumer healthcare impairment segment impairment corporate unallocated impairment impairment major restructure major restructure total impairment ppe intangible asset impairment reversal segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical rd unallocated pharmaceutical pharmaceutical impairment reversal consumer healthcare impairment reversal segment impairment reversal corporate unallocated impairment reversal impairment reversal major restructure major restructure total impairment reversal geographical information uk regard group country domicile turnover location customer restate restate uk usa rest world external turnover noncurrent asset location uk usa rest world noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount recoverable insurance contract certain noncurrent receivables gsk annual report pp stnemetat laicnanif note financial statement segment information continue restate total asset segment pharmaceuticals europe pharmaceutical emerge market pharmaceutical asia pacificjapan pharmaceuticals trading pharmaceutical pharmaceutical rd unallocated pharmaceutical pharmaceutical operating asset consumer healthcare operate asset segment operate asset corporate unallocated asset total operating asset investment associate joint venture liquid investment derivative financial instrument cash cash equivalent current defer taxation asset hold sale total asset unallocated pharmaceutical segment include asset centrally manage pharmaceutical vaccine manufacture operation depreciation total million million million recover standard cost product charge business major restructuring programme october gsk announce significant new operational excellence programme improve effectiveness productivity operation significant expansion operational excellence programme approve board announce february expansion approve board announce february total cost implementation expand programme expect increase billion approximately billion incur period approximately cost incur st december approximately expect incur balance total approximately cost expect cash expenditure expect asset writedown uncertainty exist exact time cash outflow result potential future exchange rate fluctuation element restructure programme subject employee consultation procedure make difficult predict precision procedure complete majority remain cash payment expect programme estimate deliver total annual pretax saving billion saving realise business total restructuring cost million incur million incur operational excellence programme follow area closure number manufacture site include dartford crawley uk cidra puerto rico give rise asset writedown staff reduction adoption customise sale approach lead staff reduction number sale force principally france c ost save project rd focus primarily simplification streamline support infrastructure include site rationalisation p roject simplify eliminate process lead staff reduction administrative support function addition cost million incur year restructure programme relate integration stiefel laboratories inc business usa follow acquisition july gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement major restructuring programme continue analysis cost incur programme follow asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect operate profit net finance expense effect profit taxation effect taxation effect earning asset staff impairment reduction cost total cost sale sell general administration research development effect profit taxation effect taxation effect earning asset impairment million million million net cost total million million nil noncash item charge settle cash restructuring cost report major restructuring column income statement cost relate minor restructure activity initiate prior october amount million million report result major restructuring cost major restructuring programme arise follow increase provision major restructuring programme note provision reverse unused note impairment property plant equipment note foreign exchange gainloss recognise liquidation subsidiary noncash charge cash cost net finance expense effect profit taxation noncash charge principally accelerate depreciation arise asset life shorten result major restructuring programme cash cost include termination lease site closure cost consultancy project management fee gsk annual report pp stnemetat laicnanif note financial statement operate income royalty income milestone income impairment equity investment disposal equity investment disposal asset legal settlement gain recognise creation viiv healthcare fair value adjustment derivative financial instrument income royalty milestone income principally core recur income outlicense intellectual property fair value adjustment derivative financial instrument include movement expire quest collar theravance option operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal amortisation intangible asset impairment intangible asset net reversal net foreign exchange lossesgain inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration fee payable company auditor associate audit parent company consolidated financial statement audit account group uk overseas subsidiary pursuant legislation assurance service pursuant legislation include attestation sarbanesoxley act audit assurance service tax service service include regulatory compliance treasury relate service st december pricewaterhousecooper llp associate fee invoice million comprise statutory audit million taxation service million service million fee payable pricewaterhousecooper llp associate audit assurance service remain flat cer term addition fee pay respect gsk pension scheme audit service gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity wage salary increase cer term group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial record average number person employ glaxosmithkline plc nil nil compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan finance income interest income arise cash cash equivalent availableforsale investment derivative fair value profit loss loan receivables realise gain liquid investment fair value adjustment derivative fair value profit loss net investment hedge ineffectiveness unwind discount asset derivative fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument ia interest income arise derivative fair value profit loss relate swap interest income gsk annual report pp stnemetat laicnanif note financial statement finance cost interest expense arise financial liability amortise cost derivative fair value profit loss fair value hedge fair value adjustment derivative designate hedge instrument fair value adjustment hedge item fair value adjustment derivative fair value profit loss reclassification cash flow hedge comprehensive income unwind discount provision derivative fair value profit loss designate effective hedging instrument classify heldfortrade financial instrument ia associates joint ventures associate share tax profit quest diagnostic inc share tax profit aspen pharmacare holding limit share tax loss associate share tax lossesprofit joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover quest diagnostic inc aspen pharmacare holding limit total profit quest diagnostic inc aspen pharmacare holding limited result aspen pharmacare holding limit include summarise income statement information represent estimate earning aspen group period associate undertake base analyst forecast gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement taxation taxation charge base profit year uk corporation tax uk statutory rate double taxation relief overseas taxation current taxation defer taxation additional uk corporation tax double taxation relief arise dividend receive overseas subsidiary reconciliation taxation rate group profit uk statutory rate taxation difference overseas taxation rate benefit special tax status rd credit intercompany stock profit impact share base payment tax profit associate difference prior year item restructure tax rate tax item charge equity statement comprehensive income current taxation share base payment foreign exchange movement defer taxation share base payment define benefit plan fair value movement cash flow hedge fair value movement availableforsale investment item charge statement comprehensive income tax share base payment group operate country tax rate differ uk tax rate impact overseas taxis overall rate tax show profit arise certain operation singapore accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share p p p group require ifrs create defer tax asset respect unrealise intercompany profit arise inventory hold group yearend apply tax rate country inventory hold tax rate country profit originally tax pay practice uk gaap result difference accounting treatment group tax rate current period intercompany profit ifrs increase increase decrease arise change location workinprogress finished good integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax resolution issue continue fact life gsk gsk annual report pp stnemetat laicnanif note financial statement taxation continue follow audit period irs issue statutory notice deficiency gsk assert income withholding tax deficiency associate penalty arise irss reclassification intercompany financing arrangement year debt equity consequent recharacterisation amount pay dividend subject withholding tax uk treaty amount financing arrangement pay timely basis final payment april gsk disagree irss position august initiate action united states tax court contest statutory notice deficiency th november gsk irs file stipulation tax court irs concede asserted tax deficiency penalty arise reclassification intercompany financing arrangement debt equity result additional tax cost gsk irs claim previously estimate gsk irs process finalise tax computation tax year anticipate resolution issue year reflect closing agreement resolution issue impact group result canada gsk continue contest court decision respect transfer pricing early date appeal hearing set march gsk continue believe adequate provision liability likely arise period open agree tax authority ultimate liability matter vary amount provide dependent outcome litigation appropriate agreement relevant tax authority provision taxation arise distribution profit retain overseas subsidiary ground group able control time reversal temporary difference probable reverse foreseeable future aggregate unremitte profit balance sheet date approximately billion billion introduction uk dividend exemption st july enable reasonable quantification incremental liability repatriation profit uk defer tax unremitte earning st december estimate approximately million relate taxis payable repatriation dividend withholding taxis levy overseas tax jurisdiction payable recoverable net movement current tax account st january exchange adjustment charge year cash pay movement st december movement defer tax asset liability pension manu share accelerate intra post legal facture stock option net offset defer taxation capital group retirement tax restruct valuation award temporary allowance intangible profit benefit loss dispute ure adjustment scheme difference country total assetsliabilitie defer tax asset st january defer tax liability st january st january exchange adjustment creditcharge income statement creditcharge equity creditcharge statement comprehensive income acquisition st december defer tax asset st december defer tax liability st december gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement taxation continue defer tax charge income relate change tax rate million defer tax movement arise origination reversal temporary difference net temporary difference include accrue expense provision st december group recognise defer tax asset million million respect income tax loss approximately million million loss million million expire million million expire million million available indefinitely st december group recognise defer tax asset respect income tax loss approximately million million million million expire million million expire million million available indefinitely group capital loss st december approximately billion respect defer tax asset recognise defer tax asset recognise probable future taxable profit available utilise loss factor affect tax charge future year global organisation factor affect future effective tax rate group mix profit different territory transfer pricing dispute tax authority location research development activity significant impact group effective tax rate change tax legislation territory gsk business operation impact group effective tax rate uk tax authority propose significant change uk taxation system december uk government announce intend introduce patent box regime apply reduce rate corporation tax income patent change expect effect april follow period consultation uk government continue consult business propose change control foreign company regime change expect enact earning share pence pence pence basic earning share adjustment major restructure basic earning share major restructuring dilute earning share adjustment major restructuring dilute earning share major restructure basic adjust earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share adjust earning share calculate result major restructure earning calculation result major restructuring describe note presentation financial statement dilute earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option dilute share hold esop trust exclude trustee waive right dividend share hold esop trust gsk annual report pp stnemetat laicnanif note financial statement dividend interim second interim interim fourth interim total total dividend dividend share penny paidpayable th july th october th january th april total dividend dividend share penny pay th july th october th january th april total dividend dividend share penny pay th july th october th january th april ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder property plant equipment plant land equipment asset building vehicle construction total cost st january exchange adjustment addition addition business combination disposals writeoff reclassification transfer asset hold sale cost st december exchange adjustment addition addition business combination capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost st december gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement property plant equipment continue plant land equipment asset building vehicle construction total depreciation st january exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation st december exchange adjustment provision year disposal writeoff transfer asset hold sale depreciation st december impairment st january exchange adjustment disposal writeoff impairment loss reclassification reversal impairment impairment st december exchange adjustment disposal writeoff impairment loss reversal impairment impairment st december total depreciation impairment st december total depreciation impairment st december net book value st january net book value st december net book value st december net book value st december group land building comprise freehold property million million property lease year million million property lease year million million include land building st december lease asset cost million million accumulate depreciation million million impairment nil million net book value million million include plant equipment vehicle st december lease asset cost million million accumulate depreciation million million net book value million million lease agreement include renewal purchase option escalation clause impairment loss principally arise decision rationalise facility calculate base fair value cost sell value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate country specific risk impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately impairment loss charge cost sale million rd million sga million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale gsk annual report pp stnemetat laicnanif note financial statement goodwill cost st january exchange adjustment addition business combination cost st december net book value st january net book value st december addition year translate acquisition exchange rate arise acquisition follow business stiefel laboratories inc pfizer hiv business ucb sa novamin technology inc az tika laboratoire pharmaceutique algrien note acquisition disposal detail carry value goodwill translate yearend exchange rate balance arise acquisition follow business cash generating unit stiefel laboratories inc stiefel laboratories inc reliant pharmaceuticals inc pharmaceuticals d biomedical corporation pharmaceutical segment sirtris pharmaceuticals inc pharmaceutical segment pfizer hiv business viiv healthcare group glaxosmithkline kk japan pharmaceuticals domantis limit pharmaceutical segment cns inc consumer healthcare polfa poznan sa poland pharmaceutical certain business ucb sa emerge market asia pacificjapan pharmaceuticals novamin technology inc consumer healthcare gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement goodwill continue goodwill allocate cash generating unit test impairment annually follow implementation ifrs operating segment cash generating unit goodwill balance allocate change goodwill arise acquisition d biomedical sirtris pharmaceuticals domantis split pharmaceutical segment usa europe emerge markets asia pacificjapan impairment testing purpose benefit acquire business split pharmaceutical segment generate independent cash flow valuation pharmaceutical cash generating unit reliant pharmaceutical prepare fair value cost sell basis turnover earning multiple derive observed market datum value goodwill inherent pharmaceutical cash generating unit considerably excess book value acquire goodwill recoverable amount cash generating unit assess value use fair value cost sell model value use calculate net present value project riskadjuste posttax cash flow plus terminal value cash generating unit goodwill allocate initially posttax discount rate apply calculate net present value posttax cash flow posttax discount rate base group wacc cash generating unit integrate operation large part group group wacc equivalent pretax discount rate approximately discount rate increase specific country risk sufficiently significant material impact outcome impairment test impairment test indicate recoverable value unit close carrying value test reperforme pretax discount rate pretax cash flow order determine impairment exist establish magnitude fair value calculate similar discount cash flow approach base group acquisition valuation model posttax discount rate apply project riskadjuste posttax cash flow terminal value detail relate discount cash flow model impairment test significant goodwill balance follow stiefel laboratory cgu viiv healthcare cgu pharmaceutical segment cgus valuation basis fair value cost sell fair value cost sell value use key assumption sale growth rate sale growth rate sale growth rate profit margin profit margin profit margin achievement synergy target discount rate discount rate discount rate determination growth rate internal growth rate internal growth rate internal forecast assumption forecast base internal forecast base internal base internal external market information external market information external market information margin reflect past experience margin reflect past experience margin reflect past experience adjust expect change adjust expect change adjust expect change postacquisition synergy target discount rate base discount rate base reflect management expectation group wacc group wacc cost saving achieve discount rate base group wacc period specific project cash flow year year year discount rate terminal growth rate pa pa pa gsk annual report pp stnemetat laicnanif note financial statement goodwill continue japan pharmaceuticals cgu consumer healthcare cgu poland pharmaceuticals cgu glaxosmithkline kk cns polfa poznan valuation basis fair value cost sell fair value cost sell value use key assumption sale growth rate sale growth rate sale growth rate profit margin advertising promotion profit margin discount rate investment discount rate terminal growth rate discount rate determination growth rate internal growth rate internal growth rate internal assumption forecast base internal forecast base internal forecast base internal external market information external market information external market information margin reflect past experience advertising promotion margin reflect past experience adjust expect change investment base historical adjust expect change discount rate base level adjust management discount rate base group group wacc view support need wacc adjust country innovation expansion specific risk terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc period specific project cash flow year year year discount rate terminal growth rate pa pa pa decline terminal growth rate exceed longterm project growth rate relevant market terminal growth rate value use calculation poland pharmaceutical cash generating unit reflect impact future generic competition take account new product launch consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value million million stiefel laboratory cash generating unit comprise collection small cash generating unit include asset indefinite live carry value million detail indefinite life brand give note intangible asset case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement intangible asset computer licence amortise indefinite life software patent etc brand brand total cost st january exchange adjustment capitalise internal development cost addition business combination addition disposal asset writeoff transfer asset hold sale cost st december exchange adjustment capitalise internal development cost addition business combination addition disposal asset writeoff reclassification cost st december amortisation st january exchange adjustment provision year disposal asset writeoff amortisation st december exchange adjustment provision year disposal asset writeoff amortisation st december impairment st january exchange adjustment impairment loss reversal impairment impairment st december exchange adjustment impairment loss disposal asset writeoff impairment st december total amortisation impairment st december total amortisation impairment st december net book value st january net book value st december net book value st december gsk annual report pp stnemetat laicnanif note financial statement intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development net book value computer software include million million internally generate cost licence patent etc include large number acquire licence patent knowhow agreement marketing right market use development net book value include million million internally generate cost impairment loss million million principally arise asset development long actively pursue note acquisition disposal give detail addition business combination year book value large individual item follow fluviral lovaza selzentry arzerra duac fraxiparine amortise brand include otc right relate alli book value st december million million indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc number pharmaceutical brand acquisition stiefel laboratories inc book value major brand follow panadol sensodyne stiefel trade breathe right physiogel polident corega biotene poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment apply fair value cost sell methodology generally year posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate countryspecific risk main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment brand gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement investment associate joint venture joint associate joint associated venture undertaking total venture undertaking total st january exchange adjustment addition disposal transfer investment fair value adjustment retain lossprofit year st december group hold significant associate undertakings st december quest diagnostics inc clinical laboratory business list new york stock exchange investment book value st december million million market value million million st december group own quest year group sell million share quest realise profit million group hold ownership interest voting control quest group ability exercise significant influence significant shareholding nominate director active participation quest board director board subcommittee november gsk increase shareholding aspen pharmacare holding limit acquire million share consideration transfer certain asset gsk shareholde aspen st december million share aspen list johannesburg stock exchange africa large pharmaceutical manufacturer major supplier brand generic pharmaceutical healthcare nutritional product southern african select international market elimination unrealised gain investment book value st december million include estimate goodwill million market value share hold gsk st december million group hold ownership interest voting control aspen group ability exercise significant influence shareholding nominate director active participation aspen board director transfer investment relate group hold aspen previously classify investment august gsk invest million establish interest shenzhen glaxosmithkline neptunus biological co ltd new joint venture primarily operate field research development manufacture flu vaccines gsk additional capital contribution total million shionogiglaxosmithkline holding lp summarise balance sheet information respect group associate set total asset quest diagnostic inc aspen pharmacare holding limit total liability quest diagnostic inc aspen pharmacare holding limit net asset summarise balance sheet information respect aspen pharmacare holding limit base analyst forecast available st december investments joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiglaxosmithkline holding lp develop specify chemical compound glaxosmithkline shire canada primarily comarket combivir trizivir epivir certain territory viiv healthcare business investment joint venture include interest pharmaceutical insurance limit mutual insurance company cover pharmaceutical business risk interest glaxosmithkline neptunusbio flu vaccine research development manufacturing venture gsk annual report pp stnemetat laicnanif note financial statement investment st january exchange adjustment addition net fair value movement impairment loss transfer investment associate joint venture disposal st december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate reference current market value similar instrument reference discount cash flow underlie net asset group hold number equity investment entity group enter research collaboration investment include list investment million million disposal investment fair value movement reclassify reserve income statement base average cost share acquire different time impairment loss record table recognise income statement year operate income amount reclassify fair value reserve recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement st december impair assets fair value million million include investment transfer associate relate group hold aspen pharmacare holding limit increase year noncurrent asset amount recoverable insurance contract pension scheme surplus receivables inventory raw material consumable work progress finish good gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement trade receivable trade receivables prepay pension contribution prepayment accrue income interest receivable employee loan advance receivables trade receivable include million million associate joint venture bad doubtful debt provision st january exchange adjustment charge year subsequent recovery amount provide utilise st december cash cash equivalent cash bank hand shortterm deposit asset hold sale land building plant equipment vehicle gsk annual report pp stnemetat laicnanif note financial statement trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa provision time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome amount subject change dependent thing type buy group product sale mix level provision review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption provision base change affect future result group pension postemployment benefit pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme postemployment cost cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service hybrid define benefit scheme include define contribution section gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement pension postemployment benefit continue pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive aa rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment expect rate return bond reflect portfolio mix indexlinke government corporate bond equity risk premium add long term government bond yield expect rate return equity project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt uk mortality rate determine adjust pca standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line medium cohort ie improvement recently observe high level assume continue minimum improvement year male females usa mortality rate calculate rp fully generational table project scale aa white collar adjustment average life expectancy assume individual age project apply individual age follow uk usa male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment follow asset liability study group decide adopt strategy reduce gradually allocation investment equity agree pace reallocation increase primarily investment deficit reduction contribution bond target allocation equity property scheme reduce total uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefit scheme merge addition group operate number postretirement healthcare scheme principal usa group apply follow financial assumption assess define benefit liability uk usa rest world pa pa pa pa pa pa pa pa pa rate increase future earning discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate gsk annual report pp stnemetat laicnanif note financial statement pension postemployment benefit continue amount record income statement statement comprehensive income year end st december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income postretirement pension benefit uk usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgain record statement comprehensive income total actuarial loss record statement comprehensive income st january million amount include settlement curtailment include million million million augmentation cost arise major restructuring programme note provision gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement pension postemployment benefit continue fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation unrecognise past service cost restriction surplus recognise balance sheet include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report pp stnemetat laicnanif note financial statement pension postemployment benefit continue uk usa rest world group average expect rate fair expect rate fair expect rate fair fair st december return value return value return value value equitie property bond asset fair value asset present value scheme obligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement pension postemployment benefit continue postretirement pension benefit movement define benefit obligation uk usa rest world group group obligation st january exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer provision recognise balance sheet st december unrecognise past service cost obligation st december exchange adjustment service cost interest cost settlement curtailment actuarial gain scheme participant contribution benefit pay transfer provision obligation st december exchange adjustment service cost interest cost settlement curtailment actuarial lossesgain scheme participant contribution benefit pay acquisition obligation st december unrecognise past service cost recognise balance sheet st december uk define benefit scheme include define contribution section obligation total million st december million million liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation reduce year postretirement healthcare scheme amend main change increase cap group cost pension postretirement healthcare plan amend change result oneoff gain million income statement st december plan obligation million million million accordance ias unvested benefit improvement recognise immediately balance sheet recognise gradually income statement st december unrecognised million million million primarily relate effect change postretirement scheme st december past service cost recognise scheme amount million gsk annual report pp stnemetat laicnanif note financial statement pension postemployment benefit continue define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded postretirement pension benefit movement fair value asset uk usa rest world group group assets st january exchange adjustment expect return asset settlement curtailment actuarial gainslosse employer contribution scheme participant contribution benefit pay asset st december exchange adjustment expect return asset settlement curtailment actuarial loss employer contribution scheme participant contribution benefit pay asset st december exchange adjustment expect return asset settlement curtailment actuarial gain employer contribution scheme participant contribution benefit pay acquisition asset st december uk define benefit scheme include define contribution section account balance total million st december million million group special funding contribution uk pension scheme total million million scheme million uk pension scheme gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify st december actuarial funding valuation additional contribution expect million year contribution base discount rate inflation assumption review contribution level expect st december actuarial valuation group agree review mortality assumption result early revision contribution employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement pension postemployment benefit continue postretirement pension benefit history experience gain loss uk usa rest world group group experience gain scheme asset percentage scheme asset st december experience gainslosse scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme experience loss scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme experience gainslosse scheme asset percentage scheme asset st december experience gainslosse scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset st december experience lossesgain scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficitssurpluse scheme experience gain scheme asset percentage scheme asset st december experience loss scheme liability percentage scheme obligation st december fair value asset present value scheme obligation deficit scheme gsk annual report pp stnemetat laicnanif note financial statement pension postemployment benefit continue sensitivity analysis effect change assumption annual define benefit pension postretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation provision integration legal major employee restructuring relate manufacturing dispute programme provision reorganisation provision total st january exchange adjustment charge year reverse unused unwind discount utilise acquisition subsidiary transfer pension obligation reclassification movement st december settle year settle year st december gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement provision continue employee relate provision employee relate provision include exchange offer incentive legal dispute programme operate time merger gsk involve number legal dispute encourage staff convert glaxo wellcome smithkline beecham include notification possible claim set note share option glaxosmithkline share option incentive legal proceeding provision legal dispute pay employee exercise relevant option include amount relate antitrust product liability option lapse impact discount contract termination selfinsurance environmental cleanup provision nil calculate property rental riskfree rate return group provide certain medical discount provision increase million benefit disabled employee spouse usa million decrease calculate st december provision benefit riskadjuste project cash flow riskfree rate return amount million employee benefit reflect movement include increase million variety provision severance cost jubilee awards arise change discount rate year certain longservice benefit product history claim settlement integration manufacture reorganisation make possible use ibnr incur report provision integration manufacturing reorganisation actuarial technique determine reasonable estimate reflect cost relate ongoing restructure programme group exposure unasserted claim relation include cost disclose note major product apart ibnr provision provision restructuring programme unasserted claim ultimate liability matter vary amount provide dependent provision outcome litigation proceeding investigation possible group recognise contingent consideration respect settlement negotiation acquisition bristol myers squibb pakistan private limited stiefel laboratories inc describe note acquisition nature group business number disposal contingent consideration payable matter include provide ibnr actuarial certain criterion meet certain specified date future techniquemay subject negotiation litigation initial recognition provision include year large individual amount provide expect reclassification movement aggregate provision settle year item amount million st december st december expect million million provision legal dispute reimburse party insurer include receivables note noncurrent asset note trade receivables discussion legal issue note legal proceeding major restructuring programme october gsk announce significant new operational excellence programme improve effectiveness productivity operation note major restructure programme significant expansion operational excellence programme approve board announce february expansion approve board announce february provision staff severance payment management formal decision eliminate certain position communicate group employee affect provision staff severance payment immediately pension augmentation arise staff redundancie million charge year transfer pension obligation provision show note pension postemployment benefit asset writedown recognise impairment property plant equipment note property plant equipment gsk annual report pp stnemetat laicnanif note financial statement noncurrent liability accrual defer income payable contingent liability st december contingent liability comprise guarantee discount bill item arise normal course business amount million million st december million million financial asset pledge collateral contingent liability discussion tax legal issue refer note taxation note legal proceeding net debt list exchange current asset liquid investment cash cash equivalent shortterm borrowing european medium term note london stock exchange float rate note new york stock exchange commercial paper bank loan overdraft loan stock loan obligation finance lease longterm borrowing float rate note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange loan stock bank loan loan private financing obligation finance lease net debt gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement net debt continue current asset liquid investment classify availableforsale investment st december include treasury note government bond effective interest rate liquid investment st december approximately approximately liquid investment balance st december earn interest float fix rate million million respectively million million effective interest rate cash cash equivalent st december approximately approximately cash cash equivalent balance st december earn interest float fix rate million million respectively million million gsk policy credit quality cash cash equivalent refer note financial instrument relate disclosure shortterm borrowing commercial paper comprise billion programme billion million issue st december nil nil back commit facility day duration billion billion billion billion renewable annually liquid investment cash cash equivalent show table weight average interest rate current bank loan overdraft st december longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year longterm borrowing repayable year carry interest effective rate repayment date range average effective interest rate note st december approximately approximately secure liability gsk loan secure charge noncurrent current asset year nil group pledge investment treasury note par value million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation finance lease obligation st december bear interest float fix rate million million respectively million million gsk annual report pp stnemetat laicnanif note financial statement share capital share premium account share ordinary share p premium number share capital authorise st december st december st december share capital issue fully pay st january issue share option scheme share capital purchase cancel st december issue share option scheme share capital purchase cancel st december issue share option scheme st december st december st december number share issuable outstanding option note number unissue share option st december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme company purchase share purchase st december gsk expect significant share repurchase gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement movement equity retain earning reserve amount million st december million million million million million relate joint venture associate undertaking cumulative translation exchange equity show follow table net translation exchange include total fair value retain minority translation reserve earning interest exchange st january exchange movement overseas net asset st december exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary st december exchange movement overseas net asset reclassification exchange liquidation overseas subsidiary st december analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserve total st january transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust st december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share purchase cancel ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust st december transfer income expense year disposal transfer income expense year impairment net fair value movement year ordinary share acquire esop trust ordinary share transfer esop trust writedown share hold esop trust option minority interest st december reserve include nondistributable merger premerger reserve amount million st december million million reserve include capital redemption reserve create result share buyback programme amount million st december million million gsk annual report pp stnemetat laicnanif note financial statement relate party transaction gsk hold interest quest diagnostics inc st december group quest diagnostic party longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group clinical trial testing requirement worldwide quest diagnostic provide service million million group st december balance payable gsk quest diagnostic million nil march share group associate quest diagnostic inc sell cash consideration million majority share sell direct quest diagnostic inc remainder sell market th november gsk complete extension strategic relationship aspen pharmacare holding limited acquisition minority shareholding south african base pharmaceutical company transaction result gsk acquire million share aspen consideration transfer certain asset aspen associate gain million transaction include operating income st december gsk hold million share interest aspen december gsk distribute million product aspen extensive distribution network st december balance gsk aspen million nil balance payable gsk aspen million nil group shionogi co ltd enter transaction joint venture company support research development activity conduct joint venture company gsk provide service joint venture million million st december balance gsk joint venture million million aggregate compensation director cet give note employee cost adjustment reconcile profit tax operating cash flow profit tax tax profit share tax profit associate joint venture finance income net finance cost depreciation amortisation intangible asset impairment asset write profit sale intangible asset profit sale investment associate profit sale equity investment change work capital increase inventory increasedecrease trade receivables increasedecrease receivables increasedecrease trade payable increasedecrease payable decreaseincrease pension provision sharebase incentive plan cash generate operation gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement reconciliation net cash flow movement net debt net debt begin year increase cash bank overdraft cash inflowoutflow liquid investment net increase longterm loan net repayment ofincrease shortterm loan net repayment obligation finance lease debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year analysis change net debt exchange reclassification acquisition cash flow liquid investment cash cash equivalent overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt note net debt acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture business give acquisition genelabs technologies inc th january group acquire share capital genelabs technologies inc california biotechnology company strong focused portfolio hepatitis c vaccine purchase price million include million cash cash equivalent remainder represent preliminary net asset valuation million transaction account purchase method accounting genelabs technologies inc turnover nil loss tax million year turnover nil million loss tax relate period acquisition include group account gsk annual report pp stnemetat laicnanif note financial statement acquisition disposal continue acquisition continue genelabs technologies inc continue book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax asset liability goodwill total consideration bristol myers squibb pakistan private limited th january group acquire share capital bristol myers squibb pakistan private limited certain associate trademark consideration million result group acquire portfolio wellestablishe pharmaceutical brand occupy lead market position key therapeutic disease area pakistan purchase price million represent provisional valuation intangible asset million goodwill million net asset million goodwill arise acquisition reflect potential product growth region expect synergies group transaction account purchase method accounting bristol myers squibb pakistan private limited turnover million profit tax million year million turnover million profit tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration certain business ucb sa st march group acquire ucb sa market product portfolio certain territory africa middle east asia pacific latin america include lead pharmaceutical brand number disease area subsequent date group complete country acquisition form original transaction purchase price million include million net cash million intangible asset million goodwill million net liability provisional valuation change future goodwill arise acquisition business reflect potential product growth region expect synergies group transaction account purchase method accounting transaction include acquisition number legal entity product right previously market outside entity product portfolio acquire integrate gsk business period acquisition practicable identify result tax arise result transaction period acquisition prior acquisition estimate product portfolio record turnover million acquisition gsk record turnover million product acquire gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement acquisition disposal continue certain business ucb sa continued book fair value fair value adjustment value net asset acquire intangible asset property plant equipment cash cash equivalent defer tax provision liability goodwill total consideration az tika st april group acquire share capital az tika wholly own subsidiary astra zeneca plc cash consideration million result group acquire number lead overthecounter product predominantly sell sweden include alvedon countrys lead analgesic treatment purchase price million represent intangible asset million goodwill million net liability million goodwill arise acquisition reflect potential product growth expect synergies group transaction account purchase method account prior acquisition product acquire market outside entity acquire product acquire integrate gsk business period acquisition practicable identify result tax arise result transaction period acquisition prior acquisition estimate product portfolio record turnover million acquisition gsk record turnover million product acquire book fair value fair value adjustment value net asset acquire intangible asset asset include cash cash equivalent defer tax provision goodwill total consideration stiefel laboratory inc nd july group acquire share capital stiefel laboratory inc world large private dermatological company cash consideration million net cash acquire include million debt repay acquisition purchase price million include contingent cash consideration million payable certain criterion meet specify date future include million cash cash equivalent million intangible asset million goodwill represent potential additional growth combination stiefel business gsk exist dermatology portfolio million net liability purchase price include potential obligation additional payment million million depend future performance certain product provisional valuation change future stiefel laboratory inc turnover million loss tax include restructuring cost million year end st december million turnover million loss tax include restructuring cost relate period acquisition include group account acquisition stiefel operating profit million restructuring cost intangible asset amortisation new business provide significant opportunity sale cost synergy stiefel product benefit gsk global distribution commercial organisation particularly market brazil russia india china japan gsk product benefit stiefel speciality sale force relationship experience management dermatology cost synergy new business expect primarily combine manufacture administrative function previously report gsk expect deliver annual pretax cost saving million restructuring cost approximately million million charge remainder incur year exclude restructuring cost stiefel acquisition result dilution gsk earning share expect result improvement gsk annual report pp stnemetat laicnanif note financial statement acquisition disposal continue stiefel laboratory inc continued book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration viiv healthcare limit th october gsk acquire pfizer inc hiv business combine hiv business form viiv healthcare limited subgroup own gsk pfizer consideration give gsk represent net value gsk hiv business contingent consideration transaction cost value million represent million intangible asset million defer tax liability million net asset million increase minority interest million goodwill represent economy scale gain combination business potential growth partner hiv product viiv healthcare provisional valuation change future minority interest represent pfizer interest viiv healthcare include right preferential dividend base sale performance certain product gsk recognise accounting gain million transaction arise disposal interest gsk hiv business pfizer record book value return pfizer hiv business record fair value acquire pfizer hiv business turnover million loss tax million year take account transition status territory million turnover million loss tax recognise group account include restructuring cost book fair value fair value adjustment value net asset acquire intangible asset asset include cash cash equivalent defer tax provision minority interest goodwill total consideration consideration fair value asset contribute gsk fair value contingent equity contribute gsk direct cost total consideration gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement acquisition disposal continue acquisition continue laboratoire pharmaceutique algrien th november gsk acquire share capital algerian pharmaceutical manufacturing distribution group laboratoire pharmaceutique algrien cash consideration million net cash acquire purchase price million include million cash cash equivalent million goodwill million net liability million reduction value exist investment provisional valuation change future goodwill reflect potential business synergy sale growth increase gsk market presence follow acquisition establish market participant transaction account purchase method accounting laboratoire pharmaceutique algrien turnover million year end st december result year determine estimate loss million turnover million million loss relate period acquisition record group account book fair value fair value adjustment value net asset acquire property plant equipment cash cash equivalent liability goodwill fair value loss arise increase investment lpa distribution total consideration novamin technology inc th december gsk acquire share capital novamin technology inc privately hold company cash consideration million purchase price include million intangible asset million goodwill million net liability provisional valuation change future company specialty oral care ingredient treatment dentine hypersensitivity goodwill arise acquisition represent potential additional growth combination company technology specific gsk oral care product transaction account purchase method accounting novamin technology inc turnover million loss tax million year nil turnover nil loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset defer tax provision goodwill total consideration acquisition beginning year estimate group turnover increase million year acquisition fully integrate gsk business practicable separately identify impact acquisition group profit year acquisition year include million invest shionogiglaxosmithkline holding lp joint venture group share million invest shenzhen glaxosmithkline neptunus biological co ltd associate group initial share certain stiefel laboratoire novamin bms business laboratory pharmaceutique technology cash flow genelabs pakistan ucb sa az tika inc algrien inc total cash consideration cash cash equivalent acquire net cash consideration contingent consideration net purchase consideration gsk annual report pp stnemetat laicnanif note financial statement acquisition disposal continue acquisition continue sirtris pharmaceuticals inc th june group acquire issue share capital sirtris pharmaceuticals inc biopharmaceutical company base massachusetts usa cash consideration million company focus discover develop proprietary orally available small molecule drug potential treat disease associate ageing include metabolic disease type diabete sirtris drug candidate design mimic certain beneficial health effect calorie restriction activation sirtuin recently discover class enzyme sirtris believe control ageing process transaction account purchase method accounting goodwill arise acquisition reflect potential enable gsk enhance metabolic neurology immunoinflammation research effort establish worldleading presence sirtuin field aid existence company highly experienced development team encompass aspect sirtuin biology sirtris pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration bristol myers squibb egypt th october group acquire egyptian mature product business bristol myers squibb bms cash consideration million million defer payment alternative supply arrangement establish group acquire brand product occupy lead market position therapeutic disease area egypt include duricef antibiotic capozide capoten ace inhibitor theragranh iron supplement kenacomb topical steroid total sale combine mature product pharmaceutical business million group ownership bmss high quality manufacturing facility giza great cairo continue supply acquire product group ability export generic version acquire product market outside egypt create opportunity drive sale growth middle east north africa region fact reflect goodwill arise acquisition business turnover million profit tax million year million turnover million profit tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment inventory goodwill total consideration gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement acquisition disposal continue sirtris bms egypt acquire begin combine group turnover year million combine group profit year million shionogi euclid sr glaxosmithkline cash flow sirtris bms egypt partner lp holding lp total cash consideration cash cash equivalent acquire net cash payment acquisition euclid sr partner lp additional million invest euclid sr partner lp associate group share shionogiglaxosmithkline holding lp additional million invest shionogiglaxosmithkline holding lp joint venture group share acquisition reliant pharmaceuticals inc th december group acquire issue share capital reliant pharmaceuticals inc pharmaceutical company base usa cash consideration million company specialise development marketing speciality medicine combat heart disease include right lovaza treatment adult patient high level triglyceride transaction account purchase method accounting goodwill arise acquisition reflect potential product growth usa puerto rico expect synergies group reliant pharmaceuticals inc turnover million profit tax million year million turnover million profit tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration gsk annual report pp stnemetat laicnanif note financial statement acquisition disposal continue domantis limit th january group acquire issue share capital domantis limited drug discovery company base uk cash consideration million company develop generation antibody therapy transaction account purchase method accounting goodwill arise acquisition reflect potential combine worldleading technology domantis development programme place gsk group forefront biotechnology domantis limited turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax provision liability goodwill total consideration praecis pharmaceuticals inc th february group acquire issue share capital praecis pharmaceuticals inc biopharmaceutical company base usa cash consideration million company develop efficient method identify drug lead target human disease proprietary technology transaction account purchase method accounting praecis pharmaceuticals inc turnover nil loss tax million year nil turnover million loss tax relate period acquisition include group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset include cash cash equivalent defer tax asset liability goodwill total consideration reliant domantis praecis total cash flow cash consideration cash cash equivalent acquire net cash payment acquisition reliant domantis praecis acquire beginning year combine group turnover year million combine group profit year million gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment business combination pension commitment interest loan finance lease charge commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount majority intangible commitment denominate dollar weaken foreign currency year lead decrease commitment report number commitment licensing agreement include arrangement chroma therapeutic limited concert pharmaceuticals inc idenix pharmaceuticals inc prosensa bv seattle genetics inc gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify st december actuarial funding valuation table show commitment exclude normal ongoing annual funding requirement approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap commitment noncancellable operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment noncancellable operating lease post balance sheet event th february gsk receive complete response letter fda new drug application horizant extend release tablet restless leg syndrome letter indicate question remain precluded approval horizant restless leg syndrome time gsk evaluate letter consider appropriate step group intangible asset include million relation compound possible determine impairment record future period pende completion analysis situation gsk annual report pp stnemetat laicnanif note financial statement financial instrument relate disclosure borrowing cash generate operation glaxosmithkline plc report sterling pay dividend onlent contribute equity certain subsidiary sterling profit role corporate treasury manage pay dividend acquisition gsk share monitor external internal funding requirement repurchase financial risk support strategic objective treasury total capital equity net debt group increase activity govern policy procedure approve million million increase board director recently st october million principally represents retain profit treasury management group tmg chair chief financial year offset actuarial loss define benefit pension plan officer meet monthly basis review treasury activity reduction net debt net debt reduce compare member receive management information relate treasury primarily consequence gsk decision suspend activity internal auditor review treasury internal control share repurchase group positive cash generation environment regularly issuance billion bond emtn programme billion commercial paper sufficient gsk use variety financial instrument finance operation repay mature shortterm debt finance group derivative financial instrument manage risk acquisition year whilst increase group overall operation derivative principally comprise forward cash position st december foreign currency contract interest rate currency swap liquidity risk swap borrowing liquid asset currency require group purpose manage exposure funding risk manage net borrowing requirement portfolio change foreign exchange rate interest rate longterm borrowing include bond shortterm finance billion commercial paper programme gsk hold issue derivative speculative purpose commercial paper programme back billion treasury policy specifically prohibit activity commit facility facility renew october transaction financial instrument undertake consider level commit facility adequate manage risk arise underlie business activity give current cash holding information speculation facility refer note financial statement capital management net debt benefit strong positive cash flow operating unit manage capital ensure entity group able operate go concern optimise return european medium term note programme shareholder appropriate balance debt equity billion st december billion board review group dividend policy funding note issue programme shelf requirement annually registration statement st december billion billion note issue programme tmg capital structure group consist net debt monitor cash flow forecast monthly basis note net debt shareholder equity consolidated statement change equity longterm borrowing mature date longterm debt rating remain stable continue expect investment opportunity arise february currently rate stable outlook allow group invest support strategic priority standard poor stable outlook moodys ensure sufficient flexibility advantage shortterm debt rating p standard opportunity currently expect significant share poor moodys respectively repurchase investment opportunity continue assess strict financial criterion commit facility substantial cash gsk operate global basis primarily subsidiary liquid investment amount billion company establish market trade st december benefit strong positive cash significant level patent trademark protection flow operating unit pharmaceutical product compete largely product efficacy differentiation price selling margin sufficient cover normal operating cost operation cash generative operate cash flow fund investment research development new product routine outflow capital expenditure tax dividend repayment mature debt extent determine board share repurchase policy borrow centrally variety capital market issue borrow facility meet anticipated funding requirement gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement financial instrument relate disclosure continue market risk interest rate risk management policy interest rate risk management limit float interest payment prescribe percentage trading profit use interest rate swap redenominate external borrowing interest rate coupon require gsk duration swap match duration principal instrument interest rate derivative instrument account fair value cash flow hedge relevant asset liability foreign exchange risk management foreign currency transaction exposure arise internal external trade flow hedge exposure overseas operating subsidiary transaction risk minimised match local currency income local currency cost purpose internal trading transaction match centrally manage intercompany payment term reduce foreign currency risk exceptional foreign currency cash flow hedge selectively management corporate treasury manage cash surplus borrowing requirement subsidiary company centrally forward contract hedge future repayment originate currency seek denominate borrowing currency principal asset cash flow primarily denominate dollar euro sterle certain borrowing swap currency require borrowing denominate swap foreign currency match investment overseas group asset treat hedge relevant asset forward contract major currency reduce exposure investment overseas group asset net investment hedge section note detail tmg review ratio borrowing asset major currency monthly credit risk group consider maximum credit risk million million total group financial asset exception investment bear credit risk detail group total financial asset gsk great concentration credit risk billion billion invest treasury treasury repo money market fund bear credit exposure government treasuryrelate credit risk credit risk remain high global credit crisis gsk continue maintain conservative approach counterparty risk period report relationship bank credit rating present annually tmg approval aggregate credit risk respect financial instrument group counterparty limited reference longterm credit rating assign counterparty moodys standard poor table set credit rating counterpartie liquid investment cash cash equivalent derivative gross asset position derivative contract consider purpose table isda contract risk net asset position counterparty credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security rd party financial derivative total credit rating counterparty aaaaaa aaaa aaaa aa aa baabbb baabbb total bank balance deposit treasury treasury repo money market fund corporate debt instrument government security rd party financial derivative total credit rating table assign moodys investor service standard poor respectively opinion rating agency differ gsk assign low rating counterparty local rating agency datum source available rating convert global rating equivalent moodys investor service standard poor publish conversion table figure restate reflect equivalent global sovereign rating appropriate local rating provider gsk annual report pp stnemetat laicnanif note financial statement financial instrument relate disclosure follow method assumption estimate fair value continue centrally manage cash reserve amount billion cash cash equivalent approximate st december available month group carry invest centrally manage liquid asset bank deposit aaaaaa liquid investment base quote market price rate treasurie treasury repo money market fund case marketable security base principal amount short term corporate debt instrument minimum shortterm case nonmarketable security short credit rating ap bank deposit reprice period global counterparty limit assign gsk banking investment investment trade active market investment counterpartie base longterm credit rating determine reference relevant stock exchange quote moodys standard poor corporate treasury usage bid price investment determine reference limit monitor daily corporate compliance current market value similar instrument reference officer cco operate independently corporate discount cash flow underlie net asset treasury breach limit report shortterm loan overdraft approximate carry cfo immediately cco monitor credit rating short maturity instrument counterpartie change rating occur notifie longterm loan base quote market price corporate treasury change investment case eurobond fix rate borrowing level authority limit appropriate approximate carry case float wholesale retail credit risk rate bank loan loans usa line pharmaceutical company forward exchange contract base market datum group sell product small number wholesaler exchange rate balance sheet date addition hospital pharmacie physician group currency swap base market datum balance sale large wholesaler approximately sheet date group pharmaceutical sale st december interest rate swap base net present value group trade receivable discount cash flow wholesaler total million million group expose concentration credit risk respect receivables payable approximate wholesaler encounter carry financial difficulty materially adversely affect lease obligation approximate carry group financial result fair value investment gsk share group credit risk monitoring activity relate st december employee share ownership plan wholesaler includes review quarterly financial information esop trust held gsk share carry value standard poor credit rating development gsk internal million million fair value risk rating establishment periodic review credit limit million million base quote market group believe credit risk provision price share represent purchase esop trust satisfy require excess normal provision bad doubtful future exercise option award employee incentive debt note trade receivables outside scheme carry value low cost expect usa customer account trade proceed share recognise deduction receivables balance reserve st december gsk hold treasury share cost million million fair value financial asset liability deduct retain earning table present carry amount fair value group financial asset liability commit facility st december st december group commit facility commercial paper programme billion billion billion fair value financial asset liability include billion day duration renewable annually instrument exchange st december undrawn commit facility total current transaction willing party force billion billion billion billion liquidation sale gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement financial instrument relate disclosure continue carry fair carry fair value value value value cash cash equivalent availableforsale investment liquid investment government bond total liquid investment investment loan receivables trade receivables noncurrent asset scope ias heldfortrade financial asset derivative designate accounting hedge derivative total financial asset financial liability measure amortise cost borrowing bond designate hedge relationship bond commercial paper bank loan overdraft loan private financing obligation finance lease total borrowing trade payable noncurrent liability scope ias heldfortrade financial liability derivative designate accounting hedge derivative total financial liability net financial asset financial liability gsk annual report pp stnemetat laicnanif note financial statement financial instrument relate disclosure continue follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level financial asset fair value st december level level level total heldfortrade financial asset derivative designate accounting hedge derivative availableforsale financial asset liquid investment investment financial liability fair value st december level level level total heldfortrade financial liability derivative designate accounting hedge derivative movement year financial instrument measure level valuation method present investment st january loss recognise profit loss gain recognise comprehensive income addition disposal transfer tofrom level exchange st december loss relate level financial asset include operate income attributable asset hold end year gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement financial instrument relate disclosure continue trade receivables noncurrent asset scope ias follow table reconcile financial asset trade receivables noncurrent asset fall scope ia relevant balance sheet amount financial asset predominantly noninterest earn asset include tax receivables pension surplus balance prepayment outside scope ias trade receivable note noncurrent asset note analyse financial asset scope ia asset follow table show age financial asset past provision bad doubtful debt past day past day past day past day past day amount past great day total million million balance million million relate receivable state hospital authority certain european country give profile customer include large wholesaler government back agency credit risk identify trade receivable past balance allowance trade payable noncurrent liability scope ias follow table reconcile financial liability trade payable noncurrent liability fall scope ia relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability liability include payment account tax social security payable outside scope ias trade payable note noncurrent liability note analyse financial liability scope ias liabilities gsk annual report pp stnemetat laicnanif note financial statement financial instrument relate disclosure continue debt interest rate repricing table follow table set exposure group interest rate debt effect interest rate swap maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing obligation finance lease effect effect interest interest debt rate swap total debt rate swap total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing sensitivity analysis sensitivity analysis prepare assumption net debt ratio fix float interest rate debt derivative portfolio proportion financial instrument foreign currency constant basis hedge designation place st december financial instrument affect market risk include borrowing deposit derivative financial instrument follow analysis intend illustrate sensitivity financial instrument change relevant foreign exchange interest rate foreign exchange sensitivity table show group sensitivity foreign exchange rate dollar euro yen financial instrument exclude obligation finance lease certain nonderivative financial instrument net debt present material exposure currency major foreign currency gsk financial instrument denominate gsk consider movement currency year conclude movement rate reasonable benchmark table financial instrument consider sensitive foreign exchange rate functional currency entity hold intercompany loan fully hedge maturity currency swap exclude analysis increasedecrease reduction increasedecrease reduction income equity income equity appreciation dollar appreciation euro appreciation yen depreciation state currency equal opposite effect movement income statement relate primarily hedge instrument dollar legal provision trade payable trade receivables whilst hedge instrument provide economic hedge relate provision financial instrument include table combine sensitivity hedge instrument provision insignificant provision include movement equity relate foreign exchange position hedge group asset denominate dollar euro yen depreciation currency swap rise correspond appreciation group asset foreign exchange sensitivity group asset financial instrument include gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement financial instrument relate disclosure continue interest rate sensitivity table show group sensitivity interest rate float rate sterling dollar euro financial instrument currency gsk historically issue debt hold investment gsk consider movement interest rate year conclude increase reasonable benchmark debt maturity year float rate calculation movement interest rate deem material effect equity increasedecrease increasedecrease income income increase sterle interest rate increase dollar interest rate increase euro interest rate interest rate decrease currently maximum increasedecrease income limit million million million sterling dollar euro interest rate respectively million million million interest rate movement obligation finance lease foreign currency derivative trade payable trade receivables financial instrument net debt present material exposure group balance sheet base increase decrease interest rate contractual cash flow nonderivative financial liability derivative instrument follow analysis anticipate contractual cash flow include interest payable group nonderivative financial liability undiscounte basis purpose table debt define class borrowing obligation finance lease interest calculate base debt hold st december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate st december finance charge trade obligation obligation interest finance finance payable st december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow finance charge trade obligation obligation interest finance finance payable st december debt debt lease lease net debt total year year year year year year great year gross contractual cash flow gsk annual report pp stnemetat laicnanif note financial statement financial instrument relate disclosure continue follow table provide analysis anticipate contractual cash flow group derivative instrument exclude embed derivative equity option material undiscounted cash flow cash flow foreign currency translate spot rate st december receivables payable receivables payable year year year year year great year gross contractual cash flow derivative financial instrument hedge programme follow table set fair value derivative hold gsk fair value fair value asset liability asset liabilitie cash flow hedge cross currency swap principal nil million fair value hedge interest rate swap principal million million net investment hedge foreign exchange contract principal million million derivative designate accounting hedge foreign exchange contract principal million million embed derivative derivative designate accounting hedge total derivative instrument analyse current noncurrent total gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement financial instrument relate employee share scheme disclosure continue group operate share option scheme option grant employee acquire share ad glaxosmithkline derivative financial instrument plc grant price savingsrelate share option scheme principal foreign exchange contract share award scheme addition gsk operate performance calculate base outstanding position balance sheet share plan award grant employee acquire date calculate net currency buysell position share ad glaxosmithkline plc cost subject majority contract period month achievement group specify performance target share value plan award grant employee st december group hold outstanding foreign acquire share ad glaxosmithkline plc cost exchange contract consist primarily currency swap year vest period grant restrict share award total credit fair value million million debit replace grant option certain employee represent hedge intercompany loan deposit cost scheme readily equate potential gain designate accounting hedge change fair value employee take profit loss period offset exchange gain loss relate intercompany lending borrowing grant share option scheme normally exercisable cash flow hedge year date grant grant restrict share share award normally exercisable group enter cross currency swap end year vestingperformance period grant designate cash flow hedge convert fix euro savingsrelate share option scheme normally exercisable interest euro debt group japanese subsidiary year save option share option scheme payable annually fix yen payment bond swap grant market price ruling date grant matured rd june risk hedge accordance uk practice majority option variability cash flow arise currency fluctuation savingsrelate share option scheme grant price ineffectiveness record hedge amount market price ruling date grant share option recognise comprehensive income reclassify award director effect grant income statement offset exchange gain loss cet subject performance criterion period underlie bond result revaluation relevant reporting date fair value hedge group designate interest rate swap fair value hedge risk hedge variability fair value bond arise interest rate fluctuation gain loss fair value hedge disclose note finance cost net investment hedge foreign exchange contract designate net investment hedge respect foreign currency translation risk principally arise consolidation group net investment dollar euro yen foreign operation addition euro loan capital issue billion billion previous year designate monetary net investment hedge respect foreign currency translation risk principally arise consolidation group net investment euro operation net investment hedge ineffectiveness disclose note finance income gsk annual report pp stnemetat laicnanif note financial statement employee share scheme continue option pricing purpose value option award arrive share base payment charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option share award scheme year year year weight average share price grant year ordinary share ad volatility determine base year share price history appropriate fair value performance share plan grant account market condition expect life option determine base weighted average historic exercise option option outstanding share option share option savingsrelate scheme share scheme ad share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value st january option grant option exercise option lapse st december option grant option exercise option lapse st december option grant option exercise option lapse st december range exercise price weight average market price exercise weight average remain contractual life year year year gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement employee share scheme continue order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share ad glaxosmithkline share ad programme establish additional cash benefit exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expiry share option share option savingsrelate option outstanding scheme share scheme ad share option scheme st december weight late weight late weight late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option normally exercisable year date grant certain circumstance vest early set scheme rule change effective exercise price outstanding option year share option share option savingsrelate option exercisable scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price st december st december st december gsk annual report pp stnemetat laicnanif note financial statement employee share scheme continue glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period award grant director member cet prior subject single performance condition compare gsk tsr period tsr company comparator group period award grant onwards director member cet award base achievement adjust free cash flow target year measurement period remain award base relative tsr performance comparator group describe page half tsr element award measure year half year award eligible employee prior performance condition consist part apply award performance condition compare gsk ep growth increase uk retail price index year measurement period second performance condition compare gsk tsr period tsr company comparator group period award grant onwards performance condition continue base eps second performance condition base strategic operational business measure year measurement period specific employee business area share weight ad weight number share ad issuable number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december share value plan group operate share value plan award grant form share certain employee cost award vest year performance criterion attach share weight ad weight number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement employee share scheme continue defer investment award plan group operate defer investment award plan award grant form notional share certain senior executive cost award typically vest threeyear period commence fourth anniversary date grant award initially vest subsequent year performance criterion attach share weight ad weight number share ad issuable number fair value number fair value st january award grant award exercise award cancel st december award grant award exercise award cancel st december award grant award exercise award cancel st december employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share open market finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve hold value proceed receivable employee exercise deem permanent diminution value reflect transfer retain earning trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report pp stnemetat laicnanif note financial statement principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group st december detail give principal country operation location headquarters business sector business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary sector activity england brentford glaxosmithkline holdings limited phch h brentford glaxosmithkline holding limited phch h brentford glaxosmithkline service unlimited phch brentford glaxosmithkline mercury limit ph h brentford glaxosmithkline finance plc phch f brentford glaxosmithkline capital plc phch f brentford smithkline beecham limited phch e h p r brentford wellcome limited phch h brentford glaxo group limit ph h brentford glaxo operation uk limit ph p brentford glaxosmithkline export limit ph e brentford glaxosmithkline research development limit ph r brentford glaxosmithkline uk limit ph p brentford setfirst limited phch h brentford wellcome foundation limit ph p cambridge domantis limit ph r brentford smithkline beecham overseas limit ph h brentford smithkline beecham holdings uk limit ph h brentford viiv healthcare limit ph h brentford viiv healthcare uk limit ph brentford viiv healthcare trading service limit ph e f austria vienna glaxosmithkline pharma gmbh ph belgium genval glaxosmithkline sa ph rixensart glaxosmithkline biological sa ph e p r czech republic prague glaxosmithkline sro phch denmark orestadt glaxosmithkline consumer healthcare ch brndby glaxosmithkline pharma ph finland espoo glaxosmithkline oy ph france marly le roi groupe glaxosmithkline sas ph h marly le roi laboratoire glaxosmithkline sas ph r marly le roi glaxo wellcome production sas ph p marly le roi glaxosmithkline sante grand public sas ch st amand les eaux glaxosmithkline biological sas ph p germany buehl glaxosmithkline consumer healthcare gmbh co kg ch h p r munich glaxosmithkline gmbh co kg ph h p r greece athens glaxosmithkline aebe phch hungary budapest glaxosmithkline medicine healthcare product limited phch e italy verona glaxosmithkline spa ph h r milan glaxosmithkline consumer healthcare spa ch verona glaxosmithkline manufacturing spa ph p gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement principal group company continue europe location subsidiary sector activity luxembourg mamer glaxosmithkline international luxembourg sarl phch f h netherlands zeist glaxosmithkline bv ph utrecht glaxosmithkline consumer healthcare bv ch norway oslo glaxosmithkline ph poland poznan glaxosmithkline pharmaceuticals sa ph p poznan gsk service spz oo ph warsaw glaxosmithkline consumer healthcare spz oo ch e portugal alge glaxosmithklineprodutos farmaceuticos limitada ph republic carrigaline smithkline beecham cork limit ph p r ireland cork glaxosmithkline trading service limit ph e dublin glaxosmithkline consumer healthcare ireland limited ch dublin glaxosmithkline ireland limit ph dungarvan stafford miller ireland limited ch p dungarvan glaxosmithkline dungarvan limited ch p romania brasovi europharm hold sa phch buchar glaxosmithkline gsk srl ph r russian moscow glaxosmithkline trading zao ph federation moscow glaxosmithkline healthcare zao ch spain madrid glaxosmithkline sa ph madrid glaxosmithkline consumer healthcare sa ch aranda de duero glaxo wellcome sa ph p sweden solna glaxosmithkline ab ph switzerland muenchenbuchsee glaxosmithkline ag ph usa usa coral gables stiefel laboratory inc ph h p hamilton corixa corporation ph p philadelphia glaxosmithkline llc phch e h p r pittsburgh glaxosmithkline consumer healthcare lp ch p pittsburgh block drug company inc ch h wilmington glaxosmithkline holdings americas inc phch h wilmington glaxosmithkline capital inc ph f cambridge sirtris pharmaceuticals inc ph r research triangle park viiv healthcare company ph americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc ph p r oakville glaxosmithkline consumer healthcare inc ch laval d biomedical corporation ph h quebec city d biomedical corporation quebec ph p r mexico delegacion tlalpan glaxosmithkline mexico sa de cv phch e p puerto rico guaynabo glaxosmithkline puerto rico inc ph asia pacific australia boronia glaxosmithkline australia pty ltd phch e p r china beijing glaxosmithkline china investment co ltd phch h hong kong glaxosmithkline limited phch shanghai glaxosmithkline biological shanghai ltd ph p tianjin sinoamerican tianjin smith kline french laboratories ltd ch p r gsk annual report pp stnemetat laicnanif note financial statement principal group company continue asia pacific location subsidiary sector activity india mumbai glaxosmithkline pharmaceutical limit ph p nabha glaxosmithkline consumer healthcare limited ii ch p malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd ph selangor glaxosmithkline consumer healthcare sdn bhd ch new zealand auckland glaxosmithkline nz limited phch pakistan karachi glaxosmithkline pakistan limited phch p e philippines makati glaxosmithkline philippines inc phch singapore singapore glaxochem pte ltd ph h singapore glaxo wellcome manufacturing pte ltd ph h p r singapore glaxosmithkline pte ltd phch south korea seoul glaxosmithkline korea limited ph ch thailand bangkok glaxosmithkline thailand limited phch japan japan tokyo glaxosmithkline kk phch p latin america argentina buenos aires glaxosmithkline argentina sa phch e p r brazil rio de janeiro glaxosmithkline brasil limitada phch e p colombia bogota glaxosmithkline colombia sa phch venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae ph p south africa bryanston glaxosmithkline south africa pty limited phch p turkey istanbul glaxosmithkline ilaclari sanayi ticaret phch usa location associate sector activity usa madison quest diagnostic incorporate iii clinical testing middle east africa south africa johannesburg aspen pharmacare holding limited iii phch p r exempt provision section company amendment act ireland ii consolidated subsidiary undertaking accordance section company act ground dominant influence iii equity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc key business sector ph pharmaceutical ch consumer healthcare business activity development e export f finance h hold company insurance marketing p production r research service detail group subsidiary associate undertaking attach company annual return file registrar company glaxosmithkline capital inc glaxosmithkline capital plc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement legal proceeding january neolab file action invalidate group involve significant legal administrative combination patent federal court germany revocation proceeding principally product liability intellectual property action combination patent germany tax antitrust governmental investigation related file mylan dura gmbh march hexal ag december private litigation group make provision proceeding ivax october revocation action regular basis summarise note accounting principle hear rd february court advise policy note provision respect party decision issue week number legal proceeding group involve follow hear basic patent covering combination possible reasonable estimate expect product seretide expire september subject financial effect result ultimate resolution supplementary protection certificate extend protection proceeding case group disclose september information respect nature fact case july sandoz hexal initiate revocation action provision typically intellectual property claim include district court hague group dutch challenge validity enforceability group patent combination patent relate seretide hearing originally product process assertion non schedule th february reschedule infringement patent loss case th november basic patent cover combination result loss patent protection product issue product seretide expire september subject consequence loss significant decrease supplementary protection certificate extend protection sale product materially affect future result september operation group revocation action basic patent covering seretide legal expense incur provision relate legal claim combination ireland file high court dublin charge sell general administration cost provision behalf ivax july trial take place th march take appropriate legal specialist advice th high court hand decision reasonable estimate likely outcome th june find patent invalid obviousness dispute group establish actuarially determine decision relate solely irish combination patent provision product liability claim incur report seretide bind decision group file describe note provision st december appeal decision october trial date group aggregate provision legal dispute set appeal include tax matter describe note taxation billion ultimate liability legal claim vary action revocation french seretide combination amount provide dependent outcome patent file sandoz tribunal de grande instance litigation proceeding investigation possible settlement paris th october trial date set negotiation group position change time basic patent cover combination product seretide assurance loss result expire september subject supplementary outcome legal proceeding exceed protection certificate extend protection provision report group financial account september material happen argatroban material adverse impact result operation group december encysive pharmaceuticals inc mitsubishi kasei reporting period judgement incur corporation group file action district court settlement enter significant matter southern district new york barr laboratories describe inc infringement mitsubishis pharmaceutical composition intellectual property patent cover argatroban pursuant license mitsubishi encysive develop argatroban treatment heparin advairseretide induce thrombocytopenia hold new drug application october group file complaint patent approve fda encysive license marketing dispute chamber regional court dsseldorf germany rights argatroban group mitsubishi patent neolab uk infringement german patent expire june barr file abbreviate new drug claim composition contain combination salmeterol application anda fda certification invalidity fluticasone propionate seretide know viani unenforceability noninfringement mitsubishi patent germany complaint base neolab state intention twoweek trial case hold january letter market salmeterolfluticasone combination product party await decision fda approval anda germany event occur trial take place stay early resolution patent patent dispute chamber regional court dsseldorf infringement action january result permanent injunction neolab neolab appeal appeal hearing schedule th july gsk annual report pp stnemetat laicnanif note financial statement legal proceeding continue combivir patent list orange book combivir include composition arzerra matter tclamivudine combination lamivudine azt october group file action district court lamivudine crystal form patent expire southern district florida declaration patent respectively september group received socalle cabilly ii patent own jointly notice teva file anda fda allege genentech inc city hope invalid unenforceable combination patent invalid infringe gsk product arzerra ofatumumab arzerra approve fda chronic lymphocytic leukaemia november group file action district court orphan indication october february group district delaware teva pharmaceuticals usa inc voluntarily dismiss case file new case infringement combination patent fda approval tevas district court northern district california anda stay early march resolution suit currently pende patent infringement action favourable teva case discovery phase october teva file certification avodart group patent cover crystal form lamivudine invalid january group receive notice barr laboratories infringe group file suit patent file anda fda allegation invalidity july group receive notice lupin ltd file patent list orange book cover certification fda allege combination patent active ingredient avodart use treat benign prostatic invalid infringe product lupin file certification hyperplasia bph february group file action group patent cover crystal form lamivudine district court district delaware barr invalid infringe infringement patent basic compound patent expire patent expire fda approval august group file suit lupin barrs anda stay early july resolution district court district delaware infringement patent infringement action party agree settle combination patent group file suit lupin matter term settlement subject review crystal form patent march action federal trade commission receive final court approval lupin stay mutual consent pende resolution case teva teva lupin challenge benlysta basic compound patent cover lamivudine active february uk court appeal uphold early high ingredient combivir patent expire court decision revoke hgs uk patent ep claim revocation bring eli lilly patent coreg cr claim cytokine bly antibody bind bly group file suit april district court benlysta belimumab gsk licence patent eastern district pennsylvania crystal form patent party litigation proceeding equivalent patent covering use coreg cr treat congestive heart european patent uphold october final appeal failure october group file motion dismiss european patent office follow opposition action give mutual covenant sue patent proceed file eli lilly uk decision affect mutual obtain final approval market generic product european patent arise european patent th april base datum exclusivity grant hgs gsk consider appeal uk decision fda product matter conclude uk supreme court decision affect gsk hgss hiberix infanrix hexa menitorix freedom market sell benlysta rd august novartis sue group belgium boniva patent infringement relation hiberix infanrix hexa group participate marketing boniva pursuant menitorix vaccine product relation phase development copromotion agreement roche expire january vaccine project hibmency menacwy parallel infringement september roche laboratory commence proceeding file novartis uk infanrix hexa action district court district new jersey menitorix hiberix european patent office grant generic drug manufacturer case roche group request accelerate review reconsider validity allege infringement roche patent relate boniva tablets patent december novartis claim relevant defendant file anda fda group product hold invalid uk belgian certification invalidity unenforceability noninfringement infringement trial dismiss roche patent manufacturer levitra challenge basic compound patent expire final fda approval andas stay early group participate marketing levitra pursuant november resolution relevant patent infringement copromotion agreement bayer healthcare july bayer action august roche obtain new patent bring suit teva district court district monthly dose regimen boniva bring suit delaware teva pharmaceuticals inc infringement anda filer challenge patent new patent patent relate levitra teva file anda fda expire case ongoing certification patent cover active ingredient levitra expire invalid unenforceable infringe stay fda approval effect early decision case adverse bayer november gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement legal proceeding continue treximet lovaza october group receive letter par march group receive notice teva pharmaceuticals pharmaceuticals fda accept anda treximet usa inc par pharmaceutical inc apotex inc file include certification patent own pozen andas certification patent cover lovaza inc relate treximet invalid unenforceable andor invalid unenforceable infringe patent expire infringe pozen patent license group november group licensee patent pronova pozen file suit par patent biopharma norge owner patent sue teva par district court eastern district texas november apotex district court district delaware fda group receive letter alphapharm designate approval anda stay early agent mylan pharmaceuticals fda accept decision favourable generic anda treximet include certification pozen patent relate treximet invalid unenforceable andor malarone infringe pozen file suit alphapharm mylan january august group file suit district court infringement patent district court district delaware glenmark generics inc eastern district texas delaware delaware case usa infringement patent relate malarone dismiss pozen sue teva pharmaceutical group receive notification glenmark file usa inc dr reddys patents court anda malarone certification allege treximet datum exclusivity preclude approval generic group patent invalid unenforceable infringe product april group party patent expire cover combination lawsuit bring pozen atovaquone proguanil hydrochloride use prevent malaria fda approval glenmark anda stay valtrex early january judgment adverse gsk july apotex inc file complaint declaratory judgment district court middle district north paxilseroxat carolina apotexs valacyclovir product infringe usa number manufacturers distributor generic formulation patent own group valtrex apotex file paxil file application fda market generic version para iv certification challenge patent gsk prior expiration group patent paroxetine file suit challenge certificate gsk file response hyrdrochloride hemihydrate action remain declaratory judgment complaint august pende action apotex district court contest noninfringement allegation october apotex eastern district pennsylvania patent composition file motion judgment matter pende decision matter process manufacture claim antitrust motion november ranbaxy launch generic counterclaim assert apotex discuss product valacyclovir antitrust case set trial april vesicare group market vesicare license astellas europe generic product contain paroxetine hydrochloride pharma inc september astellas file suit teva market european country group pharmaceuticals usa inc federal district court netherland patent infringement action farmaceutisch southern district new york infringement patent analytisch laboratorium duiven bv fal fal counterclaim cover active ingredient vesicare astella receive unfair competition settle july notice teva pharmaceutical file anda follow litigation canada apotex certification basic patent expire patent relate paroxetine apotex launch generic product invalid unenforceable fda approval tevas anda stay canada october apotex allege early february decision case result litigation enjoin launch favourable teva product receipt regulatory approval action apotex recover damage relate delay occasion product liability injunction ongoing preclinical clinical trial conduct development potential product determine safety efficacy requip xl product use human follow approval regulatory january group receive letter impax body notwithstanding effort drug vaccines laboratories inc actavis south atlantic llc indicate introduce marketplace unanticipated safety issue andas requip xl accept fda evident group currently defendant letter include allegation patent license number product liability lawsuit relate group group skyepharma cover extend release formulation pharmaceutical consumer healthcare product infringe product additional anda significant matter describe page file torrent pharmaceutical lupin ltd certification formulation patent infringe group bring suit company gsk annual report pp stnemetat laicnanif note financial statement legal proceeding continue claim lawsuit allege treatment paxil cause homicidal suicidal behaviour exhibit user avandia product class certification deny january group name product liability lawsuit behalf purport personal injury class action lawsuit case remain individual purport class action case assert consumer pende federal state court case file philadelphia fraud andor personal injury claim behalf purchaser coordinate mass tort program user avandia federal case multidistrict respect lawsuit file state federal court litigation proceed pende district court eastern usa canada allege paxil addictive cause district pennsylvania case file state court dependency withdrawal reaction virtually action case file philadelphia coordinate mass tort resolve california court grant plaintiff program matter discovery phase trial motion certify class consumer fraud lawsuit seek schedule june additionally purport nationwide class economic damage focus discontinuation symptom action suit file february district court canada quebec court deny plaintiff motion certify eastern district pennsylvania behalf party payer class patient allegedly experience discontinuation seek economic damage state unfair trade practice symptom decision appeal uk public funding consumer protection law plaintiff indicated grant hundred patient pursue common filing amend complaint future issue litigation allege paroxetine cause finally purport class action file israel suffer withdrawal reaction dependency trial briefing certify class action underway schedule commence january class action pende canada early stage poligrip baycol number product liability lawsuit claim file group bayer corporation principal subsidiary group state federal court usa bayer ag sign allocation agreement include purport class action allege zinc poligrip bayer corporation agree pay settlement cause copper depletion permanent neurologic injury compensatory damage judgment party retain lawsuit allege neurologic injury zinc poligrip responsibility attorney fee punitive damage file august federal case denture federal case consolidate multidistrict litigation cream adhesive multidistrict litigation district court proceed district court district minnesota southern district florida establish june multidistrict litigation process winding group procter gamble defendant plaintiff remain date statewide class action litigation include mdl purport class action assert certify medical monitoring case pennsylvania economic loss claim state consumer protection law consumer fraud deceptive business practice act case claim medical monitor exception state court illinois medical monitoring action dismiss case arkansa state court case consolidate court summary judgment supreme court illinois mass tort program philadelphia purport class action likewise dismiss consumer fraud claim summary judgment assert consumer fraud claim recently file canada december nationwide class thirdparty payer th february group announce voluntarily certify pennsylvania state court case settle withdraw zinccontaine formulation poligrip trial class action group name thimerosal defendant certify oklahoma case decertifie deadline appeal decertification order group number pharmaceutical pass claim death injury company name defendant numerous individual settle thousand allege muscle ache personal injury lawsuit state federal district court pain voluntarily involuntarily dismiss usa allege thimerosal preservative manufacture vaccine cause neurodevelopmental disorder paxil paxil cr injury include autism group receive numerous lawsuit claim allege case purport class action use paxil paroxetine cause variety injury determination case lawsuit claim allege use paxil permit proceed class action number purport pregnancy result birth child birth defect class action jurisdiction withdraw health issue lawsuit claim allege patient dismiss plaintiff seek remedy include compensatory punitive take paxil commit attempt commit suicide statutory damage cost fund medical act violence finally group lawsuit claim monitor research allege use paxil cause patient suffer symptom discontinue treatment paxil date report limited number case approach trial date vaccine manufacturer case file philadelphia allege injury pregnancy manufacturer thimerosal contain medicinal product coordinate philadelphia mass tort program successful exclude testimony plaintiff expert october trial result adverse jury verdict witness causation specifically ground plaintiff million kilker v glaxosmithkline punitive fail establish hypothesise link thimerosal damage award posttrial motion pende group neurodevelopmental disorder generally accept reliable purport class action litigation canada concern use relevant scientific community paxil pregnancy gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement legal proceeding continue average wholesale price united states department justice number state additionally february office special master putative class private payer year united states court federal claim reject investigate andor bring civil litigation allegation approximately autism claim file national numerous pharmaceutical company include gsk vaccine injury compensation program nvicp ground violate federal state fraud abuse law result claimant fail produce reliable scientific evidence link way average wholesale price awp wholesale acquisition vaccination medical condition include autism cost wac determine report drug group party proceeding finding reimburse medicare medicaid insurance evidence pende lawsuit programme group reach million civil group decision uphold appeal united settlement federal government resolve allegation state court federal claim nvicp claimant relate pricing marketing zofran kytril appeal ruling court appeal group amend exist corporate integrity agreement federal circuit claimant elect appeal requirement settlement group receive reject decision nvicp claimant final approval million nationwide private payer class option filing action group andor action settlement relate group price reporting mdl physician administer vaccine question proceed district court district massachusetts date action commence number state respective attorney general remain approximately nvicp claimant countie new york state file civil ultimately option pursue personal injury lawsuit lawsuit state federal court gsk vaccine manufacturer include group drug company claim damage restitution early determine announcement nvcip awp andor wac price report pharmaceutical product decision likely lead increase number civil case cover state medicaid programme state seek file group date report recovery behalf state payer case case schedule trial group defendant behalf instate patient consumer group separately resolve awp claim state medicaid sale marketing regulation programme twothird state marketing promotion doj settlement separate negotiation litigation concern february group receive subpoena awp issue continue state new attorney office colorado group sale york county july alabama state court jury return promotional practice relate large selling product million verdict group case file period january particular state alabama october alabama supreme government inquire allege promotion drug court reverse jury verdict render judgment gsk offlabel use groupsponsore continue medical favour court expressly find gsk defraud education programme speaker event special issue board alabama medicaid programme january alabama advisory board speaker training programme clinical study supreme court decline alabama petition reconsideration relate grant fee travel entertainment reversal original subpoena issue attorney office november kentucky state court jury return colorado scope inquiry nationwide compensatory damage verdict group government inquire group response case file state kentucky jury find october letter fdas division drug marketing group liable violate state consumer protection law advertise communication request information liable state medicaid fraud false advertising group allege promotion wellbutrin sr offlabel use statute january judge case award state group cooperate investigation provide kentucky additional statutory penalty request information group consider appeal follow united nations report allege bribe nominal pricing pay iraqi government official connection un oil group respond letter request senate food programme group receive subpoena committee finance date april february sec february respect group participation document information relate nominal price exception programme department justice initiate good price reporting requirement medicaid drug investigation december uk fraud office rebate programme january committee release issue formal notice group require production finding pharmaceutical manufacturer inappropriately document relate group participation programme nominal price exception contrary committee group cooperating investigation provide interpretation congressional intent group document responsive subpoena notice advise department justice investigate continue respond follow question request certain group nominal pricing bundle sale arrangement determine arrangement qualify exception good price reporting requirement violate civil statute law gsk annual report pp stnemetat laicnanif note financial statement legal proceeding continue cidra puerto rico manufacturing site october group announce plan cease march group receive broad letter request operation manufacturing facility locate cidra department justice seek range document relate puerto rico th july cidra site cease operation group nominal pricing arrangement commence decommissioning activity remain possible bundle sale group continue cooperate operational staff release th september investigation produce document group th october district court eastern receive subpoenas request document information district north carolina enter order vacate consent delaware michigan relate group nominal price decree group fda agree arrangement group cooperate investigation group manufacture operation site group produce responsive document addition complete decommissioning activity currently pursue governmental investigation allegation concern nominal opportunity sell site party pricing certain government payer awp litigation group enter nominal october federal government execute search price arrangement december warrant cidra facility seize record relate manufacturing operation site b programme group defend action file federal court april group receive subpoena district court northern district california attorney office boston request production records county santa clara county seek manufacturing cidra site cover information represent putative class hospital clinic entity similar seize government puerto california eligible receive discount ceiling rico subsequently group receive additional price pharmaceutical federal programme know subpoenas government relate cidra facility b programme plaintiff allege group group cooperate attorney office numerous pharmaceutical manufacturer produce record responsive subpoena addition set ceiling price higher allow law july group learn district court contract govern programme district massachusetts unseal complaint bring overcharge entity california eligible employee federal false claim act participate b programme lawsuit dismiss claim monetary damage result allege failure reinstate august follow appeal cidra facility comply fda good manufacturing actively litigate trial court level process gmp manufacture product plaintiff claim defendant miscalculate average group name purport consumer fraud class manufacturer price amp good price bps action lawsuit file california state court medicaid rebate program form district court district puerto rico allege ceiling price formula result inflated ceiling price paxil product manufacture accord gmp defendant assert continue assert plaintiff seek economic statutory punitive damage plaintiff entitle challenge calculation amp request injunctive relief summer bps lawsuit group reach tentative agreement settle paxilseroxat matter settlement cover nationwide class consumer follow group settlement lawsuit file purchaser party payer provide claim procedure new york state attorney general office allege failure class member receive payment splitdefective disclose datum use paxil child adolescent paxil cr tablets settlement receive final trial court approval similar case purport class action september objectors settlement file appeal file private plaintiff seek recover amount pay appeal dismiss february accordingly paxil purchase use patient age settlement final effective accordance follow class settlement consumer term settlement agreement consumer district court district minnesota approve fraud class action lawsuit dismiss prejudice million class settlement ensue lawsuit seek relate party payer suit file philadelphia court recovery behalf insurance company thirdparty common plea mark settle discontinue payer payment prescription paxil child end th october adolescent group deny liability settlement similar purport class action file district court district minnesota behalf federal state local government entity pay prescription paxil minor remain similar purport class action canada seek economic damage behalf individual party payer governmental entity purchase paxil use patient age gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note financial statement legal proceeding continue secondary wholesaler july rxusa wholesale inc secondary wholesaler antitrust file suit group pharmaceutical paxilseroxat manufacturer wholesaler district court trial date remain patent infringement eastern district new york complaint allege action bring group apotex apotexs defendant engage conspiracy refuse supply counterclaim remain set th april district pharmaceutical product rxusa violation federal court eastern district pennsylvania matter state antitrust law group motion dismiss group seek substantial damage apotexs allege complaint grant plaintiff file appeal infringement group patent paroxetine wellbutrin xl hydrochloride apotex turn seek damage group substantially large damage action file biovail gsk purport seek group allege violation federal antitrust class direct indirect purchaser allege unlawful law involve advertising state antitrust monopolisation antitrust violation relate consumer protection law federal antitrust enforcement biovail wellbutrin xl patent file law damage seek apotex treble biovail citizen petition group motion dismiss event adverse jury verdict group amend complaint indirect purchaser grant nd december court order group respect claim class apotex engage mediation attempt reach settlement representative claim assert indirect patent infringement claim counterclaim purchaser case proceed discovery respect remain claim one bring eu sector inquiry purport class direct purchaser january european commission announce inquiry flonase certain aspect competition pharmaceutical sector initiate inspection premise number innovator purport direct indirect purchaser class action generic pharmaceutical company include group file district court eastern district commission publish preliminary report november pennsylvania allege group illegally maintain monopoly base information provide innovator generic power market flonase charge plaintiff supra pharmaceutical company report suggest defensive competitive price additionally suit file roxane patenting strategy lead obstacle innovation laboratories inc generic competitor seek lose profit innovator company employ measure hinder generic come group allege action unlawfully delay roxane entry market final report issue july market predicate allegation contradict preliminary report final report filing group allegedly sham citizen petition concede delay generic entry fault subsequent litigation group successfully narrow regulatory environment innovator company defensive claim purport class indirect purchaser strategy report commission state motion dismiss complaint amend complaint attack legitimate patenting practice identify area follow group motion dismiss roxane complaint recently scrutiny commission recommend regulatory deny discovery regard party schedule reform improvement conclude q wellbutrin sr commercial corporate december january february lawsuit security class action purport class action file november attorney purport represent class district court eastern district pennsylvania purchasers glaxosmithkline share ad file group behalf direct indirect purchaser amend consolidated complaint group senior wellbutrin sr complaint allege violation officer district court southern district new antitrust law sham litigation fraud patent york allege group individual defendant office group obtain enforce patent cover violate security law artificially inflate price wellbutrin sr complaint follow introduction glaxosmithkline stock mislead investor safety generic competition wellbutrin sr april district avandia amend consolidated complaint allege appellate court ruling generic manufacturer current senior officer member infringe group patent class direct purchaser group engage insider trading motion dismiss certify decision complaint file behalf group court regard certification indirect purchaser class individual defendant district court enter discovery substantially complete group order dismiss case defendant plaintiff file motion summary judgment remain pende appeal court appeal second circuit august court appeal affirm district court dismissal matter conclude gsk annual report pp stnemetat laicnanif note financial statement legal proceeding continue case file district court district arizona november seek establish nationwide th july class action suit bring behalf collective action behalf entire group current employee stiefel laboratories inc pharmaceutical sale representative ground file district court southern district representative exempt employee fair florida complaint allege stiefel officer labor standard act plaintiff seek double damage director violate employee retirement income security act overtime allegedly work group pharmaceutical sale erisa federal state security law induce stiefel representative year period november employee sell share employee stock plan court grant group motion summary judgment stiefel company greatly undervalue price dismiss lawsuit ground sale disclose employee stiefel sell representative exempt employee outside january defendant motion dismiss grant sale exemption fair labor standard act plaintiff deny specifically court determine ask court reconsider amend judgment base erisa claim individual stiefel defendant rationale advance department labor federal security claim individual defendant brief department file case involve stiefel forward court dismiss florida company st february court reaffirm securities act common law breach fiduciary duty claim dismissal action plaintiff subsequently file notice hold erisa preempt state common law appeal decision court appeal malpractice claim stiefel accountant ninth circuit wage hour claim environmental matter december purport class action file gsk notify potential responsibility relate group behalf entire group past operation past waste disposal practice pharmaceutical sale representative action certain site primarily usa matter file transfer district court central subject litigation include proceeding initiate district california initially allege representative federal state government waste disposal site exempt employee california law andor remediation cost tort action bring private party fair labor standard act consequently entitle overtime pay thing gsk advise responsible party approximately site appear national plaintiff subsequently amend complaint priority list create comprehensive environmental assert class action limit solely pharmaceutical sale response compensation liability act superfund representatives work california assert claim proceeding seek require operator hazardous california wage hour law waste facility transporter waste site generator suit seek variety compensatory punitive statutory hazardous waste dispose site clean damage group move summary judgement dismiss site reimburse government cleanup cost claim putative class representative ground instance gsk involve allege generator hazardous exempt employee court hold waste superfund provide defendant appeal pende united states court appeal jointly severally liable cleanup cost proceeding ninth circuit case involve manufacturer frequently resolve basis nature quantity virtually factual legal argument waste dispose generator site gsk defer rule summary judgement motion stay proportionate liability cleanup cost substantially activity case appellate court rule determine site refer company pende case gsk potential liability vary greatly site site cost investigation study remediation site time substantial gsk routinely accrue amount relate share liability matter gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp director statement responsibility director statement responsibility disclosure information auditor relation company financial statement director office date report confirm director responsible prepare parent company financial statement remuneration report accordance far aware relevant audit applicable law regulation information company auditor unaware company law require director prepare financial statement financial year law director elect take step ought prepare parent company financial statement accordance take director aware applicable law united kingdom accounting standard relevant audit information establish company united kingdom generally accept accounting practice auditor aware information company law director approve parent company confirmation give interpret accordance financial statement satisfied true provision section company act fair view state affair company period go concern basis prepare financial statement director require make enquiry director reasonable expectation company adequate resource continue select suitable accounting policy apply operational existence foreseeable future reason consistently continue adopt go concern basis prepare judgement accounting estimate financial statement reasonable prudent combine code state regard parent company financial board consider glaxosmithkline plc apply main statement applicable uk accounting standard principle combine code corporate governance follow subject material departure disclose financial reporting council describe corporate explain financial statement governance page comply provision describe director responsible keep adequate accounting record sufficient explain company require listing rule financial service authority transaction disclose reasonable accuracy time auditor consider director statement financial position company enable ensure compliance relation point combine code parent company financial statement comply specified review company act responsible safeguarding asset company take reasonable step prevention detection fraud irregularity sir christopher gent parent company financial statement year end chairman st december comprise balance sheet year th february end st december support note set page report responsibility auditor relation parent company financial statement set independent auditor report financial statement year end st december include annual report publish hard copy print form available website director responsible maintenance integrity annual report company website accordance uk legislation govern preparation dissemination financial statement access website available outside uk comparable legislation different gsk annual report pp stnemetats laicnanif independent auditor report members glaxosmithkline plc audit parent company financial statement matter require report glaxosmithkline plc year end st december exception comprise company balance sheet uk gaap report respect follow matter relate note ah financial reporting framework company act require report apply preparation applicable law opinion united kingdom accounting standard united kingdom generally accept accounting practice adequate accounting record keep parent company return adequate audit respective responsibility director receive branch visit auditor parent company financial statement explain fully director responsibilitie statement director remuneration report audit set director responsible agreement accounting record return preparation parent company financial statement certain disclosure director remuneration specify law satisfied true fair view responsibility audit parent company financial statement accordance receive information explanation applicable law international standard auditing require audit uk ireland standard require comply auditing practice board ethical standard auditor matter report include opinion prepare report separately group financial statement companys member body accordance glaxosmithkline plc year end st december chapter company act company pass resolution accordance section purpose give opinion accept assume company act senior statutory auditor responsibility purpose person state report show hand come save expressly agree prior consent write scope audit financial statement audit involve obtain evidence amount disclosure financial statement sufficient reasonable pricewaterhousecooper llp assurance financial statement free material charter accountant statutory auditor misstatement cause fraud error include london assessment accounting policy appropriate th february parent company circumstance consistently apply adequately disclose reasonableness significant accounting estimate director overall presentation financial statement opinion financial statement opinion parent company financial statement true fair view state company affair st december h ave properly prepare accordance united kingdom generally accept accounting practice h ave prepared accordance requirement company act opinion matter prescribed company act opinion director remuneration report audit properly prepare accordance company act information give director report financial year parent company financial statement prepare consistent parent company financial statement gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp company balance sheet uk gaap st december note fix asset investment debtor e cash bank current asset creditor amount year f net current liability net asset capital reserve call share capital g share premium account g reserve h profit loss account h equity shareholder fund approve board th february sir christopher gent chairman glaxosmithkline plc register number gsk annual report pp stnemetat laicnanif note company balance sheet uk gaap presentation financial statement expenditure description business expenditure recognise respect good service receive glaxosmithkline plc parent company gsk major global supply accordance contractual term provision healthcare group engage creation discovery obligation exist future liability respect development manufacture marketing pharmaceutical past event obligation product include vaccine overthecounter otc medicine reliably estimate healthrelated consumer product investment subsidiary company preparation financial statement investment subsidiary company hold cost financial statement prepare go concern provision impairment basis draw accordance uk generally accept impairment investment accounting principle uk gaap uk accounting carrying value investment review impairment presentation st december comparative figure indication investment impaired st december appropriate comparative figure provision result impairment review charge reclassify ensure consistent presentation current income statement year concern year information share base payment permit company act profit issuance company subsidiary grant loss account company present annual report company option represent additional capital contribution accounting convention standard company subsidiarie additional investment balance sheet prepare historical cost subsidiary result correspond increase shareholder convention complie applicable uk accounting standard equity additional capital contribution base fair value grant issue allocate underlying grant accounting principle policy vest period preparation balance sheet conformity generally accept accounting principle require management taxation estimate assumption affect report current tax provide amount expect pay amount asset liability disclosure contingent apply tax rate enact substantially enact asset liability date balance sheet balance sheet date actual amount differ estimate company account taxation defer balance sheet prepare accordance accelerate reason timing difference originate company accounting policy approve board reverse balance sheet date defer tax asset describe note b recognise extent consider recoverable future taxable profit b accounting policy defer tax measure average tax rate foreign currency transaction expect apply period time difference foreign currency transaction record exchange rate expect reverse defer tax liability asset rule date transaction forward rate hedge discount forward exchange contract foreign currency asset liability translate rate exchange rule balance financial guarantee sheet date forward rate liability relate guarantee issue company behalf subsidiary hold fair value amortise life dividend pay receive guarantee dividend pay receive include account period relate dividend actually pay receive c operate profit fee relate audit company charge operating profit gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp note company balance sheet uk gaap fix asset share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited shares glaxosmithkline mercury limited capital contribution relate share base payment e debtor amount year uk corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking f creditor amount year bank overdraft amount owe group undertaking creditor company guarantee debt issue subsidiary company receive annual fee subsidiary aggregate company issue guarantee billion debt instrument subsidiary company relation guarantee fee recover life bond disclose debtor note e gsk annual report pp stnemetat laicnanif note company balance sheet uk gaap g share capital share premium account share ordinary share p premium number share capital authorise st december st december share capital issue fully pay st january issue share option scheme purchase cancel st december issue share option scheme st december st december st december number share issuable outstanding option number unissue share option st december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme h reserve profit reserve loss account total st january profit attributable shareholder dividend shareholder ordinary share purchase cancel capital contribution relate share base payment st december profit attributable shareholder dividend shareholder capital contribution relate share base payment st december profit glaxosmithkline plc year million million dividend million million give retain profit million profit million cost share purchase cancel nil million million profit loss account reserve st december stand million million million unrealised million gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information shareholder information section include financial record shareholder information present historical information prepare accordance ifrs quarterly trend adopt european union ifrs issue year record iasb product development pipeline section discuss shareholder return form dividend share product development pipeline price movement provide information shareholder share price dividend nature trading market share price movement dividend show annual general meeting graph detail price movement dividend investor relation registrar page taxation information shareholder glossary term index share price dividend share pence l uu kk ss hh aa rr ee pp rr ii cc ee l uu ss aa dd rr pp rr ii cc ee uu ss l uukk ddiivviiddeennddss ppeerr sshhaarree l uuss ddiivviiddeennddss ppeerr aaddss analysis shareholding st december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline bank new york mellon hold hold bny nominees limited represent company adr programme ad represent ordinary share p nominal value th february bny nominees limit hold ordinary share represent issue share capital exclude treasury share date th february number holders shares usa holdings share number register holder adr holdings adr certain share adr hold broker nominee result number holder record register holder usa representative number beneficial holder residence beneficial holder gsk annual report p noitamrofni redloherah shareholder information quarterly trend unaudite analysis group result pharmaceutical sale therapeutic area provide quarter sterle financial year income statement total month q q q q cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement result major restructure total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny p p p p p dilute earning share penny p p p p p calculation result major restructuring describe note financial statement presentation financial statement gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information quarterly trend unaudite analysis group result pharmaceutical sale therapeutic area provide quarter sterle financial year income statement total month q q q q cer cer cer cer cer turnover pharmaceutical consumer healthcare total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement result major restructure total turnover cost sale sell general administrative research development operating income operate profit finance income finance cost profit disposal interest associate share tax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable minority interest profit attributable shareholder adjust earning share penny p p p p p dilute earning share penny p p p p p calculation result major restructuring describe note financial statement presentation financial statement gsk annual report p noitamrofni redloherah shareholder information quarterly trend pharmaceutical turnover total group q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix stiefel product pharmaceutical turnover include copromotion income gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information quarterly trend pharmaceutical turnover usa q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover include copromotion income gsk annual report p noitamrofni redloherah shareholder information quarterly trend pharmaceutical turnover europe q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover include copromotion income gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information quarterly trend pharmaceutical turnover rest world q q q q cer cer cer cer respiratory avamysveramyst flixonaseflonase flixotideflovent seretideadvair serevent ventolin zyrtec antiviral hiv agenerase lexiva combivir epivir epzicomkivexa trizivir ziagen valtrex relenza zeffix central nervous system imigranimitrex lamictal requip requip xl seroxatpaxil treximet wellbutrin wellbutrin xl cardiovascular urogenital arixtra avodart coreg fraxiparine levitra lovaza vesicare volibris metabolic avandia product avandia avandamet bonvivaboniva antibacterial augmentin oncology emesis hycamtin promacta tyverbtykerb zofran vaccines boostrix cervarix fluarix flulaval flu pandemic hepatitis infanrix pediarix rotarix synflorix pharmaceutical turnover include copromotion income gsk annual report p noitamrofni redloherah shareholder information quarterly trend consumer healthcare turnover total group q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlick ribena consumer healthcare turnover usa q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlick ribena gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information quarterly trend consumer healthcare turnover europe q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlick ribena consumer healthcare turnover rest world q q q q cer cer cer cer overthecounter medicines alli breathe right cold sore franchise nicotene replacement therapy panadol tums oral healthcare aquafresh franchise biotene denture care sensodyne franchise nutritional healthcare lucozade horlick ribena gsk annual report p noitamrofni redloherah shareholder information year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board pharmaceutical turnover therapeutic area respiratory antiviral central nervous system cardiovascular urogenital metabolic antibacterial oncology emesis vaccine pharmaceutical turnover geographic area usa europe rest world emerge market japan asia pacific canada rest world pharmaceutical turnover include copromotion income consumer healthcare turnover otc medicine oral healthcare nutritional healthcare gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share financial result major restructuring turnover operate profit profit taxation profit taxation pence pence pence adjust earning share adjust diluted earning share million million million million million weight average number share issue basic diluted return capital employ return capital employ calculated total profit taxation percentage average net asset year balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity minority interest total equity gsk annual report p noitamrofni redloherah shareholder information number employee usa europe rest world asia pacific include china japan middle east africa latin america canada rest world manufacturing selling administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day year feb jan dec nov oct sept high low st december federal reserve bank new york cease publish noon buying rate bank england pm buy rate subsequent calculation pm buy rate th february gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp product development pipeline key inlicense alliance relationship party bla biological license application month submission maa marketing authorisation application europe month regulatory approval maa eu nda new drug application usa approval letter phase evaluation clinical pharmacology usually conduct volunteer alcr month approvable complete response letter receive indicate phase ii determination dose initial evaluation efficacy conduct ultimately approval give subject resolution small number patient outstanding query phase iii large comparative study compound versus placebo andor establish po month eu positive opinion treatment patient establish clinical benefit safety ta fda tentative approval maa ndabla regulatory milestone show table achieve future submission date include list achieve regulatory review milestone compound type indication phase maa ndabla biopharmaceutical monoclonal antibody alzheimer disease monoclonal antibody metabolic disease monoclonal antibody amyotrophic lateral sclerosis domain antibody target malignant melanoma multicomponent vaccine apn recombinant human angiotensin acute respiratory distress syndrome convert enzyme iboctadekin doxil il immunomodulator topoisomerase ii ovarian cancer inhibitor iboctadekin rituximab il immunomodulator anticd follicular lymphoma monoclonal antibody otelixizumab anticd monoclonal antibody sc type diabetes monoclonal antibody stroke ii monoclonal antibody rheumatoid arthritis ii monoclonal antibody severe asthma ii arzerra ofatumumab anticd human monoclonal antibody follicular lymphoma relapse patient ii benlysta belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus ii antibody sc mepolizumab antiil monoclonal antibody severe asthma nasal polyposis ii ofatumumab anticd human monoclonal antibody multiple sclerosis ii arzerra ofatumumab anticd human monoclonal antibody chronic lymphocytic leukaemia line therapy iii use relapse patient arzerra ofatumumab anticd human monoclonal antibody diffuse large b cell lymphoma relapse patient iii arzerra ofatumumab anticd human monoclonal antibody follicular lymphoma refractory patient iii benlysta belimumab antib lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody iv denosumab antireceptor activator nuclear kappa rank bone metastatic disease iii ligand human monoclonal antibody denosumab antirank ligand human monoclonal antibody hormone ablativechemotherapy bone loss cancer patient iii ofatumumab anticd human monoclonal antibody rheumatoid arthritis iii otelixizumab anticd monoclonal antibody iv type diabete iii syncria glucagonlike peptide agonist type diabete iii prolia denosumab antirank ligand human monoclonal antibody postmenopausal osteoporosis submit podec na arzerra ofatumumab anticd human monoclonal antibody chronic lymphocytic leukaemia refractory patient approve pojan aoct cardiovascular metabolic prolyl hydroxylase inhibitor anaemia muopioid receptor inverse agonist obesity sodium dependent glucose transport sglt type diabetes inhibitor sirt activator sarcopaenia copd psoriasis sirt activator type diabete haematologic cancer ii high affinity nicotinic acid receptor hma dyslipidaemia ii agonist oxytocin antagonist premature ejaculation ii gastrinrelease peptide gpr receptor type diabete ii agonist glycogen phosphorylase inhibitor type diabetes ii sirt activator type diabete copd haematologic cancers ii losmapimod p kinase inhibitor cardiovascular disease copd pain depression ii retosiban oxytocin antagonist threaten preterm labour ii rilapladib lppla inhibitor atherosclerosis ii avandamet xr ppar gamma agonist metformin type diabete extend release iii na avandia simvastatin ppar gamma agonist statin type diabete iii na darapladib lppla inhibitor atherosclerosis iii arixtra synthetic factor xa inhibitor treatment acute coronary syndrome approve aaug alfeb sep avandia ppar gamma agonist prevention disease progression approve aapr ajul gsk annual report p noitamrofni redloherah product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla infectious disease plasmodium electron transport chain inhibitor malaria topoisomerase ii inhibitor treatment bacterial infection novel class antibacterial agent treatment bacterial infection relenza neuraminidase inhibitor iv treatment influenza ii sitamaquine aminoquinoline treatment visceral leishmaniasis ii na tafenoquine aminoquinoline plasmodium vivax malaria ii neuroscience crf antagonist depression anxiety dopamine antagonist drug dependency sodium channel blocker bipolar disorder muscarinic acetylcholine agonist dementia nknk antagonist schizophrenia ht antagonist depression anxiety ii histamine h antagonist dementia schizophrenia ii crf antagonist depression anxiety ii orexin antagonist sleep disorder ii ht antagonist dementia ii pro antisense oligonucleotide duchenne muscular dystrophy ii firategrast dual alpha integrin antagonist vla multiple sclerosis ii horizant voltagegate calcium channel modulator migraine prophylaxis ii horizant voltagegate calcium channel modulator neuropathic pain ii losmapimod p kinase inhibitor pain cardiovascular disease copd depression ii losmapimod p kinase inhibitor depression cardiovascular disease copd pain ii orvepitant nk antagonist depression anxiety ii almorexant orexin antagonist insomnia iii horizant voltagegate calcium channel modulator restless leg syndrome submit crfeb retigabine neuronal potassium channel opener epilepsy partial seizure submit soct soct lamictal xr sodium channel inhibitor epilepsy partial generalise tonicclonic seizure oncedaily approve na ajan lamictal xr sodium channel inhibitor epilepsy partial seizure oncedaily approve na amay oncology akt protein kinase inhibitor cancer braf protein kinase inhibitor cancer pi kinase inhibitor cancer akt protein kinase inhibitor cancer sirt activator haematologic cancer type diabete ii mitogenactivate protein kinase inhibitor cancer ii mek thrombopoietin receptor agonist thrombocytopaenia ii foretinib mesenchymalepithelial transition factor papillary renal cell carcinoma cancer ii cmet kinase inhibitor revoladepromacta thrombopoietin receptor agonist oncologyrelate thrombocytopaenia ii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma unresectable disease ii votrient pazopanib multikinase angiogenesis inhibitor breast cancer adjuvant therapy ii votrient pazopanib multikinase angiogenesis inhibitor nonsmall cell lung cancer line adjuvant therapy ii votrient pazopanib multikinase angiogenesis inhibitor ovarian cancer maintenance therapy iii revoladepromacta thrombopoietin receptor agonist chronic liver disease induce thrombocytopaenia iii revoladepromacta thrombopoietin receptor agonist hepatitis c induce thrombocytopaenia iii tyverbtykerb egfr dual kinase inhibitor breast cancer adjuvant therapy iii tyverbtykerb egfr dual kinase inhibitor gastric cancer iii tyverbtykerb egfr dual kinase inhibitor head neck squamous cell carcinoma resectable disease iii votrient pazopanib multikinase angiogenesis inhibitor sarcoma iii votrient pazopanib multikinase angiogenesis inhibitor inflammatory breast cancer iii tyverbtykerb egfr dual kinase inhibitor avodart alpha reductase inhibitor reduction risk prostate cancer submit ssep duodart avodart alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fix dose combination submit sdec tajan alpha blocker revoladepromacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura approve podec anov tyverbtykerb egfr dual kinase inhibitor breast cancer line therapy approve pofeb ajan votrient pazopanib multikinase angiogenesis inhibitor renal cell cancer approve pofeb aoct ophthalmology pazopanib multikinase angiogenesis inhibitor oral agerelate macular degeneration cancer indication pazopanib multikinase angiogenesis inhibitor eye drop agerelate macular degeneration ii note financial statement post balance sheet event gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla respiratory immunoinflammation p kinase inhibitor inhale copd p kinase inhibitor iv acute lung injury acute respiratory distress syndrome chemokine receptor cxcr antagonist copd sirt activator copd psoriasis type diabetes sarcopaenia ccx ccr antagonist crohns disease pde inhibitor inhale copd ii muscarinic acetylcholine antagonist copd ii muscarinic acetylcholine antagonist copd ii longacting beta agonist chemokine receptor cxcr antagonist cystic fibrosis ii glucocorticoid agonist asthma ii transient receptor potential vanilloid trpv nonallergic rhinitis ii antagonist intranasal novel glucocorticoid agonist inhale asthma ii muscarinic antagonist beta agonist copd ii motilin receptor agonist delay gastric empty ii antiinflammatory macrolide conjugate oral inflammatory bowel disease ii ccx ccr antagonist crohns disease ii lipoxygenaseactivate protein flap asthma ii inhibitor losmapimod p kinase inhibitor oral copd cardiovascular disease pain depression ii relovair longacte beta agonist glucocorticoid asthma ii agonist relovair longacte beta agonist glucocorticoid copd iii agonist longacting beta agonist copd iii paediatric vaccine hexavalent combination conjugate neisseria meningitis c haemophilus influenzae vaccine type b diphtheria tetanus pertussis poliomyelitis disease prophylaxis heptavalent combinatio conjugate neisseria meningitis c haemophilus influenzae ii vaccine type b diphtheria hepatitis b tetanus pertussis poliomyelitis disease prophylaxis pneumoniae paediatric recombinant conjugate streptococcus pneumoniae disease prophylaxis ii generation mosquirix recombinant malaria prophylaxis plasmodium falciparum iii na nimenrix menacwytt conjugate neisseria meningitis groups c w disease prophylaxis iii menhibrix hibmencytt conjugate neisseria meningitis group c haemophilus submit saug influenzae type b disease prophylaxis hiberix conjugate paediatric booster haemophilus influenzae type b approve anov aaug synflorix conjugate streptococcus pneumoniae disease prophylaxis infant approve amar na child vaccine alzheimer disease conjugate treatment alzheimer disease cytomegalovirus recombinant cytomegalovirus infection prophylaxis hiv recombinant hiv disease prophylaxisimmunotherapy nthipneumo recombinant streptococcus pneumoniae haemophilus influenzae disease prophylaxis adult dengue fever attenuate tetravalent dengue fever prophylaxis ii tuberculosis recombinant tuberculosis prophylaxis ii zoster recombinant herpe zoster prevention ii new generation flu vaccine inactivate split trivalent seasonal influenza prophylaxis elderly iii simplirix recombinant genital herpe prophylaxis iii flu pandemic hn inactivate split monovalent pandemic influenza prophylaxis submit sjul sjun prepandemic quebec canada arepanrix flu pandemic hn inactivated split adjuvante pandemic influenza prophylaxis emergency use approve pojan aoct monovalent quebec canada cervarix recombinant cervical dysplasia cancer prophylaxis cause approve asep aoct hpv influenza hn hn inactivate split monovalent pandemic influenza hn prophylaxis approve anov monovalent vaccine quebec emergency use flu pandemic pandemrix hn inactivated split adjuvante pandemic influenza prophylaxis approve sep flu pandemic monovalent dresden gsk annual report p noitamrofni redloherah product development pipeline achieve regulatory review milestone compound type indication phase maa ndabla antigen specific cancer immunotherapeutic asci wt recombinant treatment acute myelogenous leukaemia ii magea recombinant treatment melanoma iii magea recombinant treatment nonsmall cell lung cancer iii dermatology stiefel late stage asset duac low dose clindamycinbenzoyl peroxide gel acne vulgaris iii tazarotene foam retinoid foam acne vulgaris iii calcipotriene vitamin analog mild moderate plaque psoriasis submit sdec itraconazole tablet oral antifungal onychomycosis submit smar veltin antibioticretinoid gel acne vulgaris submit soct hiv viiv healthcare hiv integrase inhibitor hiv infections ii hiv integrase inhibitor hiv infections ii idx nonnucleotide reverse transcriptase hiv infection ii inhibitor pf ccr antagonist hiv infections ii uk nonnucleotide reverse transcriptase hiv infection ii inhibitor selzentrycelsentri ccr antagonist hiv infection use treatment naive patient approve anov optionbase alliance party include asset phase phase ii development company disease area phase anacor pharmaceuticals antibacterial chemocentryx inflammatory disease ii concert pharmaceutical hiv protease inhibitor galapagos autoimmune disease neurosearch neuroscience anxiety pain oncome pharmaceutical oncology prosensa therapeutic neuroscience ranbaxy laboratory respiratory theravance gastrointestinal asset gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information ordinary share company list london stock dividend ad exchange new york stock exchange nyse form table set dividend ad dollar american depositary share ad detail list debt year translate dollar applicable list refer note net debt exchange rate share price year st january high year low year st december increasedecrease dividend calendar quarter exdividend date record date payment date table set middle market closing price companys share price increase compare q th february th february th april increase ftse index year q th th th july share price th february q th july th july th october q th october th october th january market capitalisation market capitalisation base share issue exclude financial reporting calendar treasury share glaxosmithkline st december billion date gsk fifth large company publication date market capitalisation ftse index result announcement smithkline beecham plc float rate quarter april quarter july unsecured loan stock quarter october loan stock list exchange redeem preliminaryquarter february entirety par ie loan stock hold st june annual reportsummary februarymarch loan stock holder require surrender result announcement certificate compulsory redemption automatically time cheque respect result announcement issue london stock exchange redemption value post th available news service shortly issue medium available website send taxation securities exchange commission nyse general information concern uk tax effect financial report share ownership set taxation information shareholder gsk publish annual report shareholder need detail report summary document dividend available date publication website summary glaxosmithkline pay dividend quarterly continue increase send shareholder shareholder elect receive cash return shareholder dividend policy dividend annual report writing registrar alternatively shareholder remain essential component total shareholder return elect receive notification email publication gsk commit increase dividend longterm financial report register wwwshareviewcouk detail dividend declare payment copy previous financial report available gsk website date give note financial statement dividend print copy obtain registrar uk dividend share gsk response center usa table set dividend share year corporate responsibility report year penny late march gsk publish website corporate responsibility report cover performance area include community investment ethic integrity access medicine rd environment health safety gsk annual report p noitamrofni redloherah shareholder information nature trading market annual general meeting follow table set period indicate high queen elizabeth ii conference centre th low middle market closing quotation pence share broad sanctuary westminster london stock exchange high low report london swp ee sale price dollar ad nyse penny share agm company principal forum communication high low private shareholder addition formal business quarter end st march presentation chief executive officer february performance group future development january opportunity question board chairman board committee question matter relate december committees november october investor hold share nominee service september arrange nominee service appoint corporate quarter end st december representative proxy respect shareholding order quarter end th september attend vote meeting quarter end th june adr holder wish attend meeting obtain proxy quarter end st march bank new york mellon enable quarter end st december attend vote business transact adr holder quarter end th september instruct bank new york mellon way quarter end th june share represent adr vote complete quarter end st march return voting card provide bank accordance year end st december instruction give year end st december year end st december document display memorandum articles association company document refer annual report dollar ad available inspection register office company high low quarter end st march exchange control limitation february affect security holder january currently uk law decree regulation restrict december import export capital affect remittance november dividend payment holder company share october nonresident uk limitation relate september nonresident uk english law company quarter end st december memorandum articles association right quarter end th september holder vote respect company share quarter end th june quarter end st march quarter end st december quarter end th september quarter end th june quarter end st march year end st december year end st december year end st december th february internet information company include detail share price available gsk website wwwgskcom information available website constitute annual report gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp shareholder information duplicate publications adr programme administrator query relate receipt duplicate copy gsk publication adr programme administer address registrar bny mellon shareowner services po box investor relation pittsburgh pa investor relation contact follow wwwbnymelloncomshareowner tel toll free uk tel outside usa great west road brentford middlesex tw gs email shrrelationsbnymelloncom tel administrator provide global buydirect direct ad usa purchasesale dividend reinvestment plan adr holder franklin plaza po box philadelphia pa gsk response center tel toll free tel toll free tel outside usa provision detail intend registrar invitation inducement engage investment activity company registrar advice share dealing obtain stockbroker independent financial adviser equiniti limited aspect house spencer road lance west sussex bn da wwwshareviewcouk tel inside uk tel outside uk equiniti provide follow service nominee deal account individual saving account isa g laxosmithkline corporate sponsor nominee hareview service share deal service dividend reinvestment plan share deal service shareholder trade share hold certificate corporate sponsor nominee internet telephone shareview deal share deal service provide equiniti financial service limited internet deal log www shareviewcoukdeale telephone deal inside uk nominee isa service wwwshareviewcouk deal telephone service available monday friday market trading hour glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck hp sz tel gsk annual report p noitamrofni redloherah taxation information shareholder summary certain uk tax federal income tax subject federal income tax net income basis respect consequence certain holder share adr share adr hold share adr capital asset citizen uk usa set complete resident uk uk tax purpose hold analysis possible tax consequence purchase share purpose trade profession vocation ownership security intend general guide carry uk branch agency summary holder advise consult adviser respect tax address tax treatment holder subject consequence purchase ownership share adr special tax rule bank taxexempt entity insurance consequence state local tax law usa company dealer security currency person hold implication current ukus income tax convention share adr integrate investment include straddle comprise share adr holder adr generally treat owner position person directly indirectly underlie share purpose current usauk double voting stock gsk taxation convention relate income gain income tax convention estate gift taxis estate gift tax convention taxation dividend purpose internal revenue code gross dividend receive treat foreign source amend code dividend income tax purpose eligible dividend receive deduction allow corporation dividend adr uk shareholders payable dollar dividend share payable sterling summary apply uk resident shareholder hold dividend pay pound sterling include income share capital asset dollar calculate reference exchange rate taxation dividend day dividend receive holder subject certain exception shortterm hedge position individual eligible uk resident individual shareholder generally subject uk holder subject taxation maximum rate income tax dividend pay gross respect qualified dividend receive ninth dividend tax credit tax credit set individual income tax liability respect taxation capital gain gross dividend repayable shareholders tax generally holder subject uk capital gain tax liability associate tax credit tax year subject tax capital gain realise sale subsequent tax year additional rate income disposal share adr gain longterm tax dividend impose taxpayer income capital gain subject reduce rate taxation individual uk resident shareholder corporation holder share adr hold year taxpayer note dividend pay st july generally entitle exemption corporation tax new information report backup withholding rule shareholder doubt position dividend payment proceed sale share consult professional adviser adr pay usa certain usrelated financial intermediary subject information reporting taxation capital gain subject backup withholding holder corporation uk shareholder liable uk tax gain disposal exempt recipient provide taxpayer identification share adr disposal individual capital gain number certifie loss exemption occur tax flat rate subject availability nonus holder generally subject information report exemption relief annual exempt backup withholding require provide corporation taxpayer entitle indexation allowance certification nonus status connection payment apply reduce capital gain extent receive amount withhold allow refund gain arise inflation indexation allowance reduce credit holder federal income tax liability provide chargeable gain create allowable loss require information furnish irs inheritance tax estate gift taxis individual shareholder liable inheritance tax estate gift tax convention shareholder transfer share adr tax charge generally subject uk inheritance tax value shareholder estate reduce result transfer way gift disposal stamp duty market value uk stamp duty sdrt subject certain exemption payable issue transfer share adr custodian gift disposal subject uk inheritance depository rate price issue tax estate gift tax estate gift tax convention consideration provide transfer sale value generally provide tax pay usa credit transfer consideration tax payable uk sdrt payable transfer adr uk stamp duty stamp duty payable transfer adr provide uk stamp duty stamp duty reserve tax sdrt subject instrument transfer execute remain certain exemption payable purchase share rate time outside uk stamp duty transfer adr purchase price payable rate consideration shareholder transfer sale underlie share subject certain exception result liability uk stamp duty case summary apply shareholder citizen resident sdrt rate usa domestic corporation person gsk annual report business review pp governance remuneration pp financial statement pp shareholder information pp glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenue gsk annual report p noitamrofni redloherah index performance overview interest rate risk management accounting principle policie internal control framework acquisition disposal inventory adjustment reconcile profit tax operating cash flow investment associate joint venture annual general meeting investor relation annual remuneration key accounting judgement estimate asset hold sale key performance indicator associate joint venture legal proceeding board major restructuring programme business review movement equity cash cash equivalent nature trading market chairman ceo summary net debt combine code new accounting requirement commitment nonexecutive director term condition committee report nonexecutive director remuneration competition note financial statement consolidate balance sheet operating profit consolidated cash flow statement intangible asset consolidate income statement investment consolidate statement change equity noncurrent asset consolidate statement comprehensive income noncurrent liabilitie consumer healthcare operate income contingent liability provision corporate executive team outlook corporate governance pension postemployment benefit critical accounting policy performance overview dialogue shareholder pharmaceutical turnover director senior management post balance sheet event director senior management remuneration presentation financial statement director interest principal group company director interest contract product development pipeline director statement responsibility product dividend property plant equipment donation eu political organisation eu quarterly trend political expenditure reconciliation net cash flow movement net debt earning share registrar economy regulation employee cost related party transaction employee share scheme remuneration policy employee remuneration report exchange rate report director executive director term condition research development finance cost responsibility finance income risk factor financial instrument relate disclosure segment information financial position resource share capital control financial review share capital share premium account financial review share option financial statement glaxosmithkline plc prepare share price dividend uk gaap shareholder information financial trend strategy year record taxation foreign exchange management taxation information shareholder global manufacturing supply total equity glossary term trade payable goodwill trade receivables governance policy trademark improve access medicine treasury operation incentive plan law regulation independent auditor report world economy intellectual property world market gsk annual report head office register office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel g sk change register number print uk paper annual report production document post consumer waste pulp bleach totally chlorine free process feel well live long glaxosmithkline annual report wwwgskcom